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IntroductIon 
Heart failure is a progressive clinical syndrome and the final pathway of any structuraI or 
functional cardiac disorder that leads 10 an impairment of the ability of the heal1 to fill with 
or eject blood {IJ. Ta preserve cardiac function after an injury to the myocardium, a complex 
cascade of interacting hemodynamlc and neurohormonal-cytokine mechanisms is activated, 
whieh at a later stage may be detrimental for the progression of heart failtue [2, 31. Left 
ventricular hypertrophy and left ventrietdar systolic dysfunction are generally accepted to 
precede symptomatic heart failure {l]. 
Descriptions of heart failure already exist from ancient Egypt and Greece, and even the 
Romans were known to use foxglove (digitalis) as medicine [41. However, it was not until the 
1890s that investigations in heart failure improved after the discovery of X-rays by Röntgen 
and EintllOven's development of electrocardiography [4J. The defmition of heart fallure has 
undergone many changes over the past decades, together with advancing insight into its 
pathophysiology. Nevel1heless, there is na satisfactOly definition to date that encompasses 
all features of this complex syndrome. In the first half of the 20th century, circulatory 
pathophysiology was the focus of attention. This led in the 1950s to the examination of the 
roie of cardiac hypel1rophy and in the 1960s to studies on the roie of the contractlle process 
in the failing heart [5). Studies in the 1960s, however, also demonstrated the presence of 
increased concentrations of noradrenaline in patients with heart failure. This finding led 10 a 
large number of studies on neurohormonal changes in heart fallure. It became dear only in 
the 1980s that persistent activation of these neurohormonal systems is detrimental in dlfOruC 
hcart failUfc [51. 
Heart failure constitutes a major public health problem in the western world. Prevalenee 
and incidence of heart failure are substantial (2, 6]. In the Netherlands, for example, it is 
estimated that approximately 200,000 patients suffer from heal1 failure; i.e. 1-2% of the total 
Dutch population [7, S]. In 1999, the care for these patients accounted for about 1% of the 
total costs of healthcare in the Netherlands, corresponding to € 299 million {SJ. Since age is 
an important risk factor, the burden of this syndrome on health care systems in Europe and 
the United St.1.tes will increase even nlrther as these populations age [9, lOl. In addition, the 
growing incidence of heart fallure is most likely explained b)' improved sUlvival following 
cardiac diseases that lead to this condition, of which the most important is myocardial 
infarction, without effectively providing curative treatment. I-Iospitalization mtes for hcart 
failure have increased considerably in western societies, peaking in the early 1990s [11]. 
Readmissions for exacerbating heart failure occur frequently, and the proportion of patients 
with multiple hospital admissions is growing. Despite the tremendous advances in the 
treatment of heart failure that have taken place over thc past decades, heart failure contirmes 
to be a highJ.)' fatal disease [2]. The truc magnitude of the problem of heart failure in the 
cornmunity cannot be accurateI)' described, since few large prospective population-based 
snldies have been published that provide reliable estimates of its prevalenee, inciclence and 
prognosis. r.,'Ioreover, nearly all of these studies have been performed in the United Statcs. In 
11 
Chapter 1 
addition, comparison of studies is complicated, because they have used different definitions 
and methads to establish the prescnce of heart fallure. 
In EUfope and the United States, the most comrl1on causes of heart failure are corona!)' 
artel)' diseasc, hypertension, valvular heart disease and idiopathic cardiomyopathy [1, 6, 12]. 
1\'lany other less common causes exist, such as infectious diseases, endocrÎIle diseascs and 
the use of cardiotoxic dmgs. Tllere is also substantial evidence for a genetic contribution to 
the pathophysiology of heart failure [13-16]. r..Jany studies have been published on the role 
of single gene mutations in cardiomyopathies [17, 18]. These rare mutations are important 
at an individual level and for the understanding of disease mcchanisms. In addition, genetic 
association studies have investigated the role of scvcral candidate genes in heart failure, 
albeit with contradicto!)' results. 
The diagnosis of heart l'ailure is complex and relies on clinical judgment based on a 
histOI)', physical examination alld objective evidence of cardiac dysfunction at rest, cvaluated 
e.g. by echocardiography [12J. Signs and symptoms are not specific, however, and a gold 
standard to establish the presence of this syndroll1e is lacking. Charactedstically, patients 
present with symptol11s of breathlessnes5 or fatigue, which may limit exercise tolerance, 
and signs of fluid retention, which may lead to pulmona!)7 crepitations or peripheral edell1a 
[1, 121. Symptom-free pedods arc aften alternateel with periods of exacerbating symptol11s. 
Although a clinical response to treatment directcd at heart fallure symptol11s hclps to make 
a diagn05is, it is not sufficient [12), 
During the past centuries, the therapeutic approach to heart failure has also changed 
dramatically. Blood lening and Ieeehes were used for centuries anel the benefits of digitalis 
were published for the flrst time in 1785. Diuretics were not introdllced llntil the 20th cenulry. 
However, thc early organo-mercllrial agents, developed in the 19205, were associated with 
sllbstantial toxicity. The far less taxie thiazide diuretics were marketed in the 19505 [41. Half 
a cenUn)' ago, treatment of heart fallure consisted of bed rest, a sodillm restricted diet and 
the adm.inistration of digitalis and diuretics [SJ. Present-day treatment is not only targeted 
towards symptomatie improvemcnt, but also focuses 011 the prevention of the transition 
of asymptomatic stfllctural heart disease to symptomatie heart fallure, modification of the 
progressive nature of heart fallure and rcduction of mortality [1, 121. Diuretics, angiotensin-
I conve11ing enzyme (ACE)-inhibitors anel g-blackers now form the cornerstone of heart 
failure treatment anel physical activity is encouraged. Digitalis is currently onIy indicated as 
flrst-line tllerapy in heart failure complicated by atrial fibrillation in order to slow ventriClJlar 
rate [12]. 
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Outline of this thesis 
This thesis comprises a number of epidemiologieal studies that are aimed at gaining insight 
into the effects of drugs and genetic determinants on thc occurrencc of heart fallure in the 
general population. All quantitative studies were perfornled in the Rotterdam Study, a large-
scale prospective population-based cohort study among 7983 inhabitants of Ommoord, 
a suhurb of Rotterdam, who were 55 years of age and older [19]. This study provides an 
excellent setting for observational studies on heart failure, as this is primarily a disease of the 
elderly. The baseline examinations took place in 1990 to 1993, whieh allowed for a relativcly 
long follow-up period in the prospective studies presented in this thesis. 
In chapter 2, population-based estimates of the prevalence, incidence, lifetime risk and 
prognosis of heart failure are given to dcscribe the magninlde of the prohlem of heart failurc 
in the community. This clmpter also present.,> age- and sex-specific reference values for the 
detection ofleft ventriClJlar hypertrophy on the e1ectrocardiograrn in thc elderly. These normal 
limits were established in an apparently healthy subgroup of participants of the Rotterdam 
Study and studied in relation to cardiovasclliar prognosis and the risk of heart failllre. Chapter 
3 presents two studies on drugs as determinants of heart failure. The association between 
current use of antihypertensive drugs and left ventricular geometry on the echocardiogram 
in an observational setting is describecl. Additionally, an extensive review of the medical 
literature is given in this chapter of recent fllldings on the association bet ween the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) and the OCCllfrence of heart fallure. Chapter 
4 contains studies on thc association between genetic polymorphisms and structural heart 
disorders that prccede the developmcnt of heart fallure (j.c. teft ventricular hypertrophy 
and Icft ventriclliar systolic dysfunction) and chapter 5 contains studies on the assodation 
between gcnetic polymorphisms and heart failure. In chapter 6, a pharmacogcnetic study is 
presented. The potential interaction between ACE-inhibitor therapy and the ACE Insertion/ 
Deletion polymorphism in the predietion of incident heart failure and dcath is studied in a 
subgroup of subjects with hypertension. Finally in chapter 7, methodological limitations of 
pharmaco-epidcmlologic and genetic association studies arc discusscd and a perspectivc is 
gi"cn on future directions and implications of pharmacogenetic research. 
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Quantifying the heart failure epidemie: prevalenee, 
incidence rate, lifetime risk and prognosis of heart 
failure. The Rotterdam 5tudy 
Chapter 2.1 
Abstract 
Objective: To determine the prevalenee, incidence rate, lifetime risk and prognosis of heart 
failure. 
Design: Prospective population-based cohort study. 
Setting and pal1icipants: 7,734 participants of the Rotterdam Study. 
Main outcome measures: Heart failure was iclcntified through general practitioner's medical 
records and hospital discharge letters. Presence of heart failure was eletermined according 
to criteria of the European Society of Cardiology. Jnformation on vital status was obtained 
from municipal health authorities and genera I practitioners. 
Results: Prevalenee was higher in men than in women ancl increased with age from 0.9% 
in subjects aged 55-64 years to 17.4% in those aged ;;;: 85 years. The incidence rate of heart 
[ailure was 14.4/1000 person-years (95% Cl 13.4-15.5) and was higher in men 07.6/1000 
man-years, 95% Cl 15.8-195) than in wamen (12.5/1000 woman-years, 95% Cl 11.3-13.8). 
The incidence rate increased with age [rom 1.4/1000 person-years in those aged 55-59 years 
to 47.4/1000 person-years in those aged;;;: 90 years. Lifethne risk was 33% for men ancl 29010 
for women at thc age of 55. Survival after incielent heart failure was 86% at 30 days, 63% at 1 
year, 51% at 2 years anel 35% at 5 years of follow-up anel was similar for men anel women. 
Conclusions: The prevalence anel inciclence rate of heart failure are high. In inclividuals 
aged 55 years, almast 1 in 3 wiII develop heart failure during their rcmaining lifespan. 
Heart [allure continues to be a fatal disease, dcspite advances in trcatment, with only 35% 
surviving 5 years after the flrst diagnosis. 
18 
QuantifyJng the heart (allure epidemie 
Introduction 
Heart failure constitutes a major public health burden in the western worIel. Since incidence 
rates appear to remain stabie over the years, at least in men [1], prevalence estimates of 
heart failure arc bound to increase as the population ages. Hospitalisation rates for heart 
fallure have increased considerably, peaking in the earl)' 1990s [2}. The proportion of 
patients having multiple hospital admissions is rising. In addition, large observational snldies 
have failed to show any substantial change in the prognosis of heart failure in the general 
population, despite advances in treatment BI. Hospitalisation rales do not necessarily reflect 
the true incidence and prevalence of heart failure in the general population, as only the 
more serious stages of this syndrome require in-hospita I evaluation and treatment. Although 
data regarding heart failure incidence, prevalence and prognosis in the community arc 
vital, few large prospective population-based studies have been published lhat provide 
recent estimates, especially in European populations. Furthermore, most recent population-
based estimates originate from relatively short-term studies [4-61, except for the Frdminghan1 
Heart Study [11 and Cardiovascular Health Stud}' [71, both performed in the United States. 
The diagnosis of heart failure is complex. Signs and symptoms are not specific and a gold 
standard to assess the presence of this diseasc is lacking. Previously published studies 
have used various criteria to assess the presence of healt fallure. The European Society of 
Cardiology has therefore provided guidelines for the dia gnosis of heart failure, for use in 
clinical practice and epidemiological surveys 181. According to these guidelines, objective 
evidence of cardiac dysfunction has to be present to establish the presence of heart failure, 
in addition to typical symptoms (e.g. brcathlessness) suggestive of tiie diagnosis. 
This study was designcd to calclIiate the prevalence, incidence, and lifetimc risk of heart 
failure in participants of the Rotterdam Study, a large prospective population-based cohort 
study with more than ten years of follow-up. In addition, we studied the prognosis of cases 
of incident heart failure. 
Methods 
Setting and st"dy pop"lation 
The Rotterdam Stud}' is a population-hased prospective cohort study of cardiovascular, 
locomotor, neurologie and ophthalmologic diseases in the clderly f9]. All inhabitants of 
Ommoord, a suburb of Rotterdam in the Netherlands, who were 55 years of age or older 
were invited to participate. Of the 10,275 eligible subjects, 7,983 agreed to pa11icipate (78%). 
The l\'ledical Ethics COllunittee of the Erasmus ]\'Iedical Centre approved the stud}'. The 
baseline examination was conducted bel ween Jul}' 1989 and July 1993. Participants were 
visited at home for a standardized questionnaire and were subsequently exal1lined at the 
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research ccntre. Since the start of the Rotterdam Study, cross-scctional surveys have been 
carried out periodically. In addition, participants are continuously monitored for major 
events that occur during follow-up, including heart fallure, through automated linkage 
with files from general practitioners. Information on vital status is obtained regularly from 
municipal health authorities in Rotterdam and from the general practitioners working in 
the study district of Ommoord, and was complete for all participants untll January 1, 2000. 
Furthermore, all drug prescriptions dispenscd to participants by all pharmacics in the study 
area are routinely stored in the database. 
Ta obtain recent estimates, the point prevalcnce of healt failure was determined at thc 
1H of January of 1997, 1998 and 1999. Calculations were perfoffiled in all participants of 
the Rotterdam Stud)' who were alive and present at January 1 of each of these years. Four 
participants 'were exduded because of missing medical records. For estimation of incidence 
rates and lifetime risks, the study population comprised 7,734 subjects who were free from 
heart failure at baseline. Subjects were followed from baseline until the flfst of one of the 
following: a diagnosis of incident heart failure, death, 1055 to follow-up «1%), date of last 
collection of information for determination of heart failure, or January 1, 2000. The date of 
last information on heart failure status preceded Janumy 1, 2000 for 14.4% of participants. 
For the calculation of survival estimates, incident heart failure patients were followed from 
the date of incident heart fallure until the earliest of death, removal from the study area, or 
January 1, 2000. 
Heart failure assessment 
Assessment of prevalent heart failure at the baseline examination in the Rotterdam Study 
has been described in detail earlier [101. BrieHy, a vaHdated score was uscd, similar to the 
definition of heart failure of the European Society of Cardiology [81. This score 'was based on 
the presence of at least two symptoms suggestive of heart failure (shortness of breath, ankte 
S'welling alld pulmonary crepitations) or use of medication for the indication of heart failure, 
in combination with objective evidence of cardiovascular disease. Questions on indication 
of cardiovascular medication and breathlessness were lacking at the start of lhe Rotterdam 
Study, but were subsequently addecl. Consequently, this information was obtained in 
only 5,540 participants. In addition) prevalent heart fallure cases were obtained through a 
database containing hospital discharge diagnoses from all hospitals in the Rotterdam area as 
ofjanuary 1, 1991. Records from this database were Iinked fo the Rotterdam Study database. 
For potential cases of heart fallure identified in this way, copies of discharge letters were 
requested. Furthermore, all medical records were screened in retrospect for the occurrence 
of heart failure in the majority (97%) of participants of the Rotterdam Study. With these 
duee methods, information on the presence of heart fallure at baseline was available for all 
participants. 
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Cases of incident heart failllre were obtained by continuously monitoring participants of 
the Rotterdam Study for the occurrence of heart fallure during follow-up through automated 
linkage with files from general practitioners. All available data on these events, sllch as 
hospital discharge letters and notes from general practitioners, were copied from the medical 
records. Apart from this systematic follow-up procedure, we used verified hospital discharge 
diagnoses for case finding, gathered from aU hospitals in the Rotterdam area as described 
above. The date of incident heart failure was defined as thc day of the first occurrence of 
symptoms suggestive of heart failure, obtained from the medical records, or the day of 
receipt of a first prescription for a loop diuretic or an ACE-inhibitor, whichever came flrst. 
The diagnosis of heart fallure was classified as definite, probable, possible or unlikely. 
Definite healt failure was deflned as a combination of heart failure diagnosed by a medical 
specialist anel the presence of typical symptoms of heart failure, such as breathlessness at 
rest or during exertion, ankle oedeilla anel pulmonary crepitations, conflrmed by objective 
evidence of cardiac dysfunction (chest X-ray, echocardiography). This definition is in 
accordance with the criteria of the European Society of Cardiology [S]. Probable hc;:ut faîlure 
was defllled as heart failure diagnosed by a general practitioncr, with at least two typical 
symptoms suggestiye of heart failure, and at least 1 of the following: histor)' of cardiovascular 
disease (e.g. myocardial infarction, hypertension), response 10 treatment for heart failure, 
or objective evidence of cardiac dysfunction, while symptollls could not be attributed to 
another underlying disease, such as chronic obstructive pulmonary disease. Two research 
physicians independently classified all information on potential heart failure events. If there 
was disagreement, a consensus was reached in a separate session. FinaIly, a cardiologist 
yerified all probable and possible cases, and all cases in which the two physicians could not 
reach consensus. If the cardiologist disagreed with lhe research physicians, the cardiologist's 
judgment was consielered decisive. The research physicians and tbe cardiologist based 
their decisions on the samc data. Only definite and probable cases were included in the 
analyses. 
Statistical analysis 
Prevalence ofheart failure per calendar yearwas calclilated by dividing the number of persons 
with prevalent heart failurc by the number of subjccts present in the study population at 
)anuaty I of each caleilclar year. 95% confidence intervals (CI) were cakulated with \X'iJson's 
(score) methad for a binomial proportion. Prevalence estimates were caklilated for men and 
wamen separately and in IQ-year age categories. The incidence rate of heart fanure was 
detennined by dividing the number of cases of incident heart faiJure by thc total number 
of person-years accumulated in the study population without healt failure at baseline. The 
95% Cl arollnd the estimates were calculated bascd on the Poisson distribution. Incidence 
rate estimates were cakulated by gender and age (5-ycar categories), 
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Ta calculate the risk to develop heart failure over time, cOInpeting risk of death was taken 
into account. Pirst, we calculated heart failure free survival at different ages with the Kaplan-
Meier method, using incident heart fallure and mortality data from the study COhOlt. Age 
at baseline was used as entty time varia bIe and age at the end of follow-up, incident heart 
failure, or death, as fallure time varia bIe. Bath death and incident heart failure were classified 
as fallures. Second, the cumulative absolute risk of heart fallure over a perioel was calculated 
as the integrated product of the age-specific heart fallure incidence rates and heart faiJure 
free survival UH The risks of hemt fallure over time were calculated for the total population 
anel for men and women separately at the ages of 55-, 65-, 75-, and 85 years. 
The prognosis of heart fallure was determined in 725 subjects with incident heart failure 
during follow-up. Survival after incident heart fallure OO-day, l-year, 2-year anel 5-year) was 
calculated using the Kaplan-lvleier methad. SlIIvival was also detennined after exclusion of 
patients who died in the fi.rst 30 days, therehy excluding those with a first diagnosis of heart 
fallure on the day of their eleath and the most severe cases of heart fallure. \X'e used Cox 
proportional hazards regression analysis to study gender differences in survival, adjusted 
for age, 
Results 
A totalof 245 prevalent heart fallure cases (88 men, 157 wamen) were identified at baseline 
in the Rotterdam Study. In the remaining study population (n""7,734), we identified 725 
incident cases of heart fallure (335 men, 390 wamen), of whom 673 were cIassified as 
elefinite-, and 52 as probahle cases. The median follow-up time in this pop1.J!ation was 7.1 
years (interquartile range 5.7-8.0) and we had in total 50,268 person-years of observation. 
The majority of our study population was female (61%) and mean age at baseline was 70.4 
years Cstandard deviation 9,7 years) .. Mean age at the onset of heaet fallure was significantly 
higher in wamen than in men (82.5 years and 77.5 years respectively). 
Prevalenee 
Point prevalence of heart fallure was determined at ]anuary 1 of 1997, 1998 anel 1999 and 
was 6.4% (95% cr 5.8-7.0), 6.7% (95% cr 6.1-7.4) and 7.0% (95% cr 6.4-7.7), respectively. 
Meao age of the study population iocreased from 73.3 years in 1997 to 74.5 years in 1999. 
Prevalenee was higher in men than in wamen (e.g. 1998: men 8,Cr'A>, women 6.0%). There 
was a sharp rise of prevalence estimates with age. For example, in 1998 point prevalenee 
incrcased [rom 0.9"10 (95% cr 0.5-1.6) in subjects aged 55-64 yea,s, 4.0% (95% cr 3.3-4.8) in 
subjects "ged 65-74 yea,s, 9.7% (95% cr 8.4-11.1) in those aged 75-84 yea,s to 17.4% (95% 
Cl 14.8-20.4) in those aged 85 years or over. 
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Incidence rate 
The overall incielence rate of heart [allure was 14.4/1000 person-years (95% Cl 13.4-15.5) 
anel was significantly higher in men 07.6/1000 man-years, 95% Cl 15.8-19.5) than in wamen 
(12.5/1000 woman-years, 95% Cl 11.3-13.8). The incidence rate increased with agc [rom 
1.4/1000 person-years in those aged 55-59 years to 47.4/1000 person-years in those aged 
90 ycars or older Ctable 1). This increase with age was evident [or bath genders (figures la 
and 1b). Incidence rates were on average approximately two times higher in men than in 
wamen in each agc category, except for the youngest (55-59 years), in whieh 110 male cases 
occurred. 
Table 1.lncidence rates for heart failure per 5-year age category. 
Age (ategory Number of Incident cases 
55-59years 4 
60-64years 27 
65-69years 56 
70-74years 113 
75-79years 136 
80-84years 166 
85-89years 137 
~90years 86 
"* per 1000 person-years 
Period and lifetime risk 
Person-years 
1888.6 
871l.6 
10l92.1 
9661.6 
8012.8 
5513.5 
l269.0 
1813.5 
Incidence rate lf (95%0) 
1.4 (05-l.l) 
l.I{1.H4) 
5.4 (4.J.6.9) 
11.7 (9.7-14.0) 
17.0 (14.l-20.0) 
lO.1 (21.8-l5.0) 
41.9 (l5.H9.4) 
47.4 (l8.6-58.2) 
The period and Iifetime risks for all subjects, and for men arrel women separately, at the 
ages of 55-, 65-, 75-, and 85 years are shown in table 2. All estimates account for the risk of 
competing causes of death. The lifetime risk of heart fallure for a person aged 55 was 30.2%. 
For a man aged 55 years the Jifetimc risk was 33.0% and for a woman of the same age it was 
28.5%, Lifetime risk of heart failure decrcaseel \vith age in both sexes to approximately 23% 
in persons who reached 85 years of age without having heart failure. Stratiflcation by gender 
sllO'wed that lifetime risks were higher in men than wamen at ages 55 ta 75. In subjects 
aged 85 years, however, lifetime risks for elevelaping heart fallure were comparabie and 
slightly higher in wamen Ctable 2 and figure 2). Cumulative risks in sllOrter time intervals 
(5-25 years) increased with age and \Vere higher in men at all ages, reflecting the higher 
incidence rates in men. 
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Table 2. Cumulative risk of heart failure in different time periods tor participants aged 55',65',75·, and 85 years; total and 
slratified bygender. 
Period risk* (years) 
Ag, 10 15 20 25 30 35 tifetime 
Toral 
55 0.6 2.1 4.5 9.2 14.7 21.8 27.2 30.2 
65 2.6 7.6 13.6 21.3 27.1 30.3 
75 7.5 17.2 24.6 28.7 
85 14.8 23.1 
Men 
55 0 2.8 6.8 tJA 19.6 27.9 31.6 33.0 
65 4.2 1104 18.2 27.1 31.2 32.7 
75 9.5 21.0 27.7 29.8 
85 16.2 2204 
Women 
55 1.0 1.8 3.0 6.2 11.2 17.5 24.3 28.5 
65 1.2 4.6 10.0 16.7 24.0 28.5 
75 6.2 14.1 22.6 27.9 
85 14.3 233 
*" numbers are percentages. Competing risk of death Is taken into account. 
Prognosis 
of the 725 persons with incident heart failure, 445 subjects died following the diagnosis (198 
men and 247 wamen). l'\'ledian survival was 2.1 years (range: 1 day- 9.0 years). Cumulative 
survival was 86% at 30 days after the onset of heart [allure (95% Cl 830/0)-88%), 63% at 1 
year (95% Cl 59'1/0)-66%), 51% at 2 years (95% Cl 47%-55%) and 35% at 5 years (95% Cl 31%-
390Al). There was na significant difference in clunulative survival after incident heart failure 
between men anel wamen (figure 3, log rank test: p=0.15). Age-adjusted survival in Cox 
proportional hazards analysis was similar in men and women (hazard ratio female gender: 
0.88,95% Cl 0.72-1.07). After exclusion of patients who died in the fi.rst 30 days, 1-, 2- and 
5-year sun'ival were 73%, 59010 and 41% respectively. Age- anel geoder adjusted sun'ival was 
significantly lower in subjects with incident heart failure than in the remainder of our study 
cohort (hazard ratio 4.3, 95% Cl 3.8-4.8). 
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Figure 1 a. Age~spedfic male incidence rates (/1000 man years) and 95% confidenee band. 
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Figure 1 b. Age-specific female inddence rates (/1000 woman-years) and 95% confidenee band. 
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Figure 3. Kaplan -Meier survival curve for incident heart failure cases stralified by gender. 
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Discussion 
In this long-term prospective population-based cohort study, we found that heart failure 
prevalence, incidence and risk are high. The incidence rate was significantly higher in men 
than in women and increased with age from 1.4/1000 person-years in subjects aged 55-59 
years to 47.4/1000 person-years in those aged 90 years or older. Our study showed that 
the probabHity for an individu al aged 55 years to develop heart failure dUfing his or her 
remaining lifetime is 30.2%. As expected, lifeti1lle risk decreased at older ages, probably 
because of depletion of susceptibles and a shortcr remaining lifespan. In OUf study, lifeti1lle 
risk of heart failure was higher in young men than in young women. In the older individuals, 
however, lifeti1lle risks were practically the same in men and women. Heart failure remains 
a deadly disease for both genders, with a 5-year sun'ival of only 35%. 
Our age-specific incidence rate estimates are similar to the results from an investigation 
in a general practitioner's database in the United Kingdom (12), but differ somewhat from 
other recent population-based studies. Estimates in the Cardiovascular Health Study were 
higher in all age categories. Although this study also used clinical criteria for the assessment 
of heart failure, the investigators selected their participants through a Medicare eligibility 
list [7]. This may explain some of the difference with our snIdy, whieh was performed 
in an unselected population. Besides differences in selection criteria and poplIlation 
characteristics, comparison between illvestigations is further complicated because studies 
have used different criteria to assess the presence of hemt failure. For example, in the 
Framingham Heart Study, clinical criteria were used lhat do not include evidence of cardiac 
dysfunction on echocardiography, which is an important tooi in heart failure diagnosis in 
clinical practiee [1]. Therefore, in the Framingham Heart Study, the true incidence of heart 
failure may have been underestimatcd. In the Hillingdon heart fallure study) potential cases 
were identified on thc basis of referrals by general practitioners of patients with suspected 
heart failure [6], Although similar criteria were used in this stud)', age-specific incidence 
was sOlllewhat Iower, possibly because not all potential cases were rcferred. Age-spccific 
prevalence estimates of heart failure were also somewhat higher in the Cardiovascular 
HeaIth Study, especially at younger ages [13]. Slightly lower prevalence estilllates per age-
category were faund in a study in residents of Olmsted County, lvIinnesota and in the 
Framinghalll Heart Study [4, 14]. Both used Framingham criteria for case asccl1airunent. The 
Echocardiographic Heart of England Screening study used criteria based on the guidelines 
of the European Society of Cardiology and fOllIld age-specific prevalenee estimates of heart 
failure that were similar ta ours [5]. 
Only one other study, the Framingham Heart Study) calculatcd lifetime risks for heart 
failure [151. Lifetime risk for the devclopment of heart failure in this study was approximately 
20% and was, in contrast to ollr findings, indcpendent of age and gender. The investigators 
did not find a decrease in Iifetime risk at older ages, which was attributed to an increasing 
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incidcnce with advancing age, outpacing the incrcasing mortality from competing causes. 
However, na age-limit was set for thc calculation of cumulativc risks in the Rotterdam 
Study, while in the Framingham Heart Study cumulative risks were calculated until thc age 
of 94 years. Ftil1hcrmore, lifetime risks in the Framingham Study were calculated from 1971 
through 1996, whlle in the Rotterdam Shldy they were calculated from 1989 through 2000. 
Therefore, changes in mortality from competing causes over calendar time ma)' explain 
some of the differences between the two studies. Furthermore, although questioned by 
some U6J, improvements in m)'ocardial infarction treatment over time might account for the 
higher inciclence rates of heart fallure that we found. 
Heart fai/ure is a fatal disease, despite advances in treatment over the past 15 years [31. 
\XTc found no differences between men and wamen in heart [allure prognosis. Our survival 
estimates are very similar to those found in duee other recent populatian-based studies 
U, 12, 17], However, campared ta heart fallure mal1ality in hospîtal-based studies U8-20], 
prognosis in aur population-based stud)' was better, probably as less severe cases of heart 
failure were alsa included. As thc diagnasis of heart failure is difficult, some studies applied 
scores for the classification of heart failure, while other shldies used clinical definitians 
ar relied on haspital discharge cades, Therefore, a large part of the differences between 
studies may be explained by varying criteria. Besides a baseline screening in the majority of 
participant.·, using a vaHdated score, we applied clinical criteria far heart failllre throughout 
the Rotterdam Stud)', based upon gllielelines of the European Society of Cardiology. Apart 
from hospital discharge letters, medical records [rom general practitioners were available 
for assessment of cases, Consequently, also less severe cases were induded in our study. 
However, some underestimation of the true prevalence and incidencc ma)' have been 
caused by the fact that aid and diseascd individuals were less likely to panicipate in the 
Rotterdam Stud)'. ArlOther limitatiol1 of our study is that we did not distingllish between 
lInderl)'ing causes of heart failure, Among elderl)' patients, systolic hypertension and cardiac 
h)'pertroph)' ma)' be more important than ischemie heart disease [8J. 
In condllsiol1, heart [allure prcvalence and incidencc are substantiaL As age is an 
important risk factor tor heart failure, the burelen of this disease on health care s)'stcrns in 
western societies increases as these populations age. In individuals aged 55 )'ears, 30% wiJl 
develop heal1 failure during their remaining lifespanj i.e, almast one out of duee individuals. 
Heart failurc continues to be a fatal disease, elespite advances in treatment, with anI)' 35% 
surviving 5 years aftel' the fi.rst diagnosis, Prevention of the development of heart failure in 
high-risk patients is therefore fundamental. 
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Abstract 
Background: Len ventricular hypertrophy (LVH) is an independent prerlictar of cardiovascular 
disease. Although voltage amplitudes on the clectrocardiogram (ECG) vary aeeording ta sex 
and age, referenee values for LVH arc laeking in the elderly. \\7e established age- and sex-
specifk normallimits in elderly subjeets for the Cornell, Sokolow-Lyon and l2-lead summed 
QRS voltage and voltage-duration products. Additionally, the prognostic value of all partition 
values for ECG-LVH was tested for heart fallure and cardiovascular mortality. 
lvlethods: The Rotterdam Study is a population-based cohort study in 7983 patticipants aged 
55 years or oIder. 12-lead ECGs were digitally reeorded at baseline for 6193 participants. 
Age- and sex-specific normallimits were ealculated parallletrically in 2915 apparently healthy 
participants. The 98th percentile was taken as the upper limit of norlllal. The prognostic value 
of pat1ition values for ECG-LVH was assessed wUb Cox proportional hazards analysis. 
ResuIts: Newl)' assessed reference vaIues far ECG-LVH were higher than traditional partition 
values, except for the Cornell voltage in men. 98lh Percentiles were lower in wamen than 
in men up to the age of 75 years. In wamen, narmal lilllits increased with age. In contrast, 
Sokolow-Lyon- and 12-lead sUlllmed voltage (-duration) criteria decreased with advancing 
age in men, whereas the Cornell voltage (-duration product) was not substantially influenced 
byage. ECG-L\'H was significantly associated with heart [ailure and cardiovascular mortality 
for all partition values. The strongest assaciation was seen for the Cornell voltHge-duration 
product defined aceording to the ncw narmal limits. Exccpt for the Sokolow-Lyon voltage-
duratian product, all narmal Bmi!:..., estabHshed in the present study silOwed stronger 
assaciatians for ECG-LVH than the traditional partition vallles. Differences were marc 
pronounced in women than in men. 
Condusian: \Ve provjde age- and scx-specific normal limits far three commanly used ECG-
LVH valtage equatians and their voltage-duration products in normal elderly individuals. 
ECG-LVH dctected with these normal limits was associated with bath heatt failure and 
cardiavascular mortality for all voltage criteria. 
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Introduction 
Over the past years, evidence has increased that left ventricular hypertrophy (LVH) 
is astrong and independent risk factor for cardiovascular morbidity anel mOllaHty [1-41. 
Echocardiography is considered to be a gold standard for the detection of LVH. Howcvcr, the 
greater availability, lower costs and higher reproelucihility of the electrocardiogram (EeG) 
tend to favor its use in the assessment of LVH in large observational studies and clinical trials 
ancl support its wide application in clinical practice, In addition, due to technical problems, 
it is often difficuit to obtain echacardiographic data of sufficient quality, particularly in the 
elderly [5, 6]. Bath methads independently predict mOllality, anel represent, for same part, 
different manifestations of disease [7, 8]. 
blost available methoeIs for the detection of LVH on the ECG utilize fixed voltage criteria, 
which are neither age- nor sex-specific. Evaluations of these criteria have largely been carricd 
out manuaUy and in clinical populations. Sources of normallimits for EeG measurements are 
scarce and reference values for common LVH-voltage criteria in healthl' elderll' inelividuals 
are lacking [9, 10]. Aging C<luses anatomie and functional changes in the cardiovascular 
system, which mal' affect ECG findings {IH Furthermare, mcn have significantll' langer QRS 
durations and greater ECG-voltages than women. All EeG criteria have a lower accura.cy 
for the detection of LVH in women, even when diffcrences in partition valuc selection are 
taken into account [12I. As bath agc ancl sex influence voltage amplitudes on the EeG, the 
traditional partition values used to detect LVH may not be va lid in thc elderly. Therefore, we 
pcrformed a study in an apparentll' healthy subgroup of participants of the Rotterdam Study 
to establish age- and sex-spccific reference values in the elderll' for tluee coml1lonll' used 
voltage criteria - Cornell voltage, SokolmY-Lyon voltage and 12-lcad sum of QRS voltage 
- anel their eluration prodllcts. In addition, the association between LVH cIassifted according 
to these reference values and previollsly published partition values were sntdied in relation 
to cardiovascular mortality and the risk of heart fallure. 
Methods 
Setting 
TIle Rotterdam Study is a population-bascd prospective cohort study of cardiov<lscular, locomotor, 
neurologie, and ophthalmologic diseases in the elderll' f13I. All inhabitant.'l of Ommoord, a 
suburb of Rotterdam in thc Netherlands, who were 55 ycars of age or older were invited and 
7983 agrced to participate 0&1-'0). The baseline examination was conducted between 1990 anel 
1993. Participant", were yisited at home for a standardized qllestiOIUlaire anel were subsequently 
examincd at lhe research center, where a 12-lead EeG was recorded. Information was collected 
on age, sex, present health staniS and medical history, inchtding previous myocardial infarction, 
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coronal)' bypass surgery and coronaI)' angioplasty. All reported myocardial infarctions were 
verified with the medical records, Hypertension was detined as use of antihypel1ensive 
meelication for the indication high blood pre&"iure, or as a systolic blood pressure of 160 
mm I-Ig or over andlor a diastolic blood pressure of 100 mm Hg or over (i,e. moderate to 
severe hypertension). Diabetes mellitus was defined as the use of anti-diabetic medication, 
or as a random or post-load senun glucose level higher than 11.0 mmoIJl. Information on 
medication use was assessed during the home interview. Patticipants subsequently showed 
all their cUITently used medication at the research center, where a physician determined the 
indication for ('ach drug. Since the start of the Rotterdam Study, follow-up examinations have 
been canied out periodically. In addition, paltidpants are continuously monitored for major 
events that oecur during follow-up, including heart fallure, through automated linkage WiÛl 
files from general practitioners. Information on vital status is obtained regularly from municipal 
healtll authorities in Rotterdam and from general practitioners working in tbe study district of 
Ommoord, anel was complete for all pal1idpants, 
ECG measurementl 
A 12-lead restÎllg ECG was recorded with an ACfA electrocardiograph (ESAOTE, Florence, 
Haly) at a sampling frequency of 500 Hz anel stored digitally for 619307.6%) participants. 
r..Hssing ECGs were mainly due to technical anel logistic problems. ECGs were processed 
by the Modular ECG Analysis System (A-JEANS) [141. This s)'stem computes a represcntative 
averaged beat for each of the 12 leads from which ECG measurements are dcrived. QRS 
duration is determined from the first QRS onset in any of the 12 leads to the last QRS offset 
in any lead. MEANS has been evaluated eX1:ensively, showing good performance [14, 151. 
Tluee widely used criteria fOf the detection of LVH in adult cardiology were examined: 
lhe Sokolmv-Lyon voltage: sum of the amplitudes of the S wave in lead VI and the R wave 
in lead V5 or v6 (whichever is longest) [161, the Cornell voltage: sum of the amplitudes of 
the R wave in lead aVL and the S wave in lead V3 [17] and the 12-lead slImmed QRS voltage: 
slim of peak-to-peak QRS amplitudes in aH 12 leads [18]. In addition, voltage-duration 
products were calculated by muhiplying the voltage with QRS duration. Voltage-dllration 
prodllcls have been found to improve the acclln1cy of the identification of LVH on the ECG 
[19, ZO}, 
(aleulation of normal partition valuesforE(G·lVH 
Study population 
For thc estimation of normallimits for ECG-LVH, a seell1ingly healthy subgroup of pa11icipants 
of the Rotterdam Study was selected without a known history of cardiovascular disease, and 
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for whom baseline data were complete. Participants with a history of myocardial infarction, 
heart fallure, coronary bypass surgely or coronaf}' angioplasty were excluded from our 
study population. ather exclllsion criteria werc the presence of hypertension, diabetes 
mellitus and the use of ACE-inhibitors, calcium antagonists, diuretics, f3-blockers and other 
antihypertensive drugs. Plots of all ECGs displaying wave onsets and ends as fOlmd by 
MEANS were visually checked. ECGs with complete right- or left bundte-branch block, 
\Volff-Parkinson-\V'hite (WPW) syndrome, pacemaker rhythm or waveform recognition 
errors (rnainly due to excessive noise) were also removed from the dataset, leaving a total 
study poplllation of 2915 participants. 
Normallimits estimation 
Calcl.J!ation of age- and sex-specific normal Iimits for ECG-LVH criteria was performed as 
described earlier {21J. Thc 98th percentile of the measurement distribution was a priori chosen 
as thc upper limit of normal. Briefty, a linear regression analysis on age was perfOl'llled 
in each age group. Pcrcentiles were estimated parametrically on the residllals. Possible 
non-gallssianity of the residu als was removed using a transformation procedure, iteratively 
eliminating asymmetf}' (skewness) and peakcdness (kurtosis) in two stages [22]. \Ve llsed 
the Kolmogorov-Smirnov methoeI to test the gaussianity of thc transformed distribution. 
Estimated percentiles and their 95% confldence intervals (CI) wcrc back-transformed to the 
original unit of measurement and presented according to sex anel age groups. 
In addition to this tabular presentation of normal lintits according to sex and age 
groups, age-dependent curves were created for men and women separately, presenting 
the estimated normallimits in a contimIOus form. To this end, the two-stage transformation 
procedure was applied in windows of 200 mcasurements each, moving along the age-axis 
with a stepsize of one measurement. For each window position the 98111 percentiIe and 95% 
Cl were calclliated and rclated to the median of the age values included in the window. 1'0 
allow for estim..1.tes at young ages in our study population, the procedure started with a smal! 
initial window that was enlarged until 200 measurements were included. polynomial curves 
were fitted tlu'ough the point estimates of the 98lh percentiIe values to obtain normal Iimits 
that smooth1y change with age. The order of the polynomials was dctermined by visual 
inspection of thc fit, selecting the lowest order that yielded Curves remaining within the 95% 
Cl of the 98lh percentile values. 
Prognosis of ECG-iVH for different partition va/ues 
\Ve additionally tested the prognostic value of our newly estimated agc- and sex-
specifIc reference values and of previously published partition values in heart failure anel 
cardiovascular mortality. Presence of ECG-LVH according to the different partition values 
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was assessed for all 6193 participants of the Rotterdam Study with a digitally stored ECG. 
The following 'traditional' partition values \Vere llsed: SokolO\v-Lyon voltage ~ 3500 !lV [161, 
Sokolmv-Lyon voltage-duration product >322.4 !tVs in women and >367.4 ~lVS in men [23], 
Cornell voltage >2000 ~lV in women and >2800 ~lV in men [17], Cornell voltage-dllration 
product >244 ~lVS in men or (Cornell voltage + 600 !tV) x QRS duration >244 ~tVS in women 
[19,24], 12-lead sum >18499 !tV in women and >19530 ~lV in men [23], l2-lead sum product 
>1683.8 !tVs in women and >1957.9 !lVS in men [23]. 
Heart lailure 
For the prognostie analyses with regard to heart failure, the study poplliation compriscd 
5575 subjects out of the 6193 persons with an ECG, who were free from hemt fallure at 
baseline arrel had no bundle-branch block, \'\'P\'\' syndrome or pacemaker rhythm. Subjects 
were followed from baseline until the first of one of the following: a diagnosis of incident 
heart failure, death, toss 10 follow-up, date of last collection of information for determillatioll 
of heart fallure, or January 1, 2000. Cases of incident heart failure were obtained by 
cOlltinuously monitoring participants of the Rotterdam Study for the occurrence of heart 
failure during follow-up through automated lillkage with files from genera I practitioners and 
through a hospital discharge diagnosis database. All available data on these events, such 
as hospital clischarge letters and notes from generat practitioners, \Vere copied from the 
medical records. Heart failure was defined in accordance with the criteria of the European 
Society of Cardiology, whieh include the presence of typica! symptoms of heart failure, sllch 
as Plilmonary crepitations, and objective evidence of cardiac dysfunctioll [251. 
Cardiovascular mortality 
To study the predietive vallIe of ECG-LVH accordillg to the different partition values for 
cardiovascular mortality, we included 5740 of 6193 individllals with an ECG, without bundIe-
branch block, \'{lP\,\' syndrome or pacemaker rhythm. Subjects were followed frorn baseline 
until the carliest of death, loss to follow-up, or January I, 2000. Informatioll on vital status 
was obtained from municipal health authorities and from general practitioners working in the 
snldy area. Two research physicians indcpcndently coded potential cardiovascular dealhs 
according to the 1011\ version of the International Classification of Diseases (lCDI0). If thc 
research physicians disagreed, a careliologist reviewed the event anc! gave the definitive code. 
The following ICDI0 codes were used in our analyses to deAne cardiovascular mortalily: 120 
(angina pectoris), 121 (acute myocardial infarction), 122 (subsequent myocardial infarction), 
123 (complications following acute myocardial infarctioll), 124 (other acute ischemie heart 
diseases), 125 (chronie ischemie heart disease), 146 (cardiac arrest), 149 (other cardiac 
arrhythmias), 150 (heat1 fallure), anel R96 (olher suelelen death, cause unknown). 
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Statistica I analysis 
\Ve used Cox proportional hazards regression analysis to calculate hazard ratios (HR<;) and 
95% Cl for the estimation of relative risks of heart failure and cardiovascular mortality for 
LVI-I as determined by the different partition values. Analyses were adjusted for age and 
sex. 
Results 
Caiculation of normal partition values for [(G-lVH 
Table "1 presents general characteristics of the healthy subgroup of 2915 participants who 
were used to calculate normallimits. [ ... lean age was 67 years and 5~'Ó of our study population 
was female. Body mass index and blood pressure measurements diffcred slightly between 
men and women. l\'lean voltages and voltage-duration produets were significantly higher 
in men than in women for all criteria. There were marked differences between men and 
women in the association of age with voltage criteria. Mean voltages and voltage-duration 
produets decreased with advancing age in men, except for the Cornell voltage and its 
duration product. In women, mean voltages increascd significantly with age, except for the 
Sokolmv-Lyon voltage-duration product Ctable 1). 
Table 1. Baseline characterislics of an apparently healthy sub-population of the Rotterdam Study stratified by sex. 
Variabie Men (n=1196) Women (n=1719) 
Mean (SD) Mean (SD) 
Age (years)* 66(7.6) 
Body mass Index (kg/mI). 25.5 (2.9) 
Syslo!ic blood pressure (mmHg)· IJl (15.5) 
Diaslo1Îc blood pressure (mmHg)* 73(9.8) 
Sokolow-Lyon blV)- 2406.6(714.2) 
~agel -12.1(-17.3- -6.8) 
Sokolow-Lyon (~lV) xQRS {S)l 244.4 (73.6) 
~agel -1.l (-1.8 --0.7) 
(omelI (~lV)- 1420.1(527.7) 
~agel -0.32 (-4.2-3.6) 
(ornelI (rIV) ,QRS (s)' 145.7 (59.4) 
~agel -0.06 (-0.5-{).4) 
U-lead summed (~lV)* 14926.3 (3243.5) 
~ agel -52.7 (-76.6 --28.7) 
U-lead summed (~tV) x QRS (5)- 1521.2 (365.4) 
~agel -5.7 (-8.4 --3.0) 
l!- mean difference between men and wamen: independent samples t~test: p<O.OS 
t linear regressian madel:dependent variabIe: microvoltage, independent variab!e:age; ~ (95%(1) 
67(8.4) 
25.9 (3.8) 
130(16.6) 
71 (9.5) 
2209.3 (638.3) 
3.6(0.06-7.2) 
207.3 (61.4) 
0.3 (-0.01-0.7) 
1285.3 (487.8) 
16.6 (14.0-19.2) 
)22.2 (52.4) 
1.6(1.3-1.9) 
13616.0 (2846.5) 
50.6 (34.8-66.4) 
1282.9 (301.2) 
4.9 (3.2-6.5) 
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Table 2 presents the normallimits that we estimated for each voltage index for ECG-LVH, 
stratified by age and sex. In figures 1-3, estimated reference values for the duee voltage 
criteria are also presented in age-dependent curves for men and women separatcly. In men, 
normallimits decreased with age for the SokolO\v-Lyon voltage and 12-lead sununed voltage 
and for their eluration products (tabIe 2, figures lB and 3B). There was a slight increase in 
normai limits with age for the Cornell voltage-duration product, while the 98lh percentiIc 
for the Cornell voltage remained relativcly sta bIc with age Ctable 2, figure 2B). Except for 
the Cornell voltage, normal Iimits for men found in the present stud)' \Vere higher than the 
traditional partition vaiues at all ages. In women, normai limits increased with age for all 
ECG-LVH criteria. Normal partition va lues were greater than the traditional values for every 
voltage equation at all ages in women. Age-specific reference values were lower in women 
than in men, except in the oldest age group, In these participants, aged 75 years or older, 
98th percentiles for the common voltage criteria in wamen were similar to or higher than 
in men, 
Table 2. Estimated normallimitsand 95% confidence interval forvoltage equations ofleft ventricularhypertrophyin elderly 
men and women stratified by age group. 
Voltage equatlon 5S-64years 6S-74years 75+years 
Men N~601 N~411 N~17J 
Sokolow-Lyon (~tV) 4053 (393HI78) 3977(3837-4119) 3765(3544-3996) 
50kolow-lyon Ir'V) ,QR5 (s) 41l(40H16) 405 (391-410) 387 (36H07J 
(ome!! (~tV) 1581 (1495-1669) 1609(1487-1736) 1646 (1481-1815) 
(orn,IIIr'V), QR5 (s) 177 (167-188) 184 (169-301) 193 (170-318) 
12-lead summed (~lV) 11694 (11046-13371) 11481 (11681-13317) 11111 (10JJ1-118811 
J2-lead summed htV) x QRS {sj 1349 (1183-1417) 1341 (1163-1414) 1300 (1178-1417) 
Women N~858 N~565 N~196 
Sokolow-lyon (~lV) J518 (3441-3616) 3618 (3501-3736) 381J (3678-3967) 
50kolow-lyon (rIV), QRS (s) 333 (315-341) 349 (lJ7-J6J) 385 (364-407) 
(omelI (~tV) 1153 (1091-1117) 1158 (1184-1334) 1946 (1735-3180) 
Corn,lI (rIV), QR5 (s) 116(109-114) 135 (114-146) 316(184-355) 
12-lead summed btV) 19037 (18667-19414) 10151 (19655-10876) 11096 (11196-13039) 
12-lead summed (~lVJ xQRS(s) 1837 (1801-1874) 1964 (1904-1017) 1173 (1150-1409) 
The 98:h percentiIe of the measurement distribution was taken as the upper limit of normal. 
In comparison:lradilional values m,n (all ages): Sokolow.[yon ~ 3500, Sokolow.[yon, QRS >367.4, Corn,lI > 1800,Corn,1I x QRS 
>244, 11-lead surnm,d > 19530, 12-lead summ,d, QRS > 1957.9.Tradilional "Iueswom,n (all ages):Sokolow-lyon ~ 3500, 
Sokolow.[yon ,QRS >311.4,Corn,1I >loo0,«orn,II+600mm) xQRS >244, 12-lead summ,d > 18499, 11-lead sumrn,dxQRS 
> 1683.8. 
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Table 3. Hazard ratios and 95% confidenee interva!s for heartfailure and cardiovascu!ar morta!ity by ECG-lVH partition va!ue;overa!l and for men and women separate!y. 
LVH partition value (number) Heartfailure Cardiovascular mortality 
Overall* Men- Women** Overall* Men** 
N"ofcases:432 N" of cases: 206 N" of cases:226 N" of cases:275 N" of cases: 1 35 
Sokolow-Lyon traditional 1.9 (1.4-2.4) 1.7 (1.1-2.4) 2.1 (1.5-3.1) 1.9 (1.4-2.6) 1.4 (0.9-23) 
Sokolow-Lyon new 2_1 (1-5-2_9) 1_9(1_1-3_1) 2_3 11 _5-3_6) 2_4 11.6-3_4) 2_011_1-3_7) 
SokoJow-Lyon x QRS traditional 2.6ILH3) 2.3 (1.6-3.2) 2.912.1-4.0) 2.6 (1.9-3.4) 2.3 (1.5-3.4) 
Sokolow-Lyon x QRS new 2.2 11.6-3_0) 1_711_1-2_8) 2-8 11 _8-4.3) 2.5 11.7-3-5) 2_0 11 .2-3_4) 
Comell traditional 1.9 (15-2.5) 2.3 (12-4.3) 1.911.4-25) 1.8(13-25) 0.9 (03-2.7) 
Cornellnew 2-5 11.8-3.5) 2.3 11.4-3_6) 2_711.7-4-3) 2_7 11.8-3_9) 1_610.8-3_0) 
Comell x QRS traditional 2.0 (1.6-2.5) 2.1 (15-3.0) 2.0 (15-2.7) 12(1.7-2.8) 2.0(13-3.1) 
Cornel! x QRS new 2.8 12_0-3_9) 2.3 11.4-3_7) 3_4 12.2-5_2) 3_412_4-4.8) 2.4 11 .4-4_1) 
128 lead summed traditional 1.4(1.1-1.8) 1.0 (0.6-1.5) 1.8 (13-2.6) 1.7 (1.H3) 1.1 (0.6-1.8) 
12-lead summed new 1.8 11 .2-2_7) 1-510.8-2_7) 2_1 11.2-3_6) 2_3 11.5-3-5) 1 _0 10.4-2_4) 
12-lead summed x QRS traditional 1.8 (1.4-2.2) 1.7 (11-2.4) 1.9 (1.4-25) LO (1.5-2.6) 1.8 (11-2.6) 
12-lead summed x QRS new 2_011.4-2_9) 1_7 10_9-2_9) 2.4 11.5-3_8) 2_6 11.8-3.8) 2_1 11.2-3_8) 
New:age- and sex specific normal limits Rotterdam Study, * adjusted for age and sex, ** adjusted for age 
Wamen-
N"ofcases:140 
2.4 (15-3.7) 
2_611.6-4_3) 
2.911.9-4.2) 
3.0 11.8-4_9) 
1.9 (1.)-2.8) 
4.0 12.5-6.4) 
23 (1.6-3.2) 
4.612_9-7-3) 
23115-3.4) 
3_7 12.2-6.2) 
22 (1.5-32) 
3_0 11.8-5_0) 
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A Table 4. Age- and sex·adjusted hazard ratios lor heartfailure and cardiavascular martality by ECG·LVH partitian value,stratified byage. n 0 
" Heart failure Cardiovascular mortality " ~ 
~ 
LVH partition vofue Ss..64years 65-74years 75+years 5H4years 6S-74years 7S+years .~ 
N° of cases:52 N" of cases: 167 N° of cases:213 N'ofcases:32 N° of cases: 98 N'ofcases:145 
SokoJow-Lyon traditional 1.9 (0.8-43) 2.1 (1.4-3.3) 1.7 (1.1-2.5) 2.7 (1.1-6.7) 1.4(0.7·2.7) 2.0(13-3.1) 
Sokolow-Lyon new 2.6 (' .0-7.3) '.S (1.0-3.3) 2.2 (' .4-3.4) 6.0 (2.3-' 5.7) ,., (0.4-3.0) 2.6 (' .&-4.1) 
Sokolow-Lyon x QRS traditional 2.5 (11·5.5) 2.6 (1.8-3.9) 25 (1.8-3.4) 4.5(2.0,101) 2.1 (11-3.6) 2.6 (1.8·3.8) 
Sokolow-Lyon x QRS new 2.4 (0.9-6.8) 2.2 (' .3-3.S) 2.1 (' .4-3.2) 5.6 (2.2-14.7) 2.4 (' .2-4.7) 2.2 (' .4-3.5) 
(ome!! traditional 12 (05·5.7) 21(13-35) 1.9 (13-2.6) 2.1 (05-9Dj 2.6 (15-4.6) 15 (1.0'21) 
Comellnew '.7 (0.5-5.4) 2.4 (1.5-4.0) 2.7 (' .6-4.3) 3.7 (1.3-10.5) 3.' (1.7-5.4) 2.1 (1.2-3.S) 
Camel! x QRS traditional 2.3 (1.1-4.n 23 (1.6-31) 1.9 (1.4-2.5) 3.6 (1.6-8.0) 2.7 (1.7-41) 1.8 (1.2,2.6) 
Comel! x QRS new 2.0 (0.6-6.3) 3.0 (1.8-4.S) 2.8 (1.7-4.4) 7.3 (3.0-17.7) 4.6 (2.S-7.8) 2.0 (,., -3.7) 
12-lead summed traditional 1.8 (0.8-4.0) 15 (0.9,2.3) 1.3 (0.9-1.8) 3.1 (1.3-7.4) 1.4(0.8-25) 1.7(1.1-2.5) 
12-lead summed new 2.2 (0.7-6.9) 2.3 (1.2-4.2) '.4 (0.S-2.6) 2.4 (0.6-' 0.1) 2.2 (' .03-4.8) 2.3 (1.3-4.') 
12-1ead summed x QRS traditional 2.1 (1.1-4.0) 2.1 (15'3.0) 1.6 (1.1'2.1) 6.6 ~3-13.3) 2.1 (13-31) 15(1.1-21) 
12-lead sum x QRS new 1.5 (0.4-6.3) 2.0 ('.' -3.5) 2.1 ('.3-3.4) 7.2 (2.8-'S.8) 3.4 (' .9-6.0) 1.7 (1.0-3.') 
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Prognosis based on partition values for ECG-lVH 
General characteristics of thc 5740 subjects that were included to study the risk of 
cardiovascular mortality with ECG-LVH partition values are given below. Mean agc of these 
subjects was 69 years anti 60% was female, In total, 10% had diabetes mellitus, 6% had a 
lustory of myocardial infarction, 3% had a history of heart failure and 33% had hypertension, 
Coronmy artery bypass surgery and coronary angioplasty had been perfOf1l1ed in 2% and 
1% of participants, rcspcctivcly. The numher of subjccts with ECG-LVH varied greatly with 
the use of the traditional cut-off points: Sokolmv-Lyon voltage: 452, Sokolmv-Lyon voltage-
duration product: 503, Cornell voltage: 511, Cornell voltage-duration product: 808, l2-lead 
summed voltage: 598, and 12-lead summed voltage-duration product: 865. Numhers for the 
agc- and sex-specific normal lilluts were much lower and sllOwed less variation: Sokolow-
Lyon voltage: 250, Sokolow-Lyon voltagc-duration product: 266, Cornell voltage: 259, Cornell 
voltage-duration product: 253, l2-lead sum voltage: 212 alld 12-lead sum voltagc-duration 
product: 247, A tatalof 275 subjects died of cardiovascular disease, In the population of 
5575 subjects used to evaluate the association hetwccn ECG-LVH and heart fallure, 432 
cases of incident heart fallure occurred during follow-up (mean follow-up 6.8 years, SD 2,1 
years). 
Hazard ratios of heart failure and cardiovascular mortality arc prescnted in table 3 for 
the variOlIs ECG-LVH partition values, Overall, ECG-LVH was significantly associated with 
hcalt faiJure amf cardiovascular morlalHYI regardless of the cllt-off point used, Except 
for the Sokolmv-Lyon voltagc-duration product, for every voltage equation the presence 
of LVH defined with our normal limits yielded higher HRs of incident hemt failure and 
caruiovascular mortality than LVH according to the traditional partition val lies. Differcnccs 
were more pronounceu for thc Cornell voltage and its duration product and were larger in 
cardiovascular mortality than in heart failure, LVH according to thc ncw normallimits for the 
Cornell voltage-duration product sllOwed the strongest association with both outcomes (HR 
healt failurc: 2.8, 95%CI 2,0-3.9; HR cardiovascular mortality: 3.4, 95%CI 2.4-4.8). 
Stratification by sex silOwed that age-adjusted hazaru ratios for LVH accoruing to the new 
partition values compared to LVH deflIled by the traditional vallles were increascu mainly 
in women and that differences in men were modest (tabIe 3), In women, the association 
between ECG-LVH and healt failure or cardiovascular mortality was generally stronger than 
in men, Stratification by age demonstrated slllalt differences in the magnitude of the hazard 
ratios for ECG-LVH between partition values per age group (tabIe 4). However, numbcrs 
were slllall and hcncc confidcncc intcrvals wide, especially in the youngest age-category. 
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Figure 1 a. Age-dependent curve of normallimits for Sokolow-lyon voltage criteria in women.Graph represents 2,.,j and 98tl1 
percentile with 95% confidence interval and fitted curves. 
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Figure 1 b. Age-dependent curve of normallimits for Sokolow-lyon voltage criteria in men.Graph represents 2,4 and 98tl1 
percentiIe with 95% confidence interval and fitted curves. 
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Discussion 
We established age- and sex-specific normal Iimits for tllfee voltage cquations that are 
frequently used to dcfine ECG-LVH, and for their voltage-duration prodllcts, in a healthy 
elderly population. The new rcference vallles for ECG-LVH were consistently higher than 
the traditional paltition vallles, except for the Cornell voltage criteria in men. \'I;'e found that 
98th pcrcentiles were lower in women than in men up to the age of 75 years. Agc trends 
in amplitudes, and thus in normal limits, differed bctween sexes. In women, limits for 
evely equation increascd with age. In contrast, SokolO\v-Lyon~ and 12-lead sllmmed voltage 
and voltage-duration products dccreased with agc in men, whereas the Cornell equations 
were not substantially influenced by age. ·We also studied associations bctween ECG~ 
I..VH, according to the different criteria and partition values, and incielent heart failure and 
cardiovascular mOltality. LVH as evielenced by ECG was signifIcantly associated with hoth 
heart fallure and cardiovascular mortality for all criteria and cut-off points. The strongest 
association was seen for thc Cornell voltage-duration product dcfined according to the 
new normal limits. Except for the SokolO\v-Lyon voltage-duration product, all age- anel 
gcnder-specific normallimits established in the present study silOwed stronger aS5ociations 
between ECG-L\'H and bath cardiovasclllar outcomes lhan the traditional paltition vallles. 
The differellccs in relative risks were more pronotmced in wamen than in mcn. 
1\B lhe aging proccss itself causes changes in ECG amplitudes anel QRS duration, even in 
the absence of cardiovascular disease, a normal ECG in an elderly suhject differs from that 
in a younger individllal [91. It has becn demonstrated that aging increases the probability of a 
false-positive diagnosis of ECG-I..\'H [11]. Therefore, it is essential to "defll1e cut-off points for 
ECG~LVH that, besides sex, are also dependent on age. However, normal referencc values 
for the detectian of ECG-LVIi in the elderly have not heen determined so faro Although ECG 
amplitudes are generally expected to dccrease with age, it has been shown previously that 
this does not appl)' ta all voltages UO, 26, 271. These studies descrihed sinillar differences in 
age trends between men and women as we found in our study and their rcsults also suggest 
that a partition value of 2800 ~lV for the Cornell voltage in men ma)' be excessively high. 
Besides the fact that most methods utilize fixed criteria to dctect ECG-LVH, the three 
voltage criteria we assessed in this study have mainly been developcd and evaluated in 
clinical populations. Also, the stud)' populations that were used to develop these voltage 
criteria for ECG-LVH included, if an)', only a limited number of eleIerly subjects, whcreas our 
study cohort included a large number of elderly individuals. r-.-1oreover, the validity of ECG 
criteria for IXH has largely been tested against lhe echocardiogram as a gold standard. The 
correlatian between left ventricular mass determined with the ECG and the echocardiogram 
is modest, however, and sensitivity of lhe ECG for detection of LVlI on thc echocardiogram 
is low [28]. A more useful method 10 validate ECG criteria for LVH lllight be to assess 
their prognastic ability. Therefore, we used heart failure incidence and cardiovascular 
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mortality as outcome measures in our study. Another advantagc of our snIdy is the use of a 
validated computer program (MEANS) to determine ECG amplitudes instead of manual ECG 
assessment. This reduces measurement error and intraobserver variability. 
A priori, we chose the 98th perccntile of EeG amplitudes as the upper limit of normal, 
which is a commonIy used cut-off point for the determination of reference values in normal 
populations. Howcvcr, other cut-off points are conceivable. Our choke for using the 9Sth 
percenti1e makes our age- and sex-specifIc normal limits more specijk than, for example, 
95 th percentile cut-off points. Therefore, only the more serious cases of LVH are detected. 
Cardiovascular disease risks are, however, atready elevatcd with the use of less specific limits 
for LVH, albeit probably at the expense of morc false positive misclassification. Ultimately, 
the choice for a cut-off value for ECG-LVH will depend on the preference for the a priori 
magnitude of baseline risk, 
Because of the uncertainty in LVH prevalenee estimates, which occurs when traditional 
dichotomous ECG criteria are used, multivariate continuous ECG moelels for the estimation 
of echocarJiographic left ventricular mass or the risk of cardiovascular diseasc have been 
introduccd, which include factors such as age, sex, race and body mass index [29-311. These 
algorithms perform better in estill1ating echocardiographic mass or predicting cardiovascular 
risk than voltage criteria alone. However, the application of these 1110dels is Iimited in a 
clinical setting as they are more complicated to use and more difficult to interpret than simple 
cut-off points for ECG-LVH. Moreover, a clinical diagnosis of LVH is not ani)' dependent 
on criteria of high voltage, but also includes the morphology of the QRS complex, 5T-T 
abnorl11alities, QRS-axis, left atrial hypertrophy and QRS duration [321. 
Our study is limited by the predol11inantly CatlCasian nature of our study population, 
ECG-amplitudes that are used in equations for LVH are known to Jiffer significantly 
between human races {lO, 27, 291. Consequently, our results are not generalizable to non-
white populations, Although we studied a large cohort of elderly individuals, the number 
of 'apparently healthy' subjects over 75 years oid was still somewhat limited, especially in 
men, and therefore in this age group normallimits are less accurate. \Ve prcsented age- anel 
sex-specific normal limits in tables and in plots. Although the tabular presentation is easier 
for use in clinical practice, one should be aware lhat the tabulated values are estimates 
for the median age in age groups anel that an age effect within these groups may still be 
present. Therefore, the continUQtIS age-dependent curves are preferred for computerized 
determination of ECG-INH, 
In SUlllfl1ary, ECG amplitudes are signifIcantly associated with age and sex. Also, age-
trends in amplitudes differ between men and women. Thereforc, the traditional partition 
values for ECG-LVH voltage criteria may not adequately distinguish between physiology and 
disease in eldcrly individuals. Dcspite its low sensitivity for the detection of LVH, thc ECG 
is widely useel in clinical practice and in large clinical anel observational studies because of 
its low costs, simplicity, greater availability and high reproducibility, Therefore, age- and 
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sex-speciflc cut-off points for ECG-LVH may be of great clinical importance. \X'e provide age-
and sex-spccific normallimits for three cOIllmonly used voltage equations anel their voltage-
eluration products to overcome thc lack of proper reference values for ECG-LVH in normal 
elderly individu als. ECG-LVH detected with these normal limits was assodated with bath 
heart fallure and cardiovascular m011ality for all voltage criteria. Associations were strongest 
for ECG-LVH according to the new normal Iirnits for the Cornell voltage-duration product. 
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Antihypertensive treatment is associated with 
improved left ventricular geometry.The Rotterdam 
5tudy 
Chapter 3.1 
Abstract 
Purpose: left vcntriClJlar hypertrophy (LVH) illcreases the risk of cardiovascular disease. 
\\fe evaluated the association between antihypertensivc thcrapy alld echocardiographically 
determined LVH. 
j\lethocis alld results: The Rotterdam Study is a poplllation-bascd prospective cohort study 
among 7,983 participants aged 55 years or over. Echocardiography was perfofllled in 2,823 
participallts. The study poptllation cOllsisted of 740 participants with grade 1 hypertension 
or antihypertensive mOllotherapy, without heart failure. Of these, 646 had an adequate 
echocardiogram for analysis of rclative wall thickness and 642 for left velltriClJlar mass index. 
Participants were followed fromJanuary 1, 199111ntil the date of echocardiography, between 
September 1992 aod Jllne 1993. Outcome measures were defined as being in the highest 
gender-specific quintiIe of left ventriCldar mass index and as having a relative waU thickness 
higher than 0.43. A Cox regression model with duration of use of antihypeltensives defined 
as time-dependellt covariates was used for data-a na lysis. Antihypettensive treatment lowered 
the risk of incrcased left ventrictdar mass index CRR 0.6, 95%CI 0.4-0.9). ACE-inhibitors, 
diuretics, and p-blockers all 5110wed a risk reduction. Use of antihypertensives was also 
associated, although non-signrn.cantly, with a decrease of high relative wall thickness (RR 
0.8, 95%CI 0.6-1.0), ACE-inhibitors, p-blockers, and calcium antagonists showed similar risk 
reductians, while diuretics seemed ta increase the risk, possihly by reducing left ventricular 
end diastolic diameter. 
Conclusions: The use of antihypertensive drugs is associated with a decreased risk of 
echocardiographically determined LVH in a populatian-based setting. 
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Introduction 
Left ventricular hypertrophy (LVH) is associated with an increased risk of cardiovascular 
disease, even after adjustment for major risk factors, such as hype11ension [1, 2]. Depending 
on the method of indexation of len ventriCldar mass (LV mass) and the partition values used, 
echocardiographically determined LVH is present in 42%-77% of patients with hypertension 
[3]. Several factors influence LV mass, of which blood pressure, age, gender, body mass 
index, diabetes mellitus, anel pre-existing cardiovascular disease are most important [4-6], 
Cardiovascular morbidity and mortality increase as the geometric pattern of the len ventricle 
changes from normal to concentric remodelling (increased LV wall thickness), eccentric 
LVH (increased LV mass) and concentric LVH (increased LV mass and increased LV wall 
thickness) [7J. 
Regression of LVH is associated with decreased morbidity and mortality in cssential 
hypertension. Findings indicate th at patients who fail lo achieve reduction in LV mass after 
antihypertensive treatment are at higher risk for subsequent cardiovascular cvents [8, 9l. 
Although there have been a number of clinical trials reporting regression of LVH after 
antihypertensÎve treatment [10J, its effect under cvcryday circumstances remains unclear. 
The relative efficacy of the different classes of antihypertensÎve dmgs also rcmains a matter 
of controversy [11]. In cross-sectional studies, chronic antihypertensive therapy was not 
associated with normalisation of LV geornctry, nor were there any differences between 
classes of antihypertensive drugs [12, 13]. 
The objective of this study was to evaillate the association between antihypertensives and 
echocardiographically determined LVH in a population of commllnity-dwelling e1derly. 
Methods 
SeWng 
Thc Rotterdam Study is a poplliation-based prospecth'e cohort snldy. An olltline ofthe study 
has been published previously [141. The first survey started in 1990 and was completed in 
1993. All inhabitants of Omllloord, a suburb of Rotterdam in the Netherlands, aged 55 years 
or over were invited to participate. Of the 10,275 eligible subjects, 7,983 gave informed 
consent (78%). Participants were visitcd at home for a standardised questionnaire and werc 
subsequently examined at the research centre, where echocardiography was perf0fl11ed 
in a sample of 2,823 participants. The performance of cardiac ultrasound depended on 
the availability of ultrasound technicians. Other than a small subset of participants living 
in nursing homes, no participants were a priori excluded from receiving an ultrasound. 
In 19.7% (n=556), the echocardiographic registrations were cOllsidered inadequate for a 
reliable measurement of LV dimensions. These pa11idpants were more likely 10 be oider, 
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had a higher bod)' mass index, and more often used medication for chronic obstructive 
pulmonary disease [151. In addition to medication history from computerised pharmacy 
records, information on the Cllrrent use of medication and type of medication were also 
assessed during the home interview. The participants subsequentl)' silOwed all their cUfrend)' 
used medication at the research center, where a ph)'sician dctermined the indication for 
each drug. In case of blood pressure levels below the cutoff points, originall)' at baseline 
defined as a systolic blood pressure of 160 m111 Hg or over, and/or a diastolic blood pressure 
of 95 mm Hg or over, and inconsistencies or missing values regarding indication, additional 
information was used to classify subjects as h)'pertensive. This additional information was 
obtained, first from the response to the question, "Have )'ou ever been told b)' a doctor that 
you have h)'pertension?" and, second, from the response to the question, "Were you ever 
treated with drugs because of high blood pressUfe?" [16J, 
Study population 
Ta be eligible for tlus stud)', at least 1 year of medication history before the date of 
cchocardiography had to be available. Computerised pharmacy records were available of 
all participant.'5 of the Rotterdam Study as of January I, 1991. Thercfore, those individu als 
who underwent echocardiography before January I, 1992 were excluded [rom this study 
(n~345). 
Furthermore, the study poptJlation was restricted to participants who had at least grade 
1 hypertension, and participants who used antihypertensive medication for the treatment 
of high blood pressure (remaining population: n=1015). Grade 1 h)'pertension was defined 
as a systolic blood pressure of 140-159 nUll Hg, and/or a diastolic blood pressure of 90-99 
Illill Hg, according to \Vorld Health Organization gUidelines [17J. Furthermore, subjects who 
had used multiple antihypertensive agents during the stud)' period, either concomitanti)' or 
consecutively, were excludcd (n=220), Patients with prevalent congestive heart failure at 
the time of the baseline interview or incident congestive heart failure during follow-up in 
the Rotterdam Stud)' were also excluded (n=55), Of the remaining 740 echocardiograms, 
646 (87.3%) were technically adequate for determination of relative wall thickness, and 642 
(86.8%) for determination of LV mass index, Participants were followed as of January 1, 1991 
until thc date of echocardiography, whieh varied between September 1992 and June 1993. 
Exposure definition 
All prescriptions dispensed to pa11icipants by seven automated pharmacies in the stud)' 
area were routinely stored in the database, \Ve included as antihypertensive agent.'5: ACE-
inhibitors, diuretics, B-blockers, calcium antagonists, and other antihypertensives (such as 
centrally acting antihypertensives). Participants were considered exposed if the date of the 
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echacardiagraphy feil within the legend duration (prescription length) of an antihypertensive 
agent. The legend duration was calculated by dividing the total number of filled tabletsl 
capsules of consecutive prescriptions of a drug by the prescribed daily number. \Ve added 
a carry-over periad of 3 months as we assumed that any protectÏ\'e effect on LV mass 
index and relative wall thickness wauld not immediately subside after discontinuation of an 
antihypertensive drug. A protectÎ\'e effect on both aspects of LV geometry was considered 
to require a duration of use of at least twa months [18]. The duration of exposure on the 
date of echocardiography was divided into three mutually exclusive periads: 1) nan-use; 
2) duration of use of 2 months or less (induction periad); 3) duration of use of more than 
2 months. 
Outcome definition 
1\vo manifestations of LVH were stucliecl. The first was defmed as being in the highest 
gender-specific quintile of LV mass index, the second as having an increased relative wall 
thickness. Echocardiography was carried out with the participant in the partialleft decubitus 
position using a 2.75-f..'IHz transducer (Toshiba SSH-60A Nasuworks, Otawara, Japan). 
Two-dimensional imaging using parasternal long-axis views was performed to aid M-made 
studies. tvleasurements of the teft ventricle were performed at end-diastole, as defined by 
the onset of the QRS complex, according to the American Society of Echocardiography 
(ASE) recommendations [19]. LV mass was determined using the Devereux-modified ASE 
cube formula [20]: LV mass (grams) ~ 0.8x(1.04x[(LVED+lVS+LVPW)'·(LVED)'])+0.6, where 
LVED = LV end diastolic diameter, IVS = interventricular septtun thickness, and LVP\'!;' = LV 
posterior wall thickness. LV mass was indexed to body sllrface area and divided into gender-
specific quintiles, which has been shown ta provide good cardiovascular risk estimates [211. 
Relative wall thickness (R\Vf) was calculated as R\"X'T = 2 x LVP\V ILVED [22). Increased 
relative wall thickness was present when the ratio exceeded 0.43, accarding ta previously 
published criteria [31. 
Othervariables 
Information was gathered on several potential canfounders such as age, gender, history of 
myocardiat infarction, congestive heart fallure, smoking (cmrent/former/never), and body 
mass index. Diabetes melJitus was defined as the llse of anti-diabetic medication, or as a 
random or post-Ioad serum glucose level higher than 11.0 mmolll [231. 
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Analysis 
A Cox regression model with the duration of use of antihypertensive drugs defined as 
tirne-dependent covariates was lIsed for data analysis. Non-nse of the antihypertensÎve 
drug of irlterest senred as reference. The associations were expressed as relative risks 
(RR) with 95% confidence lintits. In the multivariate analyses we adjusted for age, gender, 
smoking, body mass index, diabetes mellitus, and history of myocardial infarction. \,fe 
repeated lhe multivariate analyses after restricting the population to those subjects wUh 
hypertension defined as use of antihypertensive medication for the treatment of high blood 
pressure, or as having a systolic blood pressure of 160 mm Hg or over, or a diastolic blood 
pressure of 95 Illm lIg or over (n=317) to see if we created more or less similar groups 
[161. Additional analyses were perfornled comparing treated antihypertensive patients who 
had well-controlled hypertension (systolic blood pressure lower than 140 mm Hg and 
diastolic blood pressure lower than 90 mm Hg) with non-treated hypertensive patients, 
and comparing antihype11cnsive therapy in patients with refractor)' hypertension with non-
treated hypertcnsive patients. All statistica I analyses were carried out with the statistical 
software packages SPSS 9.0 and SAS 6.12. 
Results 
General characteristics 
In table 1 general characteristics of participants who met the inclusion criteria are presented. 
The mean age of eligible participants was 66 years. There was a small majority of wamen 
(54%). The mean follow-up was 2.2 years. i'vlean systolic blood pressure was 154 mm Hg 
anel mean diastolic blood pressure was 80 mm Hg. Mean LV mass index was 99 g/m2 and 
mean relative wall thickness was 0.42. A history of myocardial infarction was present in 
7% of participants, and 8% had diabetes mellitus. Of all participants 19% were current 
smokers, whcreas 46% were former smokers. Antihype11ensivc drugs were used by 31% of 
participants; JS-blockers (14%) and diuretics (8%) were most frequently prescribed. 
left ventricular mass index 
Tahle 2 represents the estimates of the association between the use of antihypertensive 
dmgs and LV mass index. Since sample size was too sl11all to render cstil11ates in most 
of the dmg exposure categories in the induction periad, the relative risk for exposure 
in the first two months is only shown for the use of antihypertensives in genera!. The 
use of antihypertensive dmgs decreased the risk of high LV mass index (RR 0.6, 95%CI: 
0.4~0.9) af ter adjustment for confounding variabIcs. Of the individual antihypertensives, 
onIy diuretics showed a significant redllCtion in the risk of elevated LV mass index aftel' 
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the induction period, Restriction of the analyses to suhjccts with more stringent criteria 
for hypel1ension (systolic blood pressure ~ 160 mm Hg, and/or diastolic blood pressure 
~ 95 111111 Hg, anel/or antihypertensive dmg use for the indication hypertension) revealcd 
similar rclativc risk cstimatcs (third column, table 2). Antihypel1ensive dmg use in patients 
with well-controlled treated hypertension revcalcd a RR of 0.3 (95%CI 0.2-0.7) of being in 
the highest quintile of LV mass inelex as compared to non-treatment, while treat111ent in 
refractor)' hypertension revealed a RH of 0.8 (95%CI 0.5-1.2). Point estimates for LV ffiass 
index anel relative wall thickness ,vere similar in analyses restricted to participants without 
a prior history of myocardial infarction. 
Table 1. General (haracteristics, 
Age{years) 
Fema!e 
Follow-up (years) 
Body mass index (kg/mI) 
Bodysurface area (mI) 
Systolic blood pressure (mm H9) 
Oiastolic blood pressure (mm Hg) 
Left ventricu!ar mass index (g/m l ) 
Relative wall thickness 
Fractiona! shortening (%) 
History of myocardia! infarction " 
Diabetes mellitus t 
Smoking 
Currenl 
FOImer 
Never 
Use of antihypertensive drugs during sludy period: 
Diuretics 
fi-blockers 
Calcium antagonists 
A(E-inhibito/s 
Other antihypellensives 
Population (0=646) 
66(7.3) 
347 (14%) 
2.2 (0.2) 
26(3.3) 
1.9 (0.2) 
114(16.6) 
80 (105) 
99 (21.7) 
0.42 (0.09) 
39 (7.1) 
47(7%) 
49(8%) 
121(19%) 
291 (46%) 
230(31%) 
198(31%) 
52(8%) 
93 (14%) 
20(3%) 
29(1%) 
4(1%) 
Values are means (SO) or numbers (%), * myocardial infarction according to general practitioner,cardiologist or ECG, t the use of 
anti-diabetic medication,or a random orpost-Ioad serum glucose level higher than 11.0 mmoll!. 
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Table 2. Association between lV mass index and use of antihypertensive agents. 
All antihypertenslves * 
~ 2 months 
>2monlhs 
ACE·lnhibitors § 
>2 months 
Diure!ics§ 
>2months 
R-blockers § 
>2 months 
Calcium antagonlsts § 
>2monlhs 
RR{95%CI) • 
Tota' popu'alion 
0.2 (O.Ol-l.7l 
0.6 (O.4-0.9) 
0.6 (O.HJ) 
03 (O.l-0.8) 
0.7 (O.H2) 
L5{O.H2) 
RR (95%CI)' 
Sub·popu'ation t 
0.2 (O.Ol-l.6) 
0.5 (03-0.8) 
05 (O.H2) 
03 (O.HO) 
0.7 (O.H2) 
I.l (05-V) 
* Adjusted for age,gender,diabetes mellitus,smoking,history of myocardial infarction,and body mass index, t Subjects with hy-
pertension defined as use of anlihypertensive medication for the treatment ofhigh blood pressure,or as having a systolic blood 
pressure of 160 mm Hg or over,or a diastolic blood pressure of 95 mm Hg or over,t The use of any of the described antihyperten-
sive drugs as monotherapy, § Because oflow numbers for the individual antihypertensives in the induction period (:s;; 2 months), 
only relative risks are given for use of more than 2 months. 
Relative wal! thickness 
Table 3 represenl<; the estimates of the association between the use of antihypertensive 
drugs and il1creased relative wall thickness. Treatment with antihypcrtcnsÎvcs in general 
\vas associated with a decrease in the risk of clevated relative wall thickness (RR 0.8; 95%CI 
0.6-1.0), although this failcd to reach statistica I significance. ACE-inhibitors, p-blockers, and 
calcium antagonists silOwed similar reductians in risk af increased rclative wall thickness, af 
whieh p-blackers were the aniy drug dass with a significant associatian. The use af diuretics 
was associated with a higher risk of increased relative wall thickness, which was significant 
when restricting the analyses to the stricter criteria for the presence af hypertensian. lvlean LV 
end diastalic diameter tended ta be significantly lower and mean LV posteriar wall thickness 
tended ta be sinillar with the use of diuretics, as campared ta nan-treatment (independent 
samples t-test: p=O.Ol, respectÎ\'e1y p=0.68). Again, restrictian ta more stringent criteria [or 
hypel1ension revealed similar relative risk estimates for the association betwecn clevated 
relative wall thiekness and antihypertcnsive therapy (tabie 3). Antihypertensive dmg use in 
patients with well-controlled treated hypertension revealed a RR of 0.5 (95%CI 0.3-0.8) af 
increased relative wall thickness as campared ta nan-treatment, while treatment in rcfractory 
hYPcltension yielded a RR of 1.0 (95%Cl 0.7~1.3). 
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Table 3. Association between relativewall thickness and use of antihypertensive agents. 
All antihypertenslves * 
~ 2months 
>2mnnths 
ACE-Inhibitors § 
>2months 
Dluretlcs § 
>2 mnnlhs 
B-blockers § 
>2 months 
Calcium antagonlsts § 
>2mnnths 
RR (95%(1)" 
Total populatinn 
0.7 (0.3-1.8) 
0.8 (0.6-1.0) 
0.7 (0.4-1.1) 
1.6 (1.0-1.5) 
0.6 (0.4-1.0) 
0.7 (0.3-1.6) 
RR(95%CI)" 
Sub-population t 
0.6 (0.1-1.8) 
0.8 (0.6-1.1) 
0.7 (0.4-1.3) 
1.8(1.1-3.1) 
0.6 (0.4-1.0) 
0.8 (0.4-1.9) 
* Adjusted for age,gender,diabetes mellitus,smoking, history of myocardial infarclion,and body mals index, t Subjects wilh hy-
pertension defined as use of antihypertensive medication for the treatment of high blood pressure,or as having a systolic blood 
pressure of 160 mm Hg or over,or a diastolic blood pressure of95 mm Hg or over,J The use of any of the described antihyperten-
sive drugs as monotherapy, § Because oflow numbers for the Individual antihypertensives in the induction period (5 2 months), 
only relative risks are given for use of more than 2 months. 
Discussion 
The main finclings of this study are that the use of antihypertensive dnlgs decreases the risk 
of echocardiographically determined LVH. Of all antihypel1ensive dmgs, diuretics seemed 
to be most strongly associated with dccreased LV mass index. A decrease in the risk of high 
relative wall thickness was observed with the use of ACE-inhibitors, p-blockers, and calcium 
antagonists, although with Iow statistical power. The use of diuretics secmed to increase 
the risk of elevatecl relative wall thickness. This may have been due to a tendency for LV 
end diastolic diameter to he lower and LV posterior wall thickness to be similar with the 
use of diuretics, as compareel to no treatment. However, as this was not part of our prior 
hypothesis anel numbers were smalI, these results should he interpreted with caution. 
Since all data on exposure and outcome were recorded similarly for all subjects without 
prior knowledge of our study hypotheses, selection bias and information bias are not likely 
to have influenceel the results of this study. Non-diffcrential misclassification could have 
occUfreel due to inaccurate assumptions about carry-over effects. Little is known about the 
contimlcd effect of antihypertensive agents on LVH. ·Washout periods Iasting more than 2-6 
months have been suggested before measurahle redcvclopment of hypertrophy occurs [241. 
As onIy one echocardiography was carried out, the association between antihypertensive 
dmgs and alterations of LV geometry over time couiel not be evaluated. An important problem 
in observational studies on dmg effccts is confounding by indication, due to the difficulty 
of ensuring comparability of prognosis across different treatment groups. In theory, the 
effect of confounding by indication can be completely removed by adjustment [or all patient 
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characteristics that farm the basis of the indications for treatment [251. Statistical adjustment 
will be incomplete, however, ti not all relevant determinants af the indication for treatment 
are known. Potential confounding bl' indication in this Shldl' was dealt with bl' indllding 
onll' patients with hypertension, making treatment grollps more similar in terms of prognosis. 
In additian, paticots with heart faillIre aod users of multiple antihl'peltensive drugs were 
excluded, because of the possibilitl' of substantial residual confounding in these groups. In 
the analysis, we adjusted far seveml potential canfounders that are knawn ta be associated 
with both exposure and LVH. Although blood pressure on the date of echocardiography 
was known, we considered dus as a potential intermediate for whieh we should not adjust. 
J\'loreover, adjustment for sl'stolic blood pressure did not change our results. Also, analyses 
in a poptIlation with more severe hypertension were perfOftlled, whieh silOwed si mil ar risk 
estimates. Any residu al canfaunding by inclication would have led to higher relative risk 
estimates, and not to a protective effect as seen in this shldl'. Residual confounding ma)' have 
resulted from the prescription of antihl'pertensive drugs for alternate indieations. Since we 
only selected participants with hypertension, and verified the indication af antihypertensive 
lreatment, however, it seems fair to assume that the antihl'pertensive drugs were iodeed 
prescribed for this indieatian. Alsa, specifIc patienl or physician chamcteristics mal' have 
influenced the decision to treat patients for increased blood pressure. This may have led ta 
a negative association jf patients with less severe hypertension or patients who were more 
cas)' to control were preferentially treated. In this population, however, a large proportion 
of participants was unaware of having hypertension aod their elevated blood pressure was 
discavered at the baseline examination in the Rotterdam Studl' {l61 Also, in the time of the 
baseline examination, different criteria for hypertension were used, and therefore patient<; 
with nuid hypertensian according to the new \VHO criteria \vere probably not treated. 
These characteristics would have led to higher relative risk estimates, aod do not explain 
lhe negative association seen in this Shldy. 
In several clinical trials regression of echocardiographically detennined LVH has been 
reported fallowing treatment with a wide range of aotihl'pertensive agents, including ACE-
inhibitors, diuretics, ~-blockers, alld calcium antagonists (lO]. r.,'lanl' of these trials were of 
smal! size and short follow-up. More recent large randonuzed clinical trials have suggested 
that diureties and ACE-inhibitors are most effective in rcducing LV mass [26-29]. An advantage 
of aur studl' is that it enabled us to determine the effectiveness of antihypertensive drugs 
in a general poptJlation of community dwelling elderly. So far as we are aware, population-
based studies on antihypertensives and echocardiographically detennined LVH are rare. 
There have been same cross-sectional shldies, in which chronie antihl'pertensive therapy 
was not associated with normalisation of LV geometry [12, 13]. 
Reduction of cardiac afterlaad as a rcsult of blood pressure lowering reduces myocardial 
wall stress and leads to a decrease in 1l1uscle mass. However, blood pressure reduction 
alone may nol autamatically lead ta a decrease in LV mass (30). Chronically increased 
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blooeI pressure results in concentrie remodeling, while chranie volume overload on the !eft 
ventricIe produces eccentrie hypel1rophy [311. Both forms of hypertrophy are accompanied 
by complex changes in gene programming, inclueling genes encoding components of 
hormonal pathways (e.g. renin-angiotensin system). In addition, variabIe expression occurs 
in genes that modify intracellular ion homeostasis, anel key parasympathetic anel sympathetic 
receptors are elownregulated {32]. Circulating anel tissue noradrenaline as weil as increased 
production of angiotensin 11 p;:u1icipate not only in the proeluction anel maintenance of 
the increaseel pressure load on the ventricle, but also have a direct effect on myocyte 
hypertrophy, and hypertrophy anel hyperplasia of nonmyocyte cells [311. Blockade of the 
sympathetic system with a B-hlocker or blockade of formation of angiotensin 11 with an 
ACE-inhibitor may therefore contribute to the reversal of LVH. In this study, both agents 
were associated with a reduction in risk of LVH. 
Despite activation of neurohormonal pathways by diuretics their hemodynamic effects 
seem to he more important for regression of LVH. The observed relative increase in wall 
thickness, presumably reflecting a decrease in transverse dimensions of the heart has been 
reported earlier with the use of diuretics, and may result from adaptive changes of carcliac 
ffiuscle tissue ar0lllld a smaller left ventricle [331. \\'lith sustained therapy, short-acting calcium 
antagonists anel long-acting dihydropyrielincs may promate sympathetic activation [341. This 
might explain the lack of an association between calcium antagonists anel LVH as observed 
in this study, bcsides low statistical power. L1ter introduced long-acting preparations do not 
have this characteristic anel may have more beneficial effects on LV geometry [35J. 
In conclusion, the use of antihypertensive dmgs is associateel with a decreased risk of 
echocardiographically determined LVl-I in a population-baseel setting. 
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Nonsteroidal anti-inflammatory drugs and heart 
failure 
Chapter 3.2 
Abstract 
Heart failure constinues an increasing public health problem, because of its grmving incidence 
and prevalence, poor prognosis, and high hospital (re)admission rates. Myocardial infarction 
is the underlying cause in the majority of cases, followed by hypeltension, valvular heart 
disease anel idiopathic eardiomyopathy. Nonsteroielal anti-inflammatory drugs (NSAIDs), 
which inhibit the enzymes cyclo-oxygenase (COX) 1 and 2, have been assaciated with the 
OCCUfrence of symptoms of heart failure in several case reports and quantitative studies, 
mainly in patients with a history of cardiovascular disease or lcft ventrictJlar impairment. 
NSAlDs may impair renal functian in patients with a decreased effective circulating 
volume by inltibiting prostaglandin synthesis. Cansequently, water and sodium retention, 
and decreases in rcnal blood flow and glomerular filtration rate may occur, affecting the 
unstable cardiovascular hameostasis in these patients. In patients with pre-existing heart 
failure, this may lead to eardiac decompensation. Putative renal-sparing NSAIDs, such as 
COX-2 seleetive inhibitors have similar effects on rcnal function as the traditional NSAIDs, 
and ean likewise be expected to inercase the risk of heart fallure in susceptible patients. 
NSAIDs are frequently prcscribed ta elderly patients, who are particularly at risk for the 
renal adverse effects. If treatment with NSAlDs in high risk patients cannot be avoided, 
intensive monitoring and patient education is important. 
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In!roduction 
Heart failure constinltes a major public health problem. The prevalence in the general 
poplliation is estimated to range from 0.3% to 2.0%, and incrcascs considcrably with age [1]. 
It approximately doubles wtth ever)! additional decade of life [21. Estimates of the cumulative 
incielence per year follow a similar pattern anel vary from 0.1% to 0.2% in mielelle aged 
mcn and women (1]. In the last two decades, hospita I admission rates for heart failure 
have increaseel steadily [31. Readrllissions for exacerbating heart fallure occur frequently, 
especially in thc elderly. The incidence of healt fai/ure increases over calendar time, whieh 
is most likely explained by improved survival following myocardial infarction, and increased 
longevity in industrialised countries. Prognosis remains poor, with a cUl11l1lative 5-year 
mortality of over 40% (4]. Because of the increasing number of patients with heart faiJure, 
and its high morbidity anel mortality, it is important to identify potentially preventabIe risk 
factors for the occurrence of heart faiJlIre. 
Heart failure can result from any stmcnlfal or functional disorder that impairs the 
ability of the len ventricIe to nu with or ejecl blood [SJ. Diagnosis is complex anel relies on 
clinical jlldgcl11cnt based on history, physical examination and imaging procedures, sllch 
as echocardiography. Characteristically, patients present with signs of breathlessness or 
fatigue, either at rest or during exertion, pulmonary crepitations, or peripheral edema [61. 
Symptom-free periods are aften alternated wUh periods of cxacerbating symptoms. Heart 
failure develops when compensatory hemodynamic anel neurohormonal mechanisms of the 
injureel heart are exhausted or ovenvhelmed [71. As coronary heart disease is the unelerlying 
cause in the l11ajority of cases, most patients have cvidencc of left vcntricular systolic 
dysfunction. However, nearly all patients also exhibit eliastolic impairment at rest (61. This 
report will focus mainly on heart fallure elue 10 systolie dysfunction. The most frequent non-
ischemie causes of heart fallure are hypertension, valvular disease and idiopathie dilaled 
cardiomyopathy [51. 
Several dmgs have elemonstrated to be able 10 induce or exacerbate heart failure (8]. In a 
number of reports, the occurrence of heart fallure was attributed to the use of nonsteroielal 
anti-inflammatory dmgs (NSAIDs) [9-13J. NSAIDs are used extensively in thc general 
population for rheumatologic conelitions, especially in elelerly patients. Nonrheumatie 
indications include acute anel chronic pain) blliary anel ureteric colic, and dysmenorrhoea [14]. 
In the United Statcs, 70 million NSAID prescriptions arc dispensed each year [15]. \Vorldwiele 
these agents account for approximately 2.5% of all prescription dollars, corresponding with 
6.8 blllion US dollars spent atillually [161 .. Most patients who use therapeutic dosages for a 
short perioeI of time tolerate NSAIDs weil (171. However, a considerabie subset of individuals 
elevelops adverse effects involving the gastrointestinal, renal anel cardiovascular systems. 
In this repolt, we will discuss recent findings on the association bctween the llse of NSAIDs 
and the occurrence of heart failure. Consecutively, we will focus on current knowledge of 
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the pathophysiology of heart failurc, thc mechanism of action and renal effects of NSAIDs, 
potential "rcnal-sparing" NSAIDs, cyclo-oxygenase-selectivity, and quantitativc studies on 
the association between NSAIDs and heart failure. 
Pathophysiology of heart failure 
Left ventriCldar dysfunction begins with some form of injmy to the myocardium, for 
exal11plc an acute myocardial infarction, whieh results in loss of functioning myocardial 
cells. In response, hemodynamie and neurohormonal mechanisms are activated to preserve 
cardiac function [18]. Thc decrcased capacity of the left ventricle to empty during systole 
increases diastolic wall tension in the non-injured parts of thc hcart. Thc left ventricle 
responds by enhancing its contraction, following the Frank-Starling curve. AdditionaIly, 
the sympathetic nervous system is activateci, resulting in increased force anci frequency 
of contraction. Both compensator)' mechanisms also lead to a remarkable increase 
in internal ,vall stress during diastole. In response, synthesis of myofibrillar proteins is 
stimulated, resulting in increased wall thickness anel a subsequent reeluction of ventriCldar 
wal! stress anel dilatation, whieh reduces energy cxpenditurc [7]. l\'loreover, an increase 
in eliastolic wall stress in the atria supprcsses the sympathetic nerVOlIS system {19J and 
leads to the release of atrial (A-type) natriuretic peptide. Also, IJ-type natriuretic peptide 
and C-type natriuretic peptide are released, respectively by thc ventricular myocardium 
in response to elevations of end-diastolic pressurc and volume, and by endothelial celis 
in response to shcar stress (20). The natriuretic peptides improve the loading conditions 
on the heart through their diuretic, natriuretic and vasodilator properties. In this way, a 
delicate hemodynamic balance is achieved, which rcstorcs cardiac function [7). Long-term 
activation of these mechanisms, however, diminishes their favourable physiologic effects 
and results in progressive deterioration of ventricular funetion. As cardiac output declines, 
systemie perfusion is maintained by peripheral vasoconstriction anel sodium rctention [21). 
Catecholamines, angiotensin 1I and vasopressin act to increase systemic blood pressure 
anel cxpand intravascular volume, while prostaglanelins and natriuretic peptieles limit the 
pressor, antinatriuretic anel antieliuretic etfects of these vasoconstrictor systcms. \'X'ater anel 
salt retention result mainly from direct aod indirect effects of the renin-angiotensin systcm 
on glomcrular and tubular function. 
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Nonsteroidal anti-inflammatory drugs 
Mechanism of "tion 
NSAIDs are a structurally diverse group of drugs containing the salicylates, pyrazoles, oxicams, 
fenamates, arylacetie acids anel arylpropionic aciels [22]. They exert analgesie, antipyretie, anti-
inflammatory anel platelct-inhihitory actions. Inhibition of prostaglanelin synthesis, through 
inhibition of cyclo-oxygenase (COX), is the major mechanism of action [231. This enzyme 
metabolises arachidonie acid to prostaglanc!in Gz. This is reduced to prostaglandin H2' the 
precursor of vadous other prostaglandins, prostacyclins anel thromboxanes. COX consists of 
at least two different isoenzymes. COX-l is constitutively expressed ancl regulates functions 
such as gastric cytoprotection and vascular homeostasis [24]. COX-2 is predominantly present 
throughout all stages of the inflammatory response, but is also constinltively expresscd in 
parts of the kidney [161. 1\'lost NSAIDs inhibit both COX-l and COX-2, but in recent years 
selectivc COX-2 inhibitors, such as celecoxib and rofecoxib, have been developed. 
Effects on renal function 
At present, it is believed that the central mechanisll1 by whieh NSAIDs influence cardiovascular 
homeostasis follows from their effect on renal function, Potential prostaglandin-mediateel 
renal advcrse effects of NSAfD therapy are summarized in figure 1. prostaglandins arc known 
to exert their effects at the location at which they are synthesiseel anel are therefore referred 
to as autocoids. The major sites of COX in the kidney comprisc the artcrial tree, inclucling 
the afferent anel efferent arterioles, the glomerulus, and the collecting tubule. Furthennore, 
interstitial cells aeljacent to the thick ascending limb of Henle's loop anel in the medulla are 
rich in COX [251. Under normal, euvolemk conditions, prostaglandins do not plal' a major 
role in the maintenance of renal and glomemlar circulation [26]. However, in settings of 
decreased effective circulating volume, such as heart fallure, hepatk cirrhosis, chronie renal 
insufficiency, anel dehydration, prostaglandin prodllction is enhanced to preserve renal 
perfusion [271. Whenever renaI blood flow is compromiscd, the kielneys respond by rcleasing 
two types of honnones, angiotensin 11 anel prostaglandins [211. Angiotensin 11 decreases 
renal blood flow and leads to soclillm anc! water retention, in part by stimulating the release 
of vasopressin, The principal reoat prostaglandins, prostaglandin El (PGE) and prostacl'clin 
(PGIz), increase renal blood flow and enhance the excretion of sodium anel water, partly 
by opposing the actions of vasopressin, Activation of one honnonal system Î1lll11ediately 
triggers the release of counterregulatOly factors in the kidney. Although these two systems 
exert opposite effects, both act to preserve glomerular flItration rate [21]. Angiotensin 11 
exerts a vasoconstrictor effect on the intrarenal efferent arterioles, while a vasodilator effect 
is exerted by prostaglandins on the afferent arterioles. Uneler these circllmstances, inhibition 
of prostaglanclin synthesis by an NSAID will leael to excessive vasoconstriction, with a 
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subsequent decline in renal blood flow and glomenllar filtration rate [171. Consequently, 
acute renal fallure may occur. 
Eelema and sodium retention are the most common NSAID-associated adverse effects 
involving the kidney [27}. Although both have negligible consequences in healthy individu als, 
they may affect the unstable cardiovascular homeostasis in patients with heart failure, In case 
of renal hypoperfusion, a decrease in glomenllar filtration rate results in increased water 
and electrolyte reabsorption in the proximal tubule. PGE2 decreases sodium reabsorption at 
the thick ascending limb of the loop of Henle by inhibiting chloride transport. Inhibition of 
prostaglandin synthesis under these circumstances results in increased sodium, chloride and 
water reabsorption in the proximal convoluted tubule, anel increased sodium and chloride 
absorption in the ascending limb of the loop of Henie. PGE2 also antagonises the effect 
Effectîve clrculating volume! 
Renal blood flow! 
;----------1L-_N_S_A_ID_-' 
Edema 
Mean blood 
pressuret 
Figure 1. Prostaglandin-mediated renal adverse effects of NSAIOs with a potential effect on cardiovascular homeostasis, 
Effects of angiotensin 11 and natriuretic peplides A, B,and (, which are released in response to a decrease,respectively an increase 
in effective drculating volume, are not shown in this figure. 
70 
NonsteroJdal anti-lnflammatory drugs and heart failure 
of vasopressin on the collecting tubule, hence reducing water reabsorption. Thcrcfore, by 
blocking PGE2, NSAlDs callse an increasc in water absorption, a reduction in urinary voltllue 
and consequcntly, systemic tIuid retention [26]. \Vater retention which is disproportionate to 
sodium retention may lead lo the development of hyponatremia in some patients [28]. 
The antinatriuretic and vasoconstrictor effects of NSAlDs mayalso have important 
clinical implications with regard to blood pressure regulation. Several trials have shldied 
the effect of NSAIDs on blood pressure. Results of a meta-analysis sllggest that mean blood 
pressure is elevated by approximately 5 mm Hg in patients using these drugs [29]. The 
hypertensive effect in this analysis was most marked in hypertensive patients who were 
taking medication for their blood pressure. It has been shown that the use of NSAIDs 
decreases the antihypertensive effecls of thiazides, loop diuretics, a-adrenergic blockers, fl-
adrenergic blockers, and angiotcnsin converting enzyme (ACE)-inhibitors [29, 301. r ...loreover, 
in patients with severe voltllne depletion, NSAIDs may blunt the actions of diuretics and lead 
to severe tIuid retention [31]. Renal effects of the combination of NSAlDs with ACE-inhibitors 
depend on pre-existing renal function f32]. Under baseline eonditions, this combination 
has no overall effect on the kidneys. However, onder conditions of renal hypoperfusion or 
renal impairment, the 1wo drugs will interfere with the physiologic meehanisms that serve 
to prot eet glomerular filtration rate. Hence clinicians should avoid coprescrihing an NSAID 
and an ACE-inhibitor under these circllmstances. 
Suppression of prostaglandin~mediated renin release by NSAIDs may lead to a state of 
hyporeninemic hypoaldosteronism, resulting in hyperkalemia anel typc IV renal tubular 
acidosis. The degree of hyperkalemia is usuaUy mild, but cardiac arrest and even death 
may occur [33], NSAID-induced hyperkalcmia seldom occurs in the absence of ather defects 
of potassiuIll homeostasis. Patients at risk are, for example, lIsers of potassium-sparing 
diuretics, fl-blockers, and aldosterone antagonists. Especially insulin-dependent diabetics 
with rcnal dysfunction anel patients with renal failure are at high risk [17]. 
Apart from the prostaglanelin-mcdiated renal function abnormalities, NSAIDs are also 
associated with acute renal syndromes, sllch as nephrotic syndrome, acute interstitial 
nephritis, acute tubular necrosis, papillary necrosis, and acute glomerulonephritis [18, 21}. 
This is, however, relatively rare and outside the scope of this review. 
Renal-sparing nonsteroldal anti-inflammatory drugs 
Conventional renal-sparing nonsteroidal anti-inflammatory drugs 
Efforts have been made to dcvclop NSAIDs, which do not influenee renal prostaglandin 
synthesis and thereby lack prostaglandin-mediated adverse effects on renaI and cardiovascular 
homeostasis. Compared with other eonventional NSAIDs, sulindae was reported to have a 
Iower propensity for inhibiting renal prostaglandin synthesis anel impairing rcnal function 
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[34-371. Because the active sulphide metabolite of sulindac is inactivated b)' renal oxiclative 
enzymes, this was thought to minimise the effect of the drug on local renal prostaglandin 
synthesis [311. However, clinical studies have demonstrated that this drug is capable of 
inducing the same renal toxicity as other NSAlDs [38, 391. Similarly, nabumetone has been 
postulated to have renal sparing properties [34-36, 401. Like sulindac, nabumetone is a 
pro-drug, which is rapidly transfofIlleel in the liver to its active metabolite 6-methoxy-2-
naphtylacetic aciel (6-!",INA). Before bcing excreted in the urine, 6-lvINA is metabolized to 
inactive metabolites which are weak inhibitors of COX [34]. However, renal failure has been 
reported as a consequence of nabumetone use [41]. Overall, studies assessing whether 
nabumetone has renal-sparing properties do not provide a definitive answer to this question 
f33J. Current elata strongly suggest that nabumetone anel sulindac share the risks of adverse 
renal effects with other conventional NSAIDs. Therefore, use of these agents requires the 
same precmuions in patients at risk of aelverse renal effects during use of non-renal-sparing 
NSAlDs. \Vhether these effects may be less is currently unknown. Since most studies were 
smal! and carried out in paticnts with normal renal function, tlJrther studies are needed 
before conclusions can be drawn. 
Cydo-oxygenase-2 selective inhibitors 
The COX-2 selective inhibitors, celecoxib anel rofecoxib, were originally cleveloped to rcduce 
the incidence of gastrointcstinal advcrse effects associated with the use of conventional 
NSAIDs. Initially, it was assumed that these agents would also reduce nephrotoxicity, by 
inhibiting onIy COX-2, the inducible form of cyclo-oxygenase. However, renal impairment 
and heart failure due to treatment with COX-2 selecth'e inhibitors have been suggested in 
several publications [42-451. 
AIthough COX-I is expressed constitutively anel is involved in homeostasis while COX-2 
is mainly induced during pathophysiologic processes, there seems to be a significant overlap 
between expression patterns and functions of these two isofarms [461. Both are present in 
constitutive anel inducîble farms in the kiclney [47-52]. The physiological roIes of COX-I 
and COX-2 are not fully understood. In the human .. enal cortex, COX-2 is predominantly 
expressed intraglomerularl)' in podocytes, suggesting a role in the regulation of glomemlar 
helllodynamics through contraction of podocytes [53]. COX-2 expression decreases with salt 
depletion and increases with high-salt diet and dehydration [54-56]. Aelditionally, COX-2 
expression is upregulated aftel' treatment with angiotensin 11 inhibitors [571. Based on the 
expression of COX-2 in the kidney, anel the reglllation of COX-2 b)' sodiulll intake and 
angiotensin 11, it may be anticipated that COX-2 selective inhibitors exert sÎInilar effects on 
renal function as conventional NSAIDs. It has been suggested that COX-2 sclcctive inhibitors 
spare glomerular filtration rale, which may be meeliateel primarily by COX-I, while cffects on 
sodium excretion arc similar to conventional NSAIDs {S8, 591. However, this hypothesis was 
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based on clinical studies in healthy individuals on a sodium-replete dier. Additional studies 
in healthy subjects on a sodium rcstricted diet hayc dcmonstrated significant decreases in 
glomerular filtration rate with the use of COX-2 selecti\'e inhibitors [60, 611. Thcrefore, it 
appears that COX-2 selcctiyc NSAIDs have similar effect." on renal function as conyentional 
NSAlDs. 
Data from clinical trials abo suggest that rofecoxib and celecoxib have similar effects on 
blood pressure as the conventional NSAIDs [62J. With the exception of anc stud)', which 
compared a half-maximal dose of celecoxib with a maximal close of rofecoxib [63], trials 
comparing these two agents did not show significant differcnces in effects on blood pressure 
[62]. The inciclence of edema with the use of COX-2 selecti\'e inhibitors corresponds with 
that of conventional NSAIDs [62, 641. Currently, data are lacking on the risk of heart failure 
associatecl with the use of COX-2 selective inhibitors. Most clinical trials havc been carried 
out in healthy subjects, COl11parative studies of these agents in patients who are at risk for 
NSAID-incluced heart failurc are needed to evaluate thcir safety in sllsceptible individuals. 
Since the renal effects of COX-2 selectÎ\'e inhibitors appear to be si mil ar to the effects of 
conventional NSAIDs, administration of these drugs in patients susceptible to heart failure 
shoulcl be carried out with caution. 
Recentl)', it was suggested that the use of COX-2 selecti\'e inhibitors may be associated 
with an incrcascd risk of cardiovasclliar events, one of the major risk factors for heart failure. 
In an allalysis of clinical trials, l\'lukhcrjec ct al. concludcd that the use of rofecoxib increased 
the risk of cardiovascular events [651. Their conclusion was mainly based on the results of the 
Viox.x Gastrointestinal Outcomes Research (VIGOR) trial, in whieh the gastrointestinal safety 
of rofecoxib was compared with naproxen [661. In contrast, data from the Celecoxib I.ong-
term Arthritis Safety Study (CLASS), comparing celecoxib with ibuprofcn and diclofenac, 
did not support this association [64, 67], Important differences in patient charactcristics, 
concomitant use of aspirin, and convcntional NSAID comparators ma)' partiall)' account for 
the different findings between the two large clinical trials [461. A poolcd analysis b)' Konstam 
et al of 23 phase Ub through V trials fotll1d no excess in the number of cardiovascular events 
with the usc of rofecoxih as compared to placebo or NSAIDs other than naproxen 168], The 
data did, however, indieate that use of naproxen was associatcd with a decreased risk of 
carcliovascular events relative 10 rofecoxib, Unlike conventional NSAIDs, COX-2 selecth'e 
inhibitors have na effect on platelet derh'ed thromboxane A2 (TXA) production (59). This 
thromboxane causes platelet aggregration and is a potent vasoconstrictor. Hmvever, COX-
2 selectÏ\'e inhibitors do inhibit the production of vasodilatory and antiaggregator)' PGI2, 
It was thcreforc hypothcsized that the increased risk of cardiovascular events with the 
use of rofecoxib in the VIGOR trial may be explained by tipping thc halance in favour 
of prothrombotic eicosanoids [651. However, it couicl not be exduded that a potential 
antithrombotic effect of naproxen could also cxplain the difference between rofecoxib and 
naproxen. Afso, by inhibiting the inflammation processes, COX-2 selecth'e inhibitors Illay 
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A Table I. Observationa! studies on the association between (urrent use of NSAIDs and heartfaj[ure. 
Rrst author, year of publication Study design Population characteristics, sample size 
Heerdink,19981741 Cohortstudy Elderly recipients ofdiuretics and NSAIDs,identified in 
community phannacies, n= 10519 
Page,2000 l751 Case control study Patients admitted to the emergency department of a hospita!, 
n=1023 
Feenstra,2000!761 Cohortstudy Elderly redpients ofNSAlDs, with one hospitalisation for heart 
failure,identitied in community pharmades, n=559 
Merlo,2001[77] Ecological study Nationa! patient register Sweden 
Ftenstra,2002t78] Cohortstudy E!der!y recipients ofNSA!Ds in population: 
1) without heartfailure,n=5062 
2) with incident heartfaHure, n=85 
a:Per increase of one standalll deviation ofNSAID utilisation (52 defined daily doses/1000 inhabitants/day) 
RR = relative risk,OR = odds ratio 
n 
"" Outcome definition RRJOR (95% Cl) 
"C 
~
F"1I'SthOSp"ltaiisation with a primary orsecondarydiagnosis of 12(1.4-2.4) '" ~ heartfailure 
Hospitalisation with a primary diagnosis ofheartfailure 2.1 (1.2-3.3) 
Rehospitalisation with a primary diagnosis ofheartfailure 21 (1.4-3.4) 
Hospitalisation with a primary diagnosis of heartfailure 1.08 (1.04-1.12)' 
1) First occurrenee ofheartfaHure 1) 11 (0.8-1.8) 
2) HospitaJisation for re!apse heartfaHure 2) 9.9 (1.7-57.0) 
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actually exert anti-atherogenic effects [69]. Several observationaI studies have recently been 
published that examined the relationship between the use of naproxen and inddence of 
tllfoll1botie events. Ray et al found no evidence for a protcctivc effect of naproxen [70]. 
Three other studies, however, dell10nstrated a lmver risk of cardiovascular events with the 
use of naproxen as compared to non-use or use of other NSAIDs [71-731. Therefore, the 
wcight of evidencc is in favour of a cardioprotective effect of naproxen. Howevcr, findings 
of these studies do not darify the role of rofccoxib .. Morc research is necessary to assess thc 
ttUe risk of prothrombotic cardiovascular events assodated with the use of COX-2 selective 
inhibitors. 
Quantitative studies 
As mentioned above, several case rcpol1s have been published in whieh the occurrence or 
exacerbation of heart [allure was attributed to the lIse of NSAIDs [9-131. .I\'lost of these patients 
had pre-existing heal1 disease. In view of the role of prostaglandins in the pathophysiology 
of heart failure, and the adverse renal effects of NSAIDs, it seems plausible that NSAIDs exert 
adverse effects in patients at risk for developing heart failure. So far, onl)' few observationaI 
studies on thc association between NSAlD treatment and the onset of heart failure have 
been published (table I). 
The first analytic study that was published was performed in a cohort of users of diuretics, 
aged 55 ycars and older [741. In this study, the concomitant use of NSAIDs and diuretics as 
compared with the use of diuretics alone was associated with a two-foIdly increased risk of 
first hospitalisation for heart failure. 1\'lost hospitalisations occurred within one month aftcr 
initiation of combined therapy, with the highest risk occurring within the first da)'s of NSAlD 
usc. As this study was pcrformed in a cohort of users of diuretics, and the relative risk was 
higher in individuals with a history of heavy diuretic lIse, it scems likely that a nUll1ber of these 
patients had symptomatic cardiac dysfunction preceding the date of first hospitalisation for 
hcal1 failure. Page et al. conducted a matched case-control study in two public hospitals [751. 
They found a doubling of the risk for hospitaI admission with heart fallure in patients lIsing 
NSAlDs in the preceding week. The estimated odds ratio was higher for a fiTst admission 
with hcart failure, and increased with high-close and long plasma drug half-life. A much 
stronger association was found in patients with a history of heart disease. The findings of 
this study are consistent with an in1portant effect of NSAlDs in patients with lcft ventricttlar 
impairment. In agreement with thc above mentioned studies, are the results of a cohort 
study conducted in patients aged 50 years or older with a previous hospitalisation for heal1 
failure [761. Among patients who had received at least one NSAID prescription during the 
follow up period, current lIse of NSAIDs was associated with a two-foIdly increased risk of 
rehospitalisation for beart fallure. In the total cohort, risk of reIapsing heal1 failure associated 
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with the use of NSAIDs was non-significantly increascd by 41%. To study the impact of 
NSAID utilisation on hospitalisations for heart failure in Sweden, lVlerlo ct aL pcrformed a 
nationwide ecological study [77J. The relative risk of hospitalisation because of heart failure 
was significantly increased by 8% with evcry illcrease of one standm'd deviation of NSAID 
utilisation. However, a piûall of the ecological design is that individual events are not Iinked 
10 individu al exposure or covariate data. Secondary diagnoses of heart failure were not 
uscd in this study and primary diagnoses were not valiclated. In a recently published, large 
population-based cohort study in the Netherlands, anlong community dwelling elderly, 
cunent use of NSAIDs was not associated with an increased risk of incident hcal1 failure 
[78]. Incident heart failure was defined as the flfst occurrence of heart failure, irrespective of 
whether this event led to a hospital admission. This definition is more specific than in the 
previous described studies, in whieh only hospital admissions \vere considered. The risk of 
hospital admission for relapsing heart fallure was, howevcr, signiflcantly increased in current 
users of NSAIDs among persons who had filled at least one NSAID prescription at any time 
since flrst diagnosis of heart failure (adjusted relative risk 9.9). 
Overall, the observational studies that have been published strongly suggest that the risk 
of developing symptoms of heart failure is elevated during the use of NSAIDs by patients 
who are susceptible to the dcvclopment of myocardial decompensation. No significant 
association was found between incident heart failure and NSAID treatment. 
Conclusion 
Considcring clirrent knowledge of the effects of NSAIDs on renal function and water and salt 
homeostasis, the impol1ant role of prostaglandins in the pathophysiology of heart failure, 
and evidence from observational studies, it is vely Iikely that NSAIDs may increase the risk 
of devcloping symptoms of heart fai/ure in susceptible patients. Patients with a history of 
cardiovascular disease, such as pre-existing heart failure, are pal1icularly at risk. NSAIDs 
ShOllld therefore be prescribed to sllch patients as Iittle as possible. If a prescription is 
jllstified, monitoring of renal function, adequate patient education and increascd attention 
for signs and symptoms of heal1 failure is mandator)'. It is unlikcly that these dmgs can also 
induce heart failurc in otherwise healthy individuals. 
The actual risk of NSAID-induced heart failure is currently unknown. Fcw quantitative 
studies have been performed. These studies consistently found that the risk is at least 
doubled in paticnts with teft ventricular impairment. NSAIDs are utilised widely, mainly 
among elderly individuals, who are particularly susceptible to the adversc rcnal cffects of 
these agents. At the same time, heart failure is an increasingly prevalent disease. Further 
studies are needcd to quantify the risk of NSAID-induced heart failure in patients with 
asymptomatic cardiac dysfunction and to assess the risks of individual NSAIDs. Diffcrenccs 
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between individual NSAIDs in the ability to induce heart [ailure have not yet been 
demonstrated, but may exist. Although several agents have been claimed to have renal 
sparing properties, including sulindac and nabumetone, insufficient evidence has sa far 
been provided ta suhstantiate this. Overall, it appears that COX-2 selective inhibitors have 
similar effects on renal function as the canventianal NSAIDs. Since the central mechanism 
hy which NSAIDs influence cardiovascular homeostasis is their effect on renal function, it 
seems plausible to assume that COX-2 selective inhibitors mayalso induce heart failure in 
susceptible patients. 
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Apolipoprotein E E4 allele is associated with left 
ventricular systolic dysfunction 
Chapter4.1 
Abstract 
Background: Apolipoprotein (APOE) E4 allele has been associated with cardiac dysfunction 
in Alzheimer's disease and B-thalassemia. \'{fe investigated the assodation between APOE 
genotypes and left ventriclIlar dysfunction in a poplliation of community-dwelling e!dcrly. 
r.,'fethods: This study was performed in the Rotterdam Shldy, a population-based prospective 
cohOJt study among elderly. For 2,206 participants, a baseline echocardiogram and blood 
specimens for APOE typing were available. Cardiac dysfunction was considered present jf 
fractional shortening was 25% or less. Multivariate logistic regression was used to calclliate 
odds ratios. The E3/E3 genotype sen'ed as a reference category. 
Results: In participants homozygous for the E4 aIleIe, the odds of cardiac dysfllnction was 
increased thrce-fold (OR 3.1, 9S%CI 1.2-8.1), while the odds of persons with APOE E3/E4 
was non-significantly increased (OR 1.5, 95%CI 0.9-2.5). Therc was a significant allele-effect 
relationship for the E4 aIlele (p-trend<O.OS). These elevated odds remained after adjustment 
for cholesterol levels and atherosclerosis parameters. Risks associated with APOE E4/E4 
and APOE E3/E4 \Vere more pronounced in participants agcd 65 l'ears or older. 
Conclusion: The APOE E4 allele is an independent risk factor for cardiac e1ysfllnction in the 
elderll'. Besides well-known effects on atherosc1erosis anel cholesterolleveIs, there mal' be 
other mechanisms, sllch as apoptosis, through which this allele exelts negative effects on 
myocHrdiHl performance. 
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Introduction 
It is well established that the E4 aIlele of the apolipoprotein E (APOE) gene is a major risk 
factor for Alzheimer's elisease [1], anel that it is associateel with an increased risk of coronary 
heart disease, in particular at early age [2]. The APOE gene is located on chromosome 19 
anel has dlfee common alleles (E2, E3, and E4), resulting in six APOE genotypes. The APOE 
polymorphism involvcs the coding region of the APOR gene and results in changes in the 
gene product, leading to an altered metabolism anel transport of lipoprotein particles [31. 
Besieles being a risk factor for coronaty hcmt disease in most populations, there are 
indications that the APOE Eli allele is associated with an increased risk of (a)symptomatic 
left ventricular e1)'sfunction in patients with Alzheimer's e1isease (4] anel in patients with ~­
thalasscmia [51. Asymptomatic Icft vcntricular systolic dysfunction is generally acccpted to be 
a precursor of heart failure. A redllCed ejection fraction increases the risk of cardiovascular 
mOl1ality anel hospital aelmissions for he;:ut failure [61. J'\'lost common causes are coronary 
artely disease, hypertcnsion, valvular disease and cardiomyopathy [7]. Early detection anel 
treatment of impaired left ventriclIlar function might lead to a considerable reduction in 
morbielity anel mortality in the elderly. 
So far, the role of APOE in cardiac dysfunction has not been investigated in the general 
poplliation. \\'e examined the relationship between APOE genotypes arrel left ventriClIlar 
systolic dysfunction in a poptllation of elderly. 
Methods 
Setting and st"dy pop"lation 
The Rotterdam Study is a population-based prospective cohort study of careliovasclllar-, 
locomotor-, neurologic- anel ophthalmologic diseases in thc cldcrly [SJ. Participants were 
recmited from inhabitants of Ommoord, a suburb of Rotterdam in the Netherlands, who 
were 55 years of age and older. Of the 10,275 eligible subjects, 7,983 gave informed 
consent (7S%). Participants were visited at home for a standardised qucstionnaire and were 
subsequently cxamined at the research centre, where echocardiography was performed in a 
sample of 2,S23 subjects. In 19.7% (n=556), echocardiographic registrations were considered 
inadequate tor reliable measurement of left ventricular dimensions [91. This percentage is 
comparable to other population-based shldies (10). The analyses were restricted to persons 
for whom blood specimens were available for APOE typing (n=2,206). 
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left ventri,"l" systolic dysfunction 
For assessment of left ventricular systolic function echocardiography was carried out with 
the participant in the partial left decubitus position using a 2.75-.MHz transducer (Toshiba 
SSH-60A Nasuworks, Otawara, Japan). Two-dimcnsional imaging using parasternal long-
axis views was perfofllled to aid M-mode studies. Measurements were made according to 
guidelines of the American Society of Echocardiography. Left ventricular internal dimension 
was measured at end-diastole (LVIDed), as defined by the onset of the QRS complex, and at 
end-systole (LVIDes), as determined at the nadir of septal motion. The percentage fractional 
shortening was calculated as 100 .. ((LVIDed-LVIDes)/LVIDed). This percentage reflects left 
ventricular systolic function in the absence of major waIl motion abnormalities [11]. Left 
ventrictilar systolic dysfunction was considered present if fractional shol1ening was less than 
or equal to 25%, corresponding to a left ventricular ejection fraction of 42.5% [9], 
APOE genotype 
Genotyping for APOE was perfornled on coded DNA specimens, as described in detail 
elsewhere [12]. Briefly, a polymcrase chain reaction was performed and the amplification 
products were digested with Hhal. The resulting restriction fragments were separated 
on precast gels (ExcelGel, Pharmacia Biotech, Uppsala, Sweden) by electrophorcsis 
(lvlultiPhorII, Pharmacia Biotech) and visualized by silver sta in ing. Three persons read the 
results independently, and were blinded to the participant's assessment of left ventricular 
systolic function. In case of discrepancies, APOE genotyping was repeated. 
O/her variables 
Information was gathered during the interviewand at the research centre on several potentiat 
confounders such as age, gender, pre-existing cardiovascubr disease (myocardial infarction, 
hypel1ension, history of corona!)' artel)' bypass graft (CABG), history of percutaneous 
transluminal corona!)' angioplasty (PTCA»), smoking (classified as never/former/current), 
alcohol intake, and body mass index. Hypertension was defined as use of antihypertensive 
medication for the indication high blood pressure, or as a systolic blood pressure of 160 mm 
Hg or over, or a diastolic blood pressure of 95 mOl Hg or over. Diabetes mellitus was defined 
as use of anti-diabetic medication, or a random or post-load serum glucose level higher than 
11.0 mmolil. Serum total and high density lipoprotein (HDL)-cholesterol concentrations 
were determined by using an automated enzymatic procedure. For determination of ankle-
arm index, lhe ratio of systolic blood pressure at the ankle and the systolic blood pressure at 
the right anu was calculated for each leg. peripheral arterial disease was considered present 
when the ankle-arm index was lower than 0.9 on at least onc side. Aortic atherosclerosis 
was diagnosed by radiographic detection of calcific deposits in the abdominal aorta. Lateral 
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abdominal X-rays were made from a fixed distance with the subject seated. Calcifications 
were judged to be present when linear densities were seen in an area parallel and anterior 
to the hunbar spine (11-L4). In the analyses, aorta calciflcations were classified as absent 
or present. To measure carotid intima-media thiekness, uhrasonography of the len and 
right conunon carotid artery was perfofllled with a 7.5-MHz Iinear-array transducer (A11 
Uitra-Ivlark IV). On a longitudinal, two-dimensional ultrasound image of the carotid artery, 
the anterior (near) and posterior (far) walls of the carotid artery are displayed as two 
bright white lines separated by a hypoechogenic space. The distance between the leading 
edge of the flrst bright line of the far waIl and the leading edge of the second bright line 
indieates the intima-media thiekness. The actual measurements of inti ma-media thickness 
were performed off-line. Thc procedure has been described in detail previously 03, 14]. 
The average of the mean anterior and posterior intinla-media thickness of both the left and 
right conunon carotid artery was used for thc current analyses. When one or more of thc 
intima-media thickness measurements could not be obtained, the average of the remaining 
measurements was used for analyses. 
Analysis 
Continuous variables were expressed as mean ± SD and categorical variables as proportions. 
Comparisons were evaluatcd with t-tests and xl-tests as appropriate. Agreement of the 
genotype frequencies with the Hard)'-\Veinberg equilibrium expectations was tested using 
a xl-test. For the estimation of re1ative risks of left ventricular systolic dysfl.1nction by 
genotype, a case-contra! analysis was perfofll1ed, in whieh a multiple logistic regression 
model was used to calculate odds ratios for the different genotypes plus 95% confidence 
intervals (CI). The E3/E3 genotype served as a refcrcncc category. Age (years), gender, 
hypertension, smoking, diabetes mcllitus, histOIy of myocardial infarction, history of CABG, 
history of PTCA, alcohol intake (0, <30 glday, ~30 glday), peripheral arterial disease, aorta 
calcifications, body mass index (kglm2), total cholesterol (mmoI!O, HDL-cholesterol (mmoll 
0, and mean caratid intima-media thickncss (divided in quartiles) were added to the models 
to adjust for potential confounding. None of these factors changed the point estimate of 
the associatÎon between APOE genotype and left ventricular systolic dysfunction by more 
than 10% when added to the age- and gendcr corrected 1l10deL Some of these covariates 
are not considered as confounders but as intermediates in the association between APOE 
genotype and impaÎred systolic fllnction. They were added to the model to evaluatc if other 
mechanisms besides atherosderosis and coronary heart dÎsease can be responsible for an 
association between APOE genotype and len ventricular dysfllnction. The same models 
were used to test for an aIlde-effect relationship (trend test) of thc E4 alleie. Por catcgorical 
covariates with missing va!ues we incorporated missing indicator varia bles in the model. On 
all potential confounders more than 98% of information \vas available, except on peripheral 
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arterial disease (94%), a0l1a calcifications (89%), alcohol intake (83%), and mean carotid 
intima-media thickness (7Ç)<}'Ó). To study potential effect modification by age, the population 
was divided into two strata: younger than 65 years, and 65 years of age or oider. Interaction 
terms for these two age-groups, hypel1ension and diabetes mellitus were added to the 
multivariate rnodcl. 
Results 
General characteristics of the study populatiol1 are presented in table 1. Participants with 
left ventricldar systolic dysfunction were on average older, more often male, and had a 
higher mean carotid intima-media thickness compared wÎth controis with normal cardiac 
function. AOl1a calcifications, history of myocardial infarction, CABG, or PTCA were also 
more frequent in cases than in controls, ancl the percentage of farmer smokers was higher. 
The distribution of APOE genotypes was in Hardy-\~reinberg equilibrium CX2 = 1.4, df=3, 
2p~O.7). 
A..., shown in table 2, the odds ratio (OR) for systolic dysful1ction associated with APOE 
Eq/E4 was 3.1 (95%CI 1.2-8.1), after adjustment for confounding variabies. Participants with 
APOE E3/E4 had a l.5-foldly increased odds C95%CI 0.9-2.5), although this did not reach 
statisticat significanee. However, there was a significant allele-effect relationship Cp-trend 
<0.05). According to the model, the adjusted odds of cardiac dysfunction is multiplied by 
1.57 per APOE E4 allele present (including E2/E4-, E3/E4-, and E4/E4 genotypes). Thc 
APOE E2 allele was not significantly associated with impaired systolic function, but numbers 
were small. Age, gender, histary of CABG, and history of myocardial infarction were the 
only covariates significantly associated with decreased percentage fractional shortening in 
the multivariate model. Restriction to participants without a history of myocardial infarction 
rcyealed an OR of 2.9 C95%CI 0.9-8.8) for the association between APOE E4/E4 and left 
ventricular dysfunction, and an OR of 1.4 C95%CI 0.8-2.6) for APOE E3/E4. 
Stratification of the Shldy population by age silOwed that the increase in odds associated 
with APOE E4/E4 \vas only present in pm1icipants of 65 years of age or older (OR 3.8, 
95%CI 1.1-13.1). In this age-group, APOE E3/E4 was al50 associated with a signifkantly 
increased odds of impaired systolic function (OR 2.0, 95%CI 1.0-4.0). Analyses in the 
younger age group yielded only 2 cases with APOE E4/E4 (OR 2.7, 95%CI 0.6-13.2), anel 6 
cases with APOE E3/E4 (OR 1.0, 95%CI 0.4-2.7). In a multivariate model interaction terms 
of APOE genotypes and the two age-groups, hypertensiol1 and diabetes mellitlls were non-
significant, indicating that there was 110 significant effect 11l0dification by these varia bles in 
this population. 
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Table 1. General characteristics, 
Ag, 
< 65 years 
65-75 years 
;:: 75years 
Female 
Body mass index (kglm1) 
Total (holesterol (mmol/l) 
HOL-cholesterol (mmol/l) 
Fractional shortening (%) 
Peripheral arteria! disease 
Aorta (aldficalions 
Mean carotid Intima-media thicknm (mm) 
Hypertension t 
Historyof myocardial infarclion t 
Diabetes melHtus § 
5moking: 
Cmrent 
Former 
Never 
Alcohol intake (g/day) 
Hislory of CABG 
HisloryofPTCA 
Values are means (±5D) or numbers (%) 
lf comparison cases and controls:p<O_05 
Cases (n=82) ControJs (n;=;2,124) 
27 (33%) 1,171 (55%) 
40(49%)' 693 (3J%) 
15 (18%)' 260 (12%) 
26 (32%)' 1,170(55%) 
26 (±2.9) 26 (±3.3) 
6.4 (±1.1) 6.6 (±1.2) 
1.3 (±0.4) 1.3 (±0.4) 
11(±Tl.1I" 40 (±6.7) 
Tl (16%) 197(9%) 
57 (70%)' 1,122 (53%) 
0.84 (±0.18)' 0.78 (±0.15) 
30 (37%) 648 (31%) 
24(29%)' 181(8%) 
9(11%) 149(7%) 
14(17%) 466(22%) 
52 (63%)' 940(44%) 
16(20%) 703 (33%) 
10.9 (± Tl.l) 10.4 (± 14.3) 
9 (11%)' 36(2%) 
3(4%)' 18(1%) 
t use of antihypertensive medication for treatment of high blood pressure,or systolic blood pressure of 160 mm Hg or over,or 
diaslol1c blood pressure of 95 mm Hg or over, 
* myocardial infarction according la general practitioner,cardiologisl or ECG. 
§ use of anti-diabetic medication,or as a random or post-Ioad serum glucose level higher than 11.0 mmol/l, 
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Table 2. Association between left ventricular systolic dyslunction and APOE genotypes. 
MOE genotype: Cases Control) ORadjusled Adju)ted OR" 
for age and sex 
El/ElI 41 (50.0%) 1,212 (57.0%) 1.0{reference) 1.0 (reference) 
E2!E2 1 (1.2%) 15 (0.7%) 1.5 (0.2-12.2) 2.4 (0.3-2t.0) 
E2!El 9(1\,0%) 26l (12.4%) \.1(0.5-2.5) 1.1 (0.5-2.3) 
El/E4 1(1.2%) 6l (l.O%) 0.5(0.I-l.4)1 0.5 (0.1-3.9)1 
El/E4 24(29.3%) 510(24%) \.4 (0.8-2.4)1 t.5 (0.9-2.5)1 
E4/E4 6 (7.3%) 61(2.9%) 2.8 (1.1-7.0)1 3.1 (I.2-8.1)! 
number (%);odds ralio (OR) with 95% confidence interval. 
* Adjusted for APOE genotype,age (years),gender,body mass index (kg/m'), total cholesterol (mmolIl), HDl-cholesterol 
(mmol!l),peripheral arterial disease,aorta calcificaliom, mean carotid inti ma-media thickness {quartiles),hypertension, history 
of myocardial infarction, diabetes mellitus, smoking (never, former,current), alcohol intake (0, < 30 gr/day, ~:30 gr/day),history of 
CABG,and history ol PICA. t Reference group, j E4 allele-effect relalionshlp: p-trend <0.05. 
Discussion 
The results of this study indieate that the APOE E4 allele is associated with left ventricular 
systolic dysfuncHon in an elderly population. Participants homozygolls for the E4 allelc 
carried a three-foldly increaseel odels of impaired systolic function, while thc oclds of persons 
with APOE E3/E4 was non-significantly increased by 50%, There was a significant allele-
effect relationship, The elevated risk remaincd after adjustment for tOlal- and HDL-cholesterol 
levels, atherosclerosis parameters, and coronaf)' heart disease, whieh were consiclered as 
intermcdiates in the potential association between APOE genotype and cardiac dysfunction. 
Point estimates were si mil ar in analyses restricted to partidpants without a prior histof)' of 
myocarelial infarction. The odds assodated with APOE E4/E4 ancl APOE E3/E4 \Vere more 
pronounced in pal1icipants of 65 years of age or oleler, However, numbers were smal!, and 
since there was no significant effect modification by age, these results shotild be intcrpreted 
with caution. Although no significant association was found for the APOE E2 allele, sample 
size was to~ smal! to conclllele that this allele is not associated with cardiac dysfunction, 
Two other studies have found an assodation bet\Veen cardiac dysfunction anel thc APOE 
E4 alleie, The first demonslrated lhat, in patients with Alzheimer's disease, APOE E4/E4 
carriers have a 7.2-foldly increased risk of ECG-abnormalities indieative of left ventriclliar 
elysfunction [4]. The second study compared the E4 allele frequency in patients with 13-
thalassemia major, stratifted by careliac status, with the frcquen<-y in a control sample of 
healthy blood donors [51. The E4 al!ele frequency in patients with left ventricular faillIre was 
doubled as compared to thc frequency in healthy controls. 
All advantage of the present investigation over the previous studies is that it enabled 
us to determine relative risk estimates in the general population, rather than in specifIc 
subgroups, The selection of cases and controls in this study was independent of APOE 
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genotype, whieh minimized the risk of selection bias. However, because the APOE E4 altele 
has been associated with incrcased mortality in patient,> with ischemie heart discase US], and 
as this study was perfonned in an elderly population, survival bias may have played a roie. 
]\:Ioreover, old and diseased individu als were less likely to participate, resulting in a healthier 
study population. It seems likely, however, that th is may lead 10 an underestimation rather 
than to an overestimation of the risks. Information bias is not likely, since all data on APOE 
genotype and left ventricular function were recorded similarly for all participant,,> without 
prior knowledge of our study hypotheses. The time of onset of cardiac dysfunction was 
unknown. Symptomatic dysfunction prior to the date of echocardiography may have led 10 
alterations in life style or medieal interventions, thereby altering the risk factor profile of the 
cases, making them more similar to the controls, This lllight explain the modest effect of 
some well-known confounders in th is study. 
The acnml mechanism by whieh the APOE E4 ailele increases the risk of impaired left 
ventricular function is unknown, In this snIdy, the potential influence of APOE genotype 
on senUll cholesterol and atherosderosis could not explain the relationship. Earlier, wc did 
report an effect of APOE E2 on atherosderosis [16], There are several studies in which the 
association between APOE genotype and coronaly a11ery discase or Alzheimer's disease was 
independent of atherosclerosis and plasma cholesterol concentrations [17-191. \Ve hypothesize 
that cardiomyocyte apoptosis is one of the mechanisms through whieh the APOE E4 allele 
exerts negative effects on left ventricular function, Investigations in Alzheimer's disease 
have shown that APOE is involved in apoptosis and that the E4 allele exerts isoform-
specifIc neurotoxicity through various pathways, one of whieh is Fas-mediated apoptosis 
[20, 21], Fas-mediated apoptosis has also been shown to occur in cardiomyocytes [22], 
Studies in failing human- and animal hearts have led to the hypothesis that progressive left 
ventrictdar dysfunction may result, in part, from ongoing loss of cardiomyocytes [23]. Adult 
cardiac muscle cells are thought to have a very limited capacity for self-renewaL Death of a 
significant number of adult cardiomyocytes, either by necrosis or apoptosis, could therefore 
permanently diminish cardiac performance. Apoptosis has been detected in the failing 
heart, regardless of predisposing factors, and generally affects scattered individual cells 
{24]. Cardiac dysfunction increases as a consequence of elevated reactive oxygen species 
formation, which in hun promotes myocyte apoptosis {2S]. APOE possesses anti-oxidant 
activity [51. The effect seems to be isoform-specific, with E4 expressing the least anti-oxidant 
activity [261. The aging process occurring in thc heart is characterised by a significant 10ss 
of cardiomyocytes and reactive hypertrophy of the remaining cells [27]. The sllsceptibility of 
myocytes to cell death, including apoptosis, increases with age. It is estimated that the aging 
process itself contributes to loss of nearly 30% of all left ventrîcular cardiomyocytcs [23], 
This ongoing cellioss Illay be partly responsible for the increased risk of cardiac dysfunction 
seen in the elderly, 
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In conclusion, the APOE E4 allele is an independent risk factor for len ventricular systolic 
dysfunction. Besides well-known effects on atherosclerosis and cholesterol levels, there may 
be other mechanisms, such as apoptosis, through which the APOE E4 aIlele exerts negative 
effects on myocardial performance, 
References 
L Slooter AJC, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes 
from a population-based incidence study: The Rotterdam Stud)', AfCh Neurol 1998;55:964-8. 
2. Wilson PWI~ Schaefer EJ, Utrson MG, et al. Apolipoprotein E aHeles and risk of coronary discase. 
A meta-anal}'sis. ArterioscIer Thromb Vasc BiolI996;16:1250-5. 
3. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. 
Arteriosclerosis 1988;8: 1-21. 
4. Van def Cammen 1JM, Verschoor C], van Loon CPM, et al. Risk of left ventricular d>'sftmction in 
patients with probable Alzhein1er's disease with APOE·4 aIleIe. JAm Geriatr Soc 1998;46:962-7. 
5. Economou-Petersen E, Aessopos A, Kladi A, et aL Apolipoprotein E e4 aIleIe as a genetic risk 
factor for left ventricular failure in homoz}'gous f3-thalassemia. nIood 1998;92:3455-9. 
6. McKelvie RS, Benedict CR, Yusuf S. Pre\'ention of congestive heart failure and management of 
asymptomatic left ventriCtdaf dysfunction. Hr MedJ 1999;318:1400-2. 
7. Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure. Guidelines for 
the primary care physician and the hcart failure specialist. Areh Intern Med 2001;161:342-52. 
8. Hofman A, Grobbee DE, de Jong PTVM, et al. Determinants of disease and disabilit}' in the 
elderly: Tbe Rotterdam Stud}'. Eur J EpidemioI1991;7:403-22. 
9. Mosterd A, Hoes A\Y/, de Bnwne r-,·tC, et al. Prevalenee of heart failure and Ieft ventricular 
dysfunction in the general population; The Rotterdam Stud}'. Eur HeartJ 1999;20:447-55. 
10. Savage DD, Garrison Rl, Kannel WH, et al. Considerations in the use of eehoeardiography in 
epidemiologr. The Framingham Study. Hypertension 1987;9 (2 Pt 2):1140-4, 
11. Quinones MA, Pickering E, Alexander JK. Percentage of shortening of the echocardiographic 
left ventricular dimension. ft<; use in determining ejection fraction and stroke volume. Chest 
1978;74;59-65. 
12. Van Duijn CM, de Knijff P, Cruts M, et al. Apolipoprotein E4 aIleIe in a population-hased study 
of early-onset Alzheimer's discase, Nat Genet 1994;7:74-8. 
13, \'\'endelhag I, Gustavsson T, Suurkuia M, et al. Ultrasound rneasurement of wall thickness in the 
carotid arter)': fundamental prindples and description of a computerized analysing system, Clin 
Physiol. 1991;11:565-77, 
14. flots ML, Hofman A, Grobbee DE. Comrnon carotid intima-media thickness and lower extremity 
arterial atherosclerosis. The Rotterdam Study. ArterioscIer Thrornb, 1994;14:1885-91. 
15. Frikke-Schmidt. Context-dependent and im'ariant associations between APOE genotype and 
levels of lipoproteins and risk of ischemie heart disease: a review. Scand J Clin L'lb Invest Suppl 
2000;23303-26. 
16. Slooter AL Bots AlL, Havekes L\I, et al. Apolipoprotein E and carotid arter)' atheroscIerosis: the 
Rotterdam stud}'. Stroke 2001;32:1947-52. 
17. Scuteri A, Bos AJG, Zonderman AB, et al. Is the apoE4 allele an independent predictor of 
coronary event<;? Am J J\Icd 2001;110:28-32. 
18. Räillä 1, Marniemi J, Puukka P, et al. Effect of serum lipids, lipoproteins, anel apolipoproteins on 
vascular aml nonvascular mortality in the elderly, ArterioscIer Thromb Vase Biol 1997;17:1224-
32. 
19. Prince M, Lovestonc S, Cervilla J, et al. The association between APOE alld dementia does not 
seem to be mediated by vascular factors. Neurology 2000;54:397-402. 
92 
ApoHpoprotein E f4 allete and [eft ventricutar systolic dysfunction 
20. Feuk L, PrinceJA, Breen G, et al. Apolipoprotein-E dependent role for the FAS receptor in early 
onset Alzheimer's discase: finding of a posiHve assodation tor a polymorphism in the TNFRSFG 
gene. Hum Genet 2000j107:391-6. 
21. Hashimoto Y, Jiang H, Niikura '1~ et al. Neuronal apoptosis by apolipoprotcin E4 IllfOugh lo\\'-
densit)' lipoprotein receptor-relatcd protein and heterotrimcric GTPases.J Neurosci 2000;20:8401-
9. 
22. Samste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 
2000;45628~37. 
23. Sabbah HN. Apoptotîc cell dealh in heart faîlure. Cardiovasc Res 2000;45:704-12. 
24. Olivetti G, Abbi R, Quaini P, ct al. Apoptosis in the failing human heart. N Engl J Med 
1997;336,1131~L 
25. Hare JM. Oxidative stress and apoptosis in heart failure progression. [Editorial} Circ Res 
2001;89,198~200. 
2G. Miyata M, SmithJD. Apolipoprotein E aHele-specific antioxidant activity alld effecls on cytoloxidty 
by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61. 
27. Higami Y, Shimokawa r. Apoptosis in the aging process. Cell Tissue Res 2000;301:125-32. 
93 

, 
Absence of the 192-base pair allele in a promoter 
polymorphism of the insulin-like growth factor-
I gene is associated with an increased risk of left 
ventricular hypertrophy 
Chapter 4.2 
Abstract 
Objective: Altered serum levels of insulin-like growth factor I (IGF-I) have been associated 
with adverse cardiac remodeling. A promoter polymorphism in thc IGF-I gene may alter 
senun IGF-I levels. \'\'c investigated the association between dus polymorphism and left 
ventrictIlar hypertrophy. 
r.,'lethods and results: This stud}' was perfornlcd in the Rotterdam Study, a population-
based prospective cohort study among elderly. Analyscs were perfOf1l1ed with baseline 
mcasurCl11cnts in subjects aged betweco 55 and 75 years, without a history of myocardial 
infarction (n=1,678). Lcft ventriClJlar hypeltrophy was defined as a left ventricular mass 
index ~ 104 glm2 in wamen aod ~ 116 glm2 in men. Non-carriers of the 192-base pair 
allele of a cytosine-adenosine repeat in thc IGF-I gene had a 1.5 foldly-increased risk of 
len ventricular hypertrophy as compared to subjects homozygous for the wild type aUele. 
Although we found no clearly increased association in heteroZ}'gotcs, there was a significant 
allele-effect relationship (p-trend<0.05). 
Conclusion: Non-carriers of a 192-base pair polymorphisl11 in the IGF-I gene arc more 
susccptible to the development of !eft ventricular hypertrophy than individuals homozygous 
for this allele. 
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Introduction 
Left ventricular hypertrophy is astrong predictor for cardiovascular morbidity and mortality 
[1J. The stmcture of the left ventricle is influenced by several factors such as blood pressure, 
age, gender, body mass index, diabetes mellitus, and pre-existing cardiovascular disease 
[2, 31. These factors, howevcr, do not completcly explain the variability in left ventricular 
mass_ Of the other factors involved, insulin-like growth factor I OGF-I) may explain part of 
th is variability [4]. IGF-I is a polypeptide growth factor that is expressed in many organs, It 
is the product of the IGF-I gene, which has been mapped to chromosome 12 [51 Evidence 
has accumulated that, in adclition to its growth-promoting and metabolic cffects, IGF-I has 
cardioprotective effects by reducing myocardial apoptosis and injury in response to ischemia 
[61. t\'Ioreover, fmdings suggest that lowered free IGF-I levels are associated with a higher 
prevalence of cardiovascular disease (7J. 
There are several limitations of studies conducted on serurn IGF-I levels in rclation 10 
cardiovascular clisease. J\·lost of these studies have been performed cross-sectionaHy, making 
it difficult 10 distinguish whether altered serum IGF-I levels are a cause or a consequencc 
of the underlyillg disease. In addition, scrum levels of IGF-I are profoundly influenced by 
various factors such as growth hormone, insulin, age, diet, physical activity and genetic 
factors [8, 91 A genetic polymorphism in the IGF-I promoter region has been iclentified 
which illfluences IGF-I production [10, 11]. RecentlYI we ohserved lower circulating total 
IGF-I levels in non-carriers of the wild type ailele of this polymorphism than in homozygous 
carriers [12, 131 Studying the effect ofthis polymorphism in relation to pathology may better 
reflect the cffects of long-term IGF-I exposure than studies on circulating semm IGF-I levels, 
which Illay fluctuate considerably, FUl1hermore, studies of genetic determinants of IGF-I 
levels may suffer less from the confounding influence of other factors. 
This study aims to investigate the association between a promoter polymorphism of the 
IGF-I gene and the occurrence of left ventriClJlar hype11rophy on the echocardiogram. 
Methods 
Setting and study population 
The Rotterdam Study is a population-based prospectivc cohort study of cardiovascular-, 
locomotor-, neurologic- and ophthalmologic dise,lses in the elderly [14]. All inhabitants 
of OnU11oord, a suburb of Rotterdam in the Netheriands, who were 55 years of age or 
oloer were invited to pat1icipate. Of the 10,275 eligible subjects, 7,983 agrecd to participate 
(78%). The baseline examination was condllcted between 1990 and 1993. Participants 
were visited at home for a standardized questionnaire ano were subsequently e:xamined 
at the research center, where echocardiography was performed. Dlie to casts and logistic 
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problems, cardiac ultrasound \Vas carried out in a random subpopulation of the Rotterdam 
Study consisting of 2,823 subjects, who were not living in nursing homes. In 19.7% (n=556), 
echocardiographic registrations \Vere considered inadequate for reliable measurement of left 
ventrictilar dimensions. This percentage is comparabie to other population-based studies 
(15]. The present study was perfofllled with baseline measurements in subjects between 
55 and 75 years of age. Participants with a history of myocardial infarction were excluded. 
The analyses were restricted to persons for whom blood specimens were available for IGF-I 
typing, and for whom all measurements were available to determine left ventricular mass 
index (n~1,678). 
lelt ventricular hypertrophy 
For assessment of the presence of left ventricular hypertrophy, echocardiography was caJTied 
out with the participant in the pal1ial left decubinls position using a 2.75-I",fHz transducer 
(Toshiba SSH-6oA Nasuworks, Otn.wma, japan). r.,'leasurements werc made by experienced 
starf, trained at the echo lab of the Thorax Center in the Erasmus Me in Rotterdam, according 
to a protocol based on the recommendations of the American Society of Echocardiography 
(ASE) 1161 Two-dimensional imaging using parasternal long-axis views was perfornlcd to 
aid M-mode studies. MeaslIrements of the left ventricle \Vere perfornled at end-diastole, 
as defined b)' the onset of the QRS complex, according ta ASE rcconuncndatians, Len 
ventriclllar mass was determined using the Deverellx-madified ASE cube fonllula: left 
ventric1..1Iar mass (grams) :=0 0.8x(1.04x((LVED+IVS+LVP\V)3-(LVED)3J)+o.6, where LVED = Icft 
ventrictdar end diastolic diameter, NS = interventricular septum thickness, and LVP\V = left 
ventricular posterior wall thickness {I7J. len ventrictilar mass was indexed to body surt~Ke 
area. 
Cases with left ventricular hypertrophy were dcfined as having a left ventricllJar mass 
index equal to or greater than 104 glm2 in wamen and 116 g/m2 in men [18, 191. Since there 
is na conscnsus concerning left ventricular hypertrophy thresholds in the medicalliteranlfe, 
left ventriclliar mass index was also divided into gender specifIc quintiles, whieh has been 
demonstrated to provide a good prediction of cardiovascular risk estimates (20]. For this 
sccond analysis, cases were defined as being in the highest gender spedfic quintiIe, and 
controls as being in the remaining quintiles. 
To study differences in Ieft vcntricl..Ilar remodeling patterns according ta IGP-I genotype, 
relativc wall thickness (R\"X'T) was also determined and calculated as RWT "" 2 x LVP\"X' I 
LVED [211. Increased relative wall thickness was considered present when th is ratio exceeded 
0.43, according to previously published criteria [22J. Three munlally exclusive patterns were 
identified: normal left ventriClilar geometry (normal relative wall thickness and normal left 
ventricl..Ilar mass index), concentric remodeling Oncreascd relative waU thickness but normal 
left ventricular mass index), and left ventricular hypertrophy (as defined above). 
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IGF-I genotype 
The polymorphism under study was a cytosine-adenosine repeat in the promoter region, 
1 kilobase upstream from the transcription site of the IGF-I gene. Genot)'ping for the IGF-
I polymorphism was perfofBled as described elsewbere (12). Eadier, we identified ten 
different alleles in the promoter region of tbe IGF-I gene in a sample of 900 subjects of the 
Rotterdam Study [12]. Of these participants, 88,4% carried at least one 192-base pair (bp) 
ailele, whieh sllggests that this is lhe wild type allele from wbieb all other alleles originated. 
The frequency of the other 9 alleles was low. Based on this obscrvation, using the wild type 
ailele, our study population was elivided into three genotypes: individllals bomozygolls for 
the 192-bp alleIe (43_6%), individuals heteroz)'gous for the 192-bp allele (45.6%), and non-
carriers of tbe 192-bp allele polymorphism (l0.7%). 
Othervariables 
Information on several risk factors, such as age, gender, history of myocardial infarction 
(confirmed by a general practitioner, cardiologist, or the electrocardiogram), smoking 
(classified as never/former/current), hypertension, diabetes mellitus, and body mass 
index (kglm2) was obtailled at baseline. Information on the llse of medication and type 
of meelieation was assessed during tbe home interview. Pa11icipants subseqllently sbowed 
all eurrently used medication at the research center, where a physician determined the 
indieation for eacb dmg. Systolic and diastolic blood pressures from tbe right llpper arm 
were measured with a random-zero sphygmomanometer twice with the patient in a sitting 
posilion. The mean of the two readings was used to determine blood pressure levels. 
Hypertension was defined as llse of antihypertensive medication for the indieation of high 
blood pressure, or as a systolic blood pressure of 140 mm Hg or over, or a diastolic blood 
pressure of 90 mm Hg or over [23]. Diabetes mellitus was defined as use of anti-diabetic 
medication, or a random or post-laad serum glucose level higher than 11.0 mmoI/l. 
Analysis 
Univariate comparisons \Vere evaluated with alogistic regression model. Agreement of 
the genotype frequencies with the Hardy-\~'ejnberg equilibrium expectations was tested 
using a xl-test. Ta investigate the association bet\veen left ventriclllar hypertrophy anel 
IGF-I genotypcs, we used multivariate logislic regression to calculate odds ratias plus 
95% confidence intervals (CI). An aIlele-effect model was assumed to explain differences 
betwcen genotype groups. Participant..<; homozygous for the 192-bp allele served as the 
reference category for all analyses. rvlen and wamen were pooled in the analyses, because 
there was no effect modjfication by geoder. Age (years), gender, hypertcnsion, diabetes 
mellitus, and body mass index Ckglm2) were added to the model to adjust for potential 
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confounding. Thc decision to keep potential confounders in the final model was based on 
biological plausibility. None of these factors changed the point estimate of the association 
between IGF-I genotype and left ventriClilar hypertrophy by more than 5% when added to 
thc univariate model. On each potential confOllllder more than 97% of data was available. 
For categorical covariates with missing vaiues we incorporated missing indicator varia bles 
in the model. \'\fe perfornled age- and gender adjusteel logistic regression analysis to test for 
an aIleIe (dose)-effect relationship (trend test) To evaluate the distribution of lcft ventricular 
geometry patterns according to IGF-I genotype, percentages per genotype were calculated. 
1'0 test difterences between genotypes, wc used an ordinal regression model adjusted for 
age, with the different patterns of left ventriclliar geometry as outcome variables. 
Results 
In total, 358 cases were identified with left ventricular hypertrophy. Genotype and allele 
distributions were in HardY-\'?einberg equilibrium (total population: p-value = 0.33). Table 1 
presents the baseline characteristics of the study population. P::H1icipants with left ventricular 
hypertrophy were on average two years oleler than patients with nonnal !eft ventricular 
mass index (mean age 65- anel 63 years respectively, t-test p<O.OOl). In addition, cases 
had a higher mean body mass index, systolic- anel diastolic blood pressure, and had more 
co-morbidity such as diabetes mellitus and hypertension. Thc number of smokers did not 
differ significantly between participants with or without left ventriCldar hypel1rophy. The 
difference in gender distribution was not statistically significant. 
In table 2, point estimates are presented for the association belween IGF-I genotypes and 
left ventrictdar hypertrophy on the echocardiogram. Non-carriers of lhe 192-bp allde had a 
1.50 foldly-increased odds of echocardiographically dctermined left ventrictliar hypel1rophy 
as comparcd to individllals hOl11ozygous for lhe 192-bp allde. This association remained 
significant aftcr adjustment for potential confounding factors (OR 1.49; 95%CI 1.01-2.20). 
Thc frequency of Icft ventriCldar hypertrophy was slightly but non-significantly increased 
in participanls heterozygous for the 192-bp allele. Howcver, there was a signifICant allde 
(dose)-effect rclalionship (p-trend <0.05). According to the model, the age- and gender 
adjusted odds of feft ventriCldar hypertrophy is multiplied by 1.20 per risk allde present 
(non-wild type). Findings were similar for the association between IGF-I genotypes and lhe 
highest versus alher geneIer specific quintiles of len ventriClIlar mass index Cagc-adjllsted OR 
non-carriers 192-bp allele 1,48, 95%CI 1.001-2.18). However, aftel' addilional adjustment for 
body mass index, hypertension, and diabetes melliuls this association was not statistically 
signiflcant (OR 1.46, 95%CI 0.99-2.17). 
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Table 1. General characteristics, 
Caseslf (n=358) Conlrols (n= 1320) OR (95% <I) 
(IVH+) (IVH-) 
Female 192 (54%) 754 (57%) 0.87 (0.69-1.10) 
Age(years) 65 (5.3) 63 (5.3) 1.07 (1.05-1.09) 
Oiabetes mellitus 30(8%) 62(5%) 1.85 (1.18-2.92) 
Smoking 
Never 101128%) 435 (Jl%) 1.00 (referen(e) 
Former 171148%) 584(44%) 1.16 (0.96-1.66) 
Current 84(24%) 296(23%) 1.22 (0.88-1.69) 
Hypertensiont 223 (64%) 578(45%) 2.16 (1.69-2.75) 
Body mass index (kg/mI) 27 (3.1) 26 (3.3) 1.09 (1.05-1.13) 
Systo!i( blood pressure (mm Hg) 144(21.7) 134 (21.1) 1.02 (1.02-1.03) 
Oiasto1i( blood pressure (mm Hg) 76(12.0) 74(11.0) 1.02 (1.01-1.03) 
Values for characteristics of cases and contmls are means (±50) or numbers (%) 
* (ase definition: left ventricular hypertmphy (LVHJ was considered present when left ventricular mass index was equal or greater 
than 104g/m1 inwomen or 116 g/m2 in men. 
t Defined as sysloli( blood pre"ure of 140 mm Hg or higher or diasloli( blood pre"ure of90 mOl Hg or higher or use of anlihy-
pertensive drugs with the indication hypertension. 
Tabl. 2. Assodalion belween echocardiographically delermined lefi venl,icul" hyperlrophy and IGF-I genolypes. 
IGF-Igenolyp' Cases-l' Controls OR model 11 OR model 21 
(n=358) (n=1l20) 
Homozygous 192-bpallele 145(41%) 587 (44%) 1.00 (reference) 1.00 (referencel 
Heterozygous 192-bp aUele 166(46%) 600(46%) 1.13 (0.88-1.46) 1.11 (0.86-1.43) 
Non-(arrier 192-bp aUele 47 (1J%) 1ll (10%) 1.50 (1.02-2.21) 1.49 (1.01-2.20) 
Number (% among cases or controls); odds ratio (OR) with 95% confidence interval. 
-I' (ase definition: left ventricular hypertrophy was considered present when left ventricular mass index was equal or greater than 
104g/m1 in women and 116g/m1 in men. 
t Adjusled lor age (ye"s) and gender.Allele-effeci relalionship:p-lrend <0.05. 
I Adjusled for age (ye"s), gender,body mm index (kg/Ol'), hypertension,and diabeles mellilUs. 
Figure 1 shows the percentages per IGF-I genotype of geometrie patterns of the left 
ventricle for non-carriers and participants homozygous [or the 192-bp allde. Although 
ordinal regression analysis estimates were not statistically significant (p=O.17), this graph 
shows a tendency of percentages for non-carriers to be higher in the most unfavorablc 
pattern of left ventricular gcometry, while concentric remodeling was more frequent in 
individuals homozygous for the wild lype alleie. 
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Figure l.leftvenlriml" remodeling and IGF-I genolyp". 
Discussion 
In this study, non-carriers of the 192-bp allele of a cytosine-adenosine repeat in the promoter 
region of the IGF-I gene were more susceptible to the development of left ventricular 
hypertrophy than participants homozygous for the wild type allele. To our knowiedge, this 
is the first population-based study on the assaciation between this IGF-I polymorphism 
and left ventrieular hypertrophy. The risk of e1cvated left ventrieular mass index detected 
by echocardiography in these subjects was significantly increased by 50%. Although there 
was na clearly increased differencc in risk for participants heterozygous for the ';,vild type 
aIleIe, there was a significant allele-effect relationship in this population. In additian, there 
was a tendency for non-carriers ta have a higher frequency of adverse cardiac remodeling 
with cardiac enlargement than participants homozygaus for the 192-bp allele. In contrast, 
concentric remodeling, whieh is a more appropriate response, was Illore frequent in 
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individuals homozygous for the wild type allele. Cardiovascular morbidity and mortality 
are known to incre<lse as the geometrie pattern of the left ventricle changes from normal to 
concentric remodeling and finally to left ventricular hypertrophy [241. In vilro and in vivo 
studies suggest that IGF~I may help maintain appropriate myocardial remodeling in reaction 
ta an injllry to the heart [251. This ma)' provide an explanatian far our findings. 
I\'Iost studies on the association between IGF~I senuu levels and len ventrictdar mass 
have been performed cross-sectionally, making it difficult to distinguish whether altered 
serum IGF~I levels are a cause or a consequence of left ventriclilar hypertrophy. In addition, 
serum levels of IGF~I are influenced by several factors, whieh vary over time, including 
growth horrnone, insulin, nutrition and physieal activity. Therefore, residual confounding 
can be an issue in these studies. Studying the association with the IGF-I polymorphism may 
circumvent these difficulties, since this approach will probably better approximate long~term 
exposure to circulating IGF-1. Moreover, disturbances by factors that regtilate IGP~I senuu 
levels will not influence the genetic background. Accordingly, potential confounding factors 
did not have an effect on the point estimates in dus study. 
It cannot be excluded that the IGP-I polymorphism itself is not hmctional but just serves 
as a marker for a nearby genetic variant functionally involved in IGF~I expression. However, 
the polymorphislll investigated in the present study has been associated with serum IGF~ 
I concentrations in several studies, albeit with opposite directions [11, 121. Recently, we 
found in a sample of the Rotterdam Stud)' that non-can'iers of the 192~bp allele had lower 
circulating total IGP~I levels and lower body height than carriers of this polymorphism. 
The absence of this allele was also significantly associated with an increased risk of type~2 
diabetes mellitus and myocardial infarction [12]. j\lloreover, we obsen'ed th at the normal 
gradual decline in circulating semm IGF-I levels during aging W:.1S highly influenced by 
the presence of two 192~bp alleles in the IGF-I gene [13]. These findings in subgroups of 
oUl' study poptilation make a functional relationship between this polymorphism and left 
ventrictllar remodeling plausible. 
In recent years, several studies provided support to the hypothesis that low serum IGF~ 
is a risk factor for ischemie heart disease and atherosclerosis [7, 26-281. In addition to 
its favorabie effects on glycaemic control and the lipid profile [29]. IGF-I has beneficial 
effects on cardiac rernodeling by reducing myocyte apoptosis in response to ischemia [25, 
30], and by improving myocardial contractility and stroke volume (311. Fwthenuore, IGF~ 
I promotes cardiac hypertrophy of a physiologic phenotype {32, 33] and causes systemic 
vascular vasodilatation [34J. Moreover, basal IGF-I levels are reduced in patients with dilated 
cardiomyopathy [351, and a recent stud}' demonstrated an inverse association bet ween 
the severity of healt fallure, by both clinical assessment and left ventrictilar performance, 
and IGF~I levels [361. This may imply that progression of disease from compensated to 
decompensated heart failure may be partly influenced by the ability to generate IGF~I for 
cardiac remodcling. Hence, evidence suggests that IGF-I deficiency may lead to diminished 
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cardiac performance and adverse remodeling in rcaction to an injury to the heart. On 
the other band, IGF-I directly stimulates growth of cardiac myocytes through indllction 
of cardiac protcin synthesis. In patients with acromegaly, IGF-I hypersecretion leads to 
ventricular hypeltrophy with interstitial fibrosis [37]. AIso, in a cross-sectional snldy of 
patients with untreated essential hypertension and normal glucose tolerance, IGF-I was a 
powerful independent determinant of left ventriClllar m<lSS [41. Thercfore, both Iow and high 
levels of IGF-I seem to have ach'ersc effects on cardiac function and structure. 
This observational snldy is potentially Iimited by selection- and information bias and 
confounding. Old and diseased individuals were less likely to participate, resulting in a 
healthier study population, Random misclassification of the outcome may have occurred 
due 10 measurement error, but this wilt onIy lead to conservative risk estimates. Potential 
confouncling factors were dealt with in the analyses. None of these factors had a major 
inflllence on the association studied. 
In conclusion, non-carriers of a 192-bp allele polymorphislll in tbc promoter region of 
the IGli'-I gene are more sllsceptible to the development of left ventricular hypeltrophy than 
participants homozygous for the wild type ailele. This may be thc consequence of a rclative 
IGF-I deficiency, leading lo a fault)' remodeling in response lo myocardial injury. 
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Abstract 
Heart fallure is a complex clinical syndrome, There is evidence for a genetic contribution to 
the pathophysiology of heart failure. Considering the fundamental roie of neurohormonal 
factors in the pathophysiology and progression of cardiac dysfunction and hypertrophy, 
variants of genes involved in this system are logical candidate gencs in heart failure. 
In th is report, genetic polymorphisms of the major neurohormonal systems in heart 
fallure will be discllssed. Studies on polymorphisllls of the renin-angiotensin-aldosterone 
systcm (RAAS), adrenergic receptor polymorphisms, endothelin (receptor) polymorphisms 
and a group of miscellaneous polymorphisms that ma)' be involved in the developmcnt 
or phenotypic expression of heal1 failure wiII be reviewecl. Research on left ventricl.1iar 
hypertrophy is also included, 
The majority of genetic association studies focused on the ACE liD polymorphism, Initial 
genetic associations have often been difficllit to replicate, mainly due to problems in study 
design and lack of power. Promising reslllts havc becn obtained with genetic polymorphisms 
of the RAAS and sympathetic system, Considering the evidence so far, a modifying roIe for 
thesc polymorphisms seems morc Iikely than a role of these varimlts as susceptibility genes, 
Besides the need for larger studies to examine the effects of single nucleotide polymorphisms 
and haplotypcs, funlre studies also need to focus on the complexity of these systems and 
study gene-gene interactions and gene-environment interactions. 
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Introduction 
Heart fallure is a complex clinical syndrome with high morbiclity and mortalitl' [I, 2]. 
Impairment of cardiac fimction actiyates compensatory neurohormonal mechanisms, whieh 
at a later stage mal' be detrimental for progression of heart failurc [3]. CoronaI]' heart disease 
and hypertension are major underlying causes of heart fallure. ather frequent underll'ing 
conditions include yalyular heart discase and idiopathie dilated cardioml'opathy. It is 
difficult to predict who will deyelop heart failure in response to myocardial injUI]r. Radal 
differcnces in occurrence and outcome of heart failure [4, 5] and heritabilitl' estimates of 
yariabilitl' in teft ycntricular mass of 28% to 65% [6, 7] suggest a genetic contribution to the 
pathophysiology of teft yentricular remodeling and heart fallure. 
r-.bnl' studies have been pubHshed on the role of single gene mutations in (familial) 
cardioml'opathies (8, 91. These i'vIendelian traits are by nature rare, and although important at 
an indiyidualleyel and for the understanding of discase mechanisms, of Iimited significance 
in terms of prcdiction of heart failure occurrence in the population UOJ.ivIoreoyer, in patients 
with identical gene mutations clinical manifestations of cardiomyopathy mal' differ. This 
suggcsts that probably also enyironmental- and/or other genetic factors plal' a role. 
In this report, genetic polymorphisms of major neurohormonal systems inyolyed in 
the pathophl'siology of heart fallure will be disclissed, including the renin-angiotensin-
aldosterone system (RAAS), adrenergic receptor polymorphisms, endothelin (receptor) 
polymorphisms and a group of miscellaneous polymorphisms. Research on left ventriclliar 
hypertrophl' is also included, because this condition often preccdes heart failure. Studies 
on the association between heart fallure and human lellcocyte antigen complex alleles and 
pharmacogenetic studies are outside the scope of this review. 
Methods 
Literature [or this report was systematically identified by searching PubMed for all 
English-Ianguage articles published up to July 2003 related to heart failure and genetic 
polymorphisms. Bibliographies in articles provided further references. A m'o-step approach 
was used. Pirst, genetic polymorphisms were identifIed in a search with the keywords 'heart 
failure' anc! 'polymorphism'. Second, polymorphisms that were identified with this scarch, 
were used as keywords with the addition of one of thc following keywords 'heart failure', 
'left ventricular hYPcl1rophy', 'left ventricular mass', and 'cardiomyopathy'. \Y/e focused on 
genetic association studies. 
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Heart failure pathophysiology 
Left ventrictdar dysfunction begins with an injury to the myocarelium, e.g. myocardial 
infarction, \vhich results in 10s5 of fUIlctiona1 ce1ls. In response, a complex cascade of 
interacting hemodynamic anel neurohormonal mechanism5 is activated to preserve 
cardiac function [31. These factors alter the shape and function of the ventricle through a 
process called teft ventricular remode1ing, in which fibrosis anel myocyte damage appear 
to be decisive morphological alterations [11, 121. The most important regulators of this 
process are compollents of the RAAS, growth factors and endocrine hormones such as 
norepinephrine. 
A decreased capacity of the left ventricle to empty during systole increases diastolic wall 
tension. The ventricle responds by enhanced contraction, following the Frank-Starling curve 
f131. Additionally, the sympathetic nervous systelll is activated, which provides inotropic 
support and maintains cardiac output [31. 130th compensatory mechanisms also lead to 
increased internal wall stress during diastole. In response, synthesis of myofibrillar proteins 
is stirnulated, reslilting in increased wall thickness and a reduction in ventricular wall stress 
anel dilatation [13]. Sustained sympathetic stimu1ation, however, activates the RAAS and other 
neurohormones. The main effector of the RAAS is angiotensin 11, a potent vasoconstrictor 
anel stimulator of renal sodiulll reabsorption and aldosterone anel vasopressin release [141. 
Hypoxia, shear stress, and vasoactive hormones Hbo stimulate the generation of endothelin, 
the most potent endogenous vasoconstrictor [15]. Endothe1in has positive inotropic and 
chronotropic effects, influences salt anel water homeostasis, stimulates the RAAS and 
sympathetic systcm and appears to play a role in cardiac remadeling [161. With WOrSeIllng 
fibrosis and careliac myoc.:yte degeneration, left ventrictllar enel-diastolic pressure increases 
anel later ejection fraction elecreases [121. 
To counterbalance the pressar and volume expanding effects of vasoactive ncurohormones, 
natriuretic peptides are generatcd, which exert diuretic, natriuretic and vasodilator properties 
[17J. Also, the kallikrein-kinin system farms bradykinin, which results in natriuresis anel 
vasodilatation, anel stimulates the proeluction of prostaglanelins [31. In this way, a delicate 
hemodynamic balance is achieved, which restores cardiac function temporarily. Long-term 
activation of these mechanisms, however, rcsults in progressive deterioration of ventricular 
function. 
Genetic polymorphisms 
In common multi-factorial diseases, such as heart fallure, the candidate gene approach is 
widdy used to study genetic po1ymorphisms [181. This allows for the identification of gene 
defects directly involved in the pathophysio10gy of heart failure (susceptibility genes), or 
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variants involved in modification of its phenotypic expression (moclifier genes), The case-
control study is the most freqllently tlsed design. Canclidate genes arc selected based tlpon 
their biologica I plallsibility, Polymorphisms located in coding or promoter regions of a 
gene may altcr the fllnction or expression of proteins encocled by the gene. Even if these 
polymorphisms are not functionaI, they are more likely to hc in Iinkage diseqllilibrillm with 
causative alleles [IO]. 
Considering the fundamental role of neurohormonal factors in the pathophysiology ancl 
progression of cardiac dysfunction ancl hypertrophy, variants of neurohormonal genes are 
logical candidate genes in heart f(lilure. Succcssively, we will describc thc potential role of 
these variants as sllsceptibility genes and as moclifier gencs in heart failure elue to ischemie 
and/or dilated cardiomyopathy and in hypertrophic cardiomyopathy. Also, studies on !eft 
ventricular dimensions will be discussed. Table 1 shows genetic polymorphisms that have 
been associated with anc or more of these disease manifestations in at least one study, 
Renin-angiotensin-aldosterone system 
The RAAS is one of the major systems involved in the pathophysiology of heart faillIre. 
Since it is a complex systcm, cffects of polymorphisms influencing the expression of one of 
its components may he countefbalanced b)' compensator)' changes in athef camponents. 
Thereforc, for individual mutations, associations are prob;:lbly modest. 
Angiotensin converting enzyme 110 polymorphism 
ACE cnzymatically transfarms angiotensin I lo angiotcnsin ft The human ACE gene is 
located on chromosorne 17q23. A genetic polymorphism in intron 16 of this genc is strongly 
associated with semm levels of ACE [191. ft is characterized by an insertion (I) or a deletion 
(D) of a 287 non-coding base pair (bp) sequence within an Alu repeat. lts functional role has 
been debated, Probably, th is polymorphism is in strong linkage disequilibrium with anothcr 
functional mutation within the gene [20], 
Raynolds and colleagues published an assodation betwccn the ACE I/D polymorphism 
and hemt fallure slIsccptibilit)' in Caucasians [211. Thcy observed an excess of DD genotype 
both in subjccts with ischemic- and idiopathic dilated cardiomyopathy compared to organ 
donors, However, since their control group was not in Hardy-\V'einberg equilibrium, results 
may have been biascd. Subsequentl)', many conflieting studies followed, A stud)' in 70 
Chinese patients appeared to confirm thc presence of an assodation (22] but was also not 
in Hardy-\V'einberg equilibrium. lvIost studies did not find an association between the ACE 
polymorphism and healt failure secandary ta ischemie and/or dilated cardiamyopathy in 
1506 Caucasian- [23-26J, 287 Chincsc- [27], 281 ]apanese- [28J and 724 black South Afeican 
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subject'i [29, 301. Hence, it seems unlikely that susceptibility to ischemie or idiopathic dilated 
cardiomyopathy in the general population is associated with the ACE liD polymorphism. 
In contrast, studies have reported more promising results on the potential role of the 
ACE polymorphism as a modifier gene in heart fallure, at least in Caucasian populations. 
Andersson fOlll1d an association between paar survival and DD genotype in 194 Swedish 
patients with hea11 failure [31]. A stud)' in 57 white Ameriean patient'i del110nstrated that 
DD genotype was associated with irnpaired exercise tolerance [32]. Others found that the D 
allcle was aS50ciateei with an increased risk of death or heart transplantation in 328 Ameriean 
patients [331. Two small studies in 90 Czech- anel 84 Turkish sllbjects could, however, not 
detect an association between heart failure phenotypc anel ACE genotype [24, 261. Studies 
in )apanese (28, 341 and Chinese patients [351 failed to associate this polymorphism with 
heart fallure phenotype, while studies in blacks were contradictory. Candy et al. fOlil1d an 
aS50ciation between DD genotype and reduced cardiac function and increased cavit)' size in 
South Afriean patient<; with cardiomyopathy 1301. whereas others did not (29]. 
The fust study on the ACE polymorphisl11 and hypertrophic cardiomyopathy f0lll1d 
an excess of DD genotype in CallCasian patients, especially in families with a histOly of 
sudden cardiac death [361. Other studies have since then confirmed the higher frequency 
of DD genotype in hypertrophie cardiomyopathy in white and ]apanese patients 137-391. 
Yamada ct al. did not detect an association between ACE genotypes anel hypertrophie 
cardiomyopathy in Japanese. In addition, no association was fmmd between ACE genolypes 
and echocardiographic measurements [281 A150, a study in 104 Dutch patients did not 
supp011 a role for the liD polymorphism as a modifier in this disorder [401. An association of 
ACE genotype with phenotl'pic expression of hypertrophic cardioml'opathy was, however, 
observed in Callcasians bl' others [411. A study conducted in a family affected by a single 
mutation in the myosin binding protein-C (J\JyBP-C) gene confirmed these results (42]. It 
scems that thc influence of ACE genotype in patients with hl'pertrophic cardiomyopathy 
depends on the specific disease-causing nmtation, which may offer an explanation for the 
conflicting results [431. Similar to ischemie and idiopathic dllated cardiomyopathy, it is more 
likcly that the ACE liD polymorphislll acts as a modifier in hypcrtrophic cardiomyopathy 
than as a susceptibility gene. 
IVlany studies have investigated the influence of the ACE polymorphism on left ventricular 
hypertrophy. There is considerabie controversy on this topie. Schunkert and colleagues 
described an association between DD genotype and electrocardiographic left ventrieular 
hypertrophy in 1428 Ellropeans {44J. Another large-scale investigation was carried out in 
the Framingham Heart Study in 2439 subjects [451. No association was fOlll1d between ACE 
genotypes and echocardiographic left ventriCldar hypertrophl'. Kuznetsova et al. have 
summarized the majority of studies (n=28, overall sample size 6638) in a meta-analysis [461. 
There was significant het~rogeneitl' among studies and the definition of left ventrictIlar 
hypertrophy varied widcly. Using data from 12 case-contral shldies, the pooled odds 
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ratio (OR) of left ventrieular hypertrophy with presenee of the D aBele was 1.09 (95% 
eonfidencc interval (CI) 0.98-1.21). Subgroup analyses, however, silOwed that in untreated 
hypertensives, the risk of cardiac hypertroph)' for the DD genotype compared to the II 
genotype was significanti)' increased (OR 2.92; 95% Cl 1.50-5.70). Also, len ventricular mass 
as a continuous trait was only assodated with ACE genotype in never-treated hypertensives. 
Therefore, findings suggest that the ACE polymorphism may onl)' have an impact on cardiac 
dimensions in hypertensives. From a clinical perspecthre one might speeulatc that th is effect 
can be neutralized by the use of antih)'pertensive drugs. Although there are man)' studies on 
the ACE lID polymorphîsm, stud)' populations arc often not in Hard)'-Weinberg equilibrium. 
Therc ma)' be variOlIs explanations, including differential m011alit)', but also genotyping 
error cannot be cxcluded. ThÎs eaUs for a different approach in which multiple markers are 
tested that are more robust than the original ACE I/D variant. 
Angiotensinogen M235T polymorphism 
Angiotensinogen is converted to angiotensin I. The human angiotensinogen gene is located 
on chromosome 1q42-43 [471. Three polymorphisllls have been studied: two mutations 
in exon 2 resulting in a methioninc to threonÎne exchange at position 235 0\'1235'1') and a 
threonine to methionine substitution at position 174 (T174i\n, and a G-6A variant, whieh 
represents a guanine to adenine substitution 6 bp upstream [rom the initiation site of 
transeription in the promoter region [48]. The G-6A variant is in close linkagc disequilibrium 
with the M235T polymorphism and will not be discussed scparatcly. As the T174M variant 
has been studied onl)' onee with respect to eardiae dimcnsions [49], we focus on the M23ST 
polymorphism. 
Thc 2351' allele is associatcd with a stepwise increase in angiotcnsinogen levels and with 
a moderate increasc in risk of hypertension [501. Nevcrtheless, most snldies did not fmd an 
association between the 1'v1235T polymorphism and development or progression of ischemie 
and dilated cardiom)'opath)' {2S, 28, 29, 351. Therefore, it is unlikely that this polymorphism 
plays a role in these disorders. An increased risk of heart failure in subjects carr)'ing bath 
23SM/T and --6G/G genotypes has been reported, however, suggesting the presence of a 
diseasc related haplotype (SU 
In h)'pertrophie cardiomyopathy, conflicting findings have been published. In ]apanese 
subjects, onc study revealed a higher frequenc)' of the 23ST allele in hypertrophic 
cardiomyopathy (38J. This could not be confirmed b)' others [28]. A study by Oltlepp and 
colleagues in 26 family mcmbers carrying a single mutation in the M)'BP-C gene revealed a 
significant association between the angiotensinogen polymorphis1ll and cardiac hype11roph)' 
[42]. In contrast, the extent of hypcrtrophy in 108 unrelated Canadian patients was not 
influenced by angiotcnsinogen genotype [52]. 
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Most studies on left ventricuJar hypertrophy have been performed in Caucasians [48, 49, 
53-581. The majority did not [md an association [49, 54-581. In contrast, studies in Chinese 
dialysis patients [59], South Korean patients with chest discomfort or hypertension {60] 
and Japancse outpatients of a cardiovascuJar clinic [61] fotInd an association between 11' 
genotype and cardiac hypertrophy. This suggests a morc important roIe for the ~'o'f235T 
polymorphism in Asian populations, corresponding with a higher frequencl' of the T allele 
in these populations [351. A study in 103 ]apanese patients, however, did not show an 
association between this polymorphism and left ventriclllar remodeling after myocardial 
infarction [62]. 
Angiotensin 11 receptor polymorphisms 
The gene for hllman angiotensin II type 1 receptor (ATIR.) is located on chromosomc 3. 
Stimulation of the AT IR results in vasoconstriction, increased atherogenecity, inflammation, 
growth, proliferation or coagulation, depencling on Iocal conditions [63]. In chronic heart 
failllre, the ATIR is down regulatcd in the heart. Various polymorphisms have been detected 
in this receptor, of which an adenine/cytosine (Ne) sllbstitution located at position 1166 
has been associated with heart failure ancl cardiac dimensions. Th1s variant is probably not 
functional {40J. The C allele is considered to be the risk alleie. 
A potential inleraclion between ACE DD and ATlR AC/CC genotypes was described 
as a predictor of survival in Swedish patients with healt fallure [31]. A large study in a 
French poptIiation (CARDIGENE study) falled to detect an association between the 
ATIR polymorph1sm and idiopathic dilated cardiomyopathy [25]. This study, however, 
used unconditional analyses despite matching of cases ancl controls on gendcr anel age-
distribution. Sanderson anel colleagues did find an association bet ween clinical course of 
heart fallure anel the C allele in 82 Chinese patients [351. 
Onc study has been performed on hypertrophic cardiomyopathy in Japanese subjects. 
Although there was a significant difference in aliele frequencies between patients anel 
relatives, no difference in genotype frequencies was found between patients and healthy 
contIuis [641. Hmvever, controls were not in Hardy-\\7einberg equilibrium, which may have 
biased the results, anel statistical analysis was performed unconditionaI, despite matching on 
age and gender. Two studies in Caucasian populations also found no association betwecn 
the ATIR polymorph1sm and occurrence of hypertrophic cardiomyopathy [40, 521. Some 
studies silOwed that the 1166c allele might adversely affect the phenotypic expression of 
hypertrophic cardiomyopathy [40, 421. Therefore, A1166c polymorphism does not seem to 
increase heart failure susceptibilîty, but may play a modifying rale. As only onc out of sL" 
studies found an association belween this variant and cardiac hypertrophy, a role for the 
A1166c polymorphism in left ventricular remodeling seems unlikely, at least in Caucasians. 
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!",Ioreover, this positive study was small and, unexpectedly, the A allele was more frequent 
in cases [53l. 
The angiotensin Ir type 2 receptor (AT2R) gene is located on the X chromosome. The 
AT2R probably counteracts the effects of ATIR [63]. Deinum investigated the association 
between a polymorphism in exon 3 CA3123C) of the AT2R gene and cÀ1:ent of hypcrtrophy 
in 103 Dutch patients with hypertrophic cardiomyopathy. The extent of echocardiographic 
hypertrophy decreased with the number of C alleles in women [651. A potential interaction 
between ATIR A1166c anel AT2R A3123C polymorphisms was detected in men only. 
Erdmann and colleagues found no significant differences between allele frequencies 
of a G1675A polymorphism in intron 1 of the AT2R in 107 paticnts with hypeltrophic 
cardiomyopathy, 95 patients with dilated cardiomyopathy and 160 normal controls [66]. In 
120 young white males, however, an association between the 1675A allele and structural 
cardiac changes was found in mildly hypertensive persons [671. Two independent studies 
on left ventrictdar hypertrophy in Glasgow residents silOwed inconsistent results [68]. As 
the G 1675A polymorphism is located in a gene region that is involved in the transcriptional 
control of the AT2R gene, this variant is potentially functional (67, 681. Therefore, more 
studies are needed to determine the role of this polymorphism in heart fallure. 
Aldosterone synthase C-344T polymorphism 
Aldosterone excess is a well~documented cause of hypertension and there is convindng 
evidence that mincralocorticoids have adverse effects in healt failure [69]. The key enzyme in 
aldosterone synthesis is aldosterone synthase. The corresponding gene CYPll132 is located 
on chromosome 8 POl. A cytosine/thymidine CC/T) substitution in the 5' promoter region 
at location -344 of the CYPllB2 gene has been identified. The functionality of this variant 
is unclear [70). Few studies have described the association between heart failure and C~ 
344'1' polymorphism. Studies in Caucasian and )apanese patients did not find an association 
between this variant and idiopathic dilated cardiom)'opathy [25, 71]. However, the C allele 
was associated with increased left ventriclilar volume in the )apanese patients [71]. This 
fincling cOllld not be conflfmed in black South Africans with heart fallure {29J. Studies in 
hypertrophic cardiomyopathy also yielded conflicting results [42, 72]. Consequently, there is 
no fum evidence for a mie of this polymorphism in heart failure. 
An association between the C-344T variant anel left ventrictdar hypertrophy was detected 
in young healthy Finns [73]. Although one small study confirmed this association [74], other 
larger studies faHed to detect a significant effect of this polymorphism on left ventricldar 
structure [75, 76]. Mayosi et al. investigated the contribution of several markers in the 
CYPll132 gene, including the C~344T polymorphism, as individual variants aod haplotypes 
P7]. Polymorphisms and haplotypes at the CYPllB2 locus were associated with a small 
but significant effect on variation in septal wall thickness and left ventricular cavily size 
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(variants G5937C and A4450C respectively). No significant association was detected with 
cardiac mass. 
Sympathetic system 
Adrenergic receptors are divided into u- and ~-adrenergic receptors. u,-Adrenergic receptors 
are mediators of cardiomyocyte hypertrophy, while u 2-adrenergic receptors are pre-synaptic 
inhibitors of norepinephrine release [78]. ~,- and ~2-adrenergic receptors increase cardiac 
inolropy and chronotropy, the i3,-receptor being the dominant subtype [79]. In heart fai/ure, 
chranie sympathetic activation leads to selective down-reglilation of p,-adrenergic receptors 
and uncoupIing of 131- and i32-adrenergie receptors, markedly blunting bath signaling 
pathways [78]. Therefore, one may hypothesize that genetic variants of adrenergic receptors 
play a role in healt failure. In addition, i3-adrencrgic receptor blockers have been found 
to improve symptoms and mortality in heart failure, albeit with substantial interindividual 
variation [791. 
u,-adrenergic receptor Oe1322-325 polymorphism 
The De1322-325 polymorphism in the gene for the u 2c-adrcncrgic receptor, located on 
chromosame 4, causes a substantial loss of agonist-mediated receptor function in vHro 
[801. So far, onIy one study addressed the potential role of this polymorphism in hemt 
failurc susceptibility. Small ct al. found that black subjects who were homozygous for the 
a lc Del322-325 variant were more than 5 times as Iikely to have heart failure as those who 
\Vere not. A two-Iocus analysis indicated a significant interaction between the a lcDe1322-
325 polymorphism anel the 389Arg variant of the i3,-adrenergic receptor [811. Althollgh not 
significant, associations for white subjects were similar in magnitude and direction. The 
a 2çDe1322-325 variant was more than 10 tirnes more conunon in black- than in white contrais. 
AB this polymorphism potentially changes the functionalily of the a 2ç-adrenergic receptor, it 
is an important candidate for further research on genetic factors in healt failure. 
i3,-adrenergic receptor polymorphisms 
Two major polymorphic loci have been identified in the gene coding for the ~l-adrenergic 
receptor Jocated on chromosome 10. A guanine/cytosine slibstitution at nucleotide 1165 
produces a change in the amino acid sequence, substituting a glycine (Gly) for an arginine 
(Arg) residue at position 389. This residlle lies within the intraceHllJar carboÀ1'-terminus 
that is critical for G-protein cOllpling. Data indicate that this polymorphism has functional 
consequences for intracellular signaling [82]. The second variant, an adenine/guanine 
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substitution at nucleotide position 145, results in a serine (Ser) or glycine (Gly) at amino 
acid 49 [831. Genetic yariation in this residue has been shown in yjtro to affect receptor 
dcsensitization and agonist-dependent down-regulation [841. Sa, both polymorphic loci may 
lead to functional changes of thc f3l-adrenergic receptor and hence both may pIay a role in 
heart failure. Genetic association studies, however, have been contradictory, 
In the CARDIGEl\TE study, no association was found between the Arg389Gly polymorphism 
and idiopathic dilated cardiomyopathy and disease seyerity [851. Others have confmned the 
lack of an association with heart failllfe occurrence [34, 81, 86]. Small and colleagues did 
find a significant interaction betwecn the u 2cDe1322-325 variant and the 13 1 Arg389 allele in 
heart failure susceptibility [81]. An impaired exercise performance was demonstrated in 
patients with ischemie or idiopathic dilated cardiomyopathy, who were homozygous for 
Gly389 comparcd to Arg389 homozygotes, with an intermediate level of performance in 
heterozygotes [87J. This may suggest a role for the Arg389Gly polymorphism as a disease 
modifIer, Also, a study in patients with renal disease found higher cardiac mass in Gly389 
homozygotes [88], In contrast, a Shldy in Japanese cardiomyopathy patients 5110wed a 
protectiye effect of the Gly389 ailele in susceptibility to ycntricular tachycardia [34]. 
Few studies have been puhlished on the Ser49Gly polymorphism. A study in dilated 
cardiomyopathy demonstrated that 5-year transplant-free survival \vas worse in Ser49 
homozygotes than in patients with the Ser49Gly variant [83], Allele frcquencies in patients did 
not differ from those in normal controIs, Another shlcly found impaired exercise capacity in 
patients with ischemie or dilated cardiomyopathy homozygous for the Ser49 ailele compared 
to Gly49 carriers {S7}. In contrast, Podlowski anel colleagues onIy founel the Gly49 mutation 
in patients with idiopathic elilated cardiomyopathy anel not in healthy volunteers [861. 
One other polymorphie locus in the gene for the f3t-adrenergic receptor, T-2146C, has 
been associated with idiopathic dilated cardiomyopathy [891. Thus far, there is not enough 
evidence to draw fmn conclusions about the roie of f\-adrenergic receptor polymorphisms 
in heal1 failure, 
fl,-adrenergic receptor polymorphisms 
An intronless gene on chromosome 5 encodes the f3z-adrenergic receptor. Altention has 
focused on dlfee polymorphisms that display altered receptor function in experimental 
studies [79, 901. The most functionally altered receptor is due to a threonine (Tllf) to isoleucine 
(Ile) switch at amino aciq 161. This rare variant receptor exhibits abnormal coupling to 
stimulatory G-protein [911. The other two polymorphic loci occur on amino acid positions 
16 (arginine (Arg)(glycine (Gly) substitution) and 27 (glutamine (Gln)(glutamic acid (Glu) 
substitution) {90]. There is marked linkage disequilibrium between these two polymorphisms 
[92]. The Gly16 receptor displays enhanced agonist-promoted down regulation, while thc 
Glu27 form is rcsistant to down regulation {90, 931. 
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Two studies have investigated the effect of I\-adrenergic polymorphisllls in heaet failure. 
Especially the Thr164Ile variant scelllS to be important in its phenotypie expression. The 
fiTst study fOllIld na difference in frequency of the three polymorphisms between heart 
failure patients and normal subjects [901. However, patients who were heterazygous for 
the Ile164 nll.1tation had significantly worse survival than homozygous Thr164 patients. 
Trends for Arg16Gly and Gln27Glu did not reacll statistical significance. The secOild study 
demonstrated that patients with heart failure carrying the J1e164 aIleIe had a luwer exercise 
capacity lhan patients homoz)'gous for Thr164 [94]. Patients homozygous for the Gly16 aIleIe 
also demonstrated lower exercise capacity than Arg16 homozygotes. AB the Thr164Ile variant 
is rare, both studies did not include hOIllOZygOllS Ile164 subjects. A study in normotcnsive 
twins indicated that all three polymorphisms mighl be associated with ventricular wall 
thickness [92]. However, other studies have failed to detect any association between the 
Arg16Gly and Gln27Glu polymorphisms and cardiac dimensions [95-971. These studies did 
not investigate the role of the Thr16411e variant. 
Endothelln 
There is considerable evidence 10 support a rale for the endothelin system in heart failure 
[981. The endothelin A receptor mainly mediates the vasoconstrietor effects of enclothelin-l, 
the predominant endothelin isoform. The endothelin B receptor has similar affinity for all 
isofarms and mediates vasodilatation in endothelial cells and vasoconstriction in sl1100th 
muscle eells [161. Few genetic association studies have been performeel. 
Studies on dilated cardiOlnyopathy did not detect a role of genetic polymorphisms in the 
endothelin-l gene [99, 100]. Bmgada and colleagues silOwed that a G8002A polymorphism 
located in the 4th intron of the endothelin-l gene on chramosome 6 might act as a modi fier 
gene in hypertrophic cardiomyopathy [521. Two variants of the endothelin A receptor 
have been studied with promising results. In the CARDIGENE study, a cytosine/thymidine 
(C/T) substitution in exon 8 at nucleotide position 1363 was associated with idiopathic 
dilatcd cardiomyopathy (991. Individuals homozygous for the T allele were at signilicantly 
increased risk for this disease. A C/Y substitution in exon 6 at position 69, which does 
not alter the amino acid sequence of the receptor, has been associated with survival in 
patients with non-ischemie dilated cardiomyopathy [100l. Carriers of the T allele had a 
more than 5-fold increased risk of death within 2 years after the diagnosis. A study in 528 
never-treated hypertensives demonstrated that variants in the genes encoding endothelin-
1 and the endothelin A receptor arc not significant determinants of cardiac morphometric 
parameters [lOl]. Although several studies also investigated the role of endothelin B receptor 
polymorphisms, no significant associations were fOllI1d {99-10lJ. 
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Tabla 1. Genetic polymorphisms that have been aS50ciated with heart failure occurrence (susceptibiHtygene),- phenotype 
(modifier gene) andJor left ventricular structure In genet/c association studies. 
Gellette pofymorphism RiskaffeleJi Heart failure Heart failure O(M/O(M H<M/H(M lVHIlV 
o((urrellcd phellotype* phellotype phenotype dimensions § 
Renin-angiotensln-aldosterone 
A(EIIO D + + + + + 
AGTMlJST T + + + 
AGT -G6A G + + 
AGTT174M M + 
ATlRAI166( C + + + (A) 
AT2RAlI23( A + 
AT2RGI675A A + 
<YPI1B2(-344T C + + + 
Sympathetic system 
A2AR «"WVOeIl22-m Del + 
BIAR5er49Gly Ser + + 
BlARA'91B9Gly t + + + 
BIART-2146( C + 
B2ARA'9 16Gly Gly + + (A'9) 
B2ARGlo27Glu Glu + 
B2ARTh,I64l1e lIe + + 
Endothell" 
EHOI GBOO2A A + 
ETAR(JJ63T T + 
ETAR(69T T + 
Miscellaneous 
Bradyklnin receptor I!et) +9 + 
CMA A-1903G 111,41,1JJj A + + 
TNF G-30SA !I1.1·)à,1;S] A + + 
TGF81leul0Pro imi heterozy + + 
SOOl Afa16Vai 1111] Val + 
PAF G994f111l,lU) T + + 
CCRl Val64l1e IlUl lIe + 
NOS3 Glu29SAsp (115] Asp + 
APOE eY e3/ 1;:4 jl!ó-l!!) ,4 + + 
a-addudn Gly460Trp I>~l Trp + 
GNB3 CS26Tl1lW)! T + 
AMPOl +/_(111) + + 
* in majority studies, t indecisive,t heart failure with multiple causes, not exdusive in DCM or HCM, § in patients without 
heart failure; +: at least one positive study, -: no positive association studies, OCM: dilated cardiomyopathy, HCM: hypertrophic 
cardiomyopathy, l VH: teft ventricular hypertrophy, ACE: angiotensi n converting enzyme, AGT: angiotensinogen, A Tl R: a ngiotensi n 
II type 1 receptor, AT2R: anglotensin 11 type 2 receptor,CYPllB2:atodosterone synthase gene, ul-AR:al-adrenergic receptor, 
B1AR: ~ l-adrenerglc r"eplor, B1AR: ~l-adreoergic re<eplor, ENDl :endolhelin-l, HAR: endolhelin Iype A r"eplor, CMA: ca,diac 
chymase, TNF:tumor necrosÎs factor a, TGFB1: transforming growth factor (3-1, SOD:superoxide dismutase, PAF: platelet-actj-
,,1Ing faclor, CCR:chemokine r"eplor, NOS: nil'ic oxide synlhase,APOE: apolipoprolein E,GNB3:G-proleln ~,subuoil,AMPDI: 
adenosine monophsophate deaminase 1. 
Miscellaneous genetic polymorphisms 
i\'lultiplc other polymorphisms have been invcstigatcd in heart fallure, with variabIc slIccess. 
These are mainly gencticvariants offactors that playa role in cardiac remodeling, inflammation, 
121 
Chapter 5.1 
signal transduction or protection from oxidative damage. Genetic polymorphisms that have 
been associated with heart failure, heart fallure phenotype and/or left ventricular structure 
are presented in table 1. However, few studies have been published for most of these 
variants and their exact role in heart failure susceptibility and modification needs to be 
elucidated further. 
Comment 
There is substantial evidence that genes pIa)' a mie in the pathophysiology of heart failure. 
Numerous studies have investigated the association of heart failure with polymorphisms in 
candidate genes. Even more snldies examined the roie of genetic variants in left ventricular 
hypel1rophy. A/lost studies focused on thc ACE IID polymorphism. In addition, genetic 
polymorphisffi.<; have been snldied of other RAAS components, adrenergic receptors, 
endothelin-l and endothelin receptors and of tflctorS that pIa)' a role in cardiac remodeling, 
inf]ammation, signal transduction or protection of cells from oxidative damage. Still, man)' 
genes in healt failure remain to be discovered. So far, genetic association studies in heart 
failure and cardiac remodeling have been highly inconsistent. As heart failure is a complex 
trait, there are probably several genctic variants that together result in the expression of its 
pathologie phcnotypc [79]. Thcrcforc, for individual polymorphisms, associatians arc likcly 
to he modest. The same halds for variants associated with cardiac hypertrophy. The ultimate 
evidence of these genetic polymorphisms being more than just risk markers elepends on 
the chamcterization of intermediate phenotypes rhat can be linked to the disease [1021. 
Since most studies on heart fallure susceptibility did not find an association, a role for 
neurohormonal polymorphisms as modificr genes seems more likely. 
Genetic associations that were found in initial snldies have often been difficuIt to reproduce. 
There are scveral potential explanations for this, The major prohlem has been lack of power 
to detect the typically small effects in genetic association studies of ll1ultifactorial traits [103]. 
Besides increasing the sample size of a study population, this problem may be resolved by 
studying the combination of several genetic markers into haplotypes [771. Small studies with 
statistically significant associations are more readily published, This may overestimate the 
true effect. Several studies used unconditional statistical methods [or data analysis, despite 
the fact that they matched their cases and controls on poplliation characteristics {c.g, 25, 31, 
34,37,64,71,851. This may underestimate the effect of the polymorphisms snldied, as it wiII 
bias the results towards the null hypothesis. 
An association between a genetic polymorphism and a disease (phenotype) may 
merely be callsed by its linkage disequilibrium with a Illutation of a nearby gene that is 
the actual functional gene. Patterns of linkage diseqllilibrium can vary significantly within 
and between populations elue to several factors, including population admÎ.:\'tl.1fe and 
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age of the mutation [18]. If a polymorphism is not functional, varying degrees of linkage 
disequilibrium may explain variations between populations. i\iluch emphasis has been put 
on the role of population stratification in the generation of false positive results. When 
the population under snIcly eonsists of a mixture of subpopulations that have different 
allele frequencies and disease risks, genetic associations ean be eonfounded by popl.J!ation 
stratifieation [103], The most important confounder in this respect is ethnicity. Frequency 
and outcome of heart failure differ significantly between races [4, SJ, as do ailele frequendes 
of genetic polymorphisms [28, 35, 38, 80]. Nearly all populations are confounded by genetic 
admixture at same level [1041. Lack of replicability of an association in different etlmic 
groups does not ruIe out the possibility of a causal association, because of potentially 
different background risks, allde frequendes and environmental factors. Genotyping error 
mayatso affect the results of genetic association studies and is the most conunon cause 
of deviations [rom the Hardy-\Veinberg equilibrium. An important example of this type of 
exposure miscIassification is the undcrcstimation of ACE IlO heterozygotes that may oecur 
with tbe conventional genotyping method [l051. .Most studies on heart failure used this 
non-I-allele-specific method for ACE genotyping may have underestimated the effect of the 
DD genotype. In addition, large heterogencity in outeome measures between studies may 
account for contradictory findings. 
In summary, genetic association studies on beart failure .md cardiac remodeling have 
foclIsed on polymorphisms that may influence neurohormonal factors. Initial genetic 
associations have aften been difficuit to replicate, mainly due to faulty study designs and 
lack of power. J\'lost promising results have been obtained with polymorphisms of RAAS and 
sympathetic system. A mie for these polymorphisms as modifier rather than susceptibility 
genes seems more likely considering the evidence so faro Heart failure is probably caused 
hy many genetic factors that are all components of largel' complex systems and interact with 
envimnmental factors. Besides the need for larger studies to examine the effects of single 
genetic variants and haplotypes, fUhue studies also need to focus on the complexity of these 
systems and shldy gene-gene interactions and gene-environment interactions. 
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Insulin-like growth factor-I gene polymorphism and 
risk of heart failure. The Rotterdam 5tudy 
Chapter 5.2 
Abstract 
Objective: Low serUIn insulin-Iike growth factor:I (IGF-I) levels have been associated with 
heart fallure. A polymorphism in the IGF-I promoter region may influence the expression of 
IGF-I. \'\'e studied the association between this polymorphism and incident hea11 fallure. 
r.,'lethods and results: \'\'e used data from 4963 participants of the population-based Rotterdam 
Study without heart failure at baseline aged 55 to 75 years. Incident heart failure was 
determined according 10 established criteria. IGF-I genotypes were classified based upon 
presence or absence of the 192-bp atlele and upon presence or absence of the following 
combination of genotype" 192-bp/192-bp, 192-bp/194-bp and 194-bp/194-bp. Persons 
with any other genotype than 192-bp/192-bp, 192-bp/19.j-bp and 194-bp/19.j-bp had an 
increased risk of heart failure (RR 1.39, 95% Cl 1.06-1.80). 
Conclusions: Our study confirms recent findings and suggests that genetically determined 
chroillc exposure to low IGF-I levels is associated wilh an increased risk for hemt failure in 
c1derly individllals. 
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IntroductIon 
Heart failure is a complex clinical syndrome with high morbidity and mortality (1, 21. Over 
the years, evidence for the cardioprotective cffects of serum insulin-like growth factor-I 
(IGF-I) has accumulated [3, 41. In a recent prospective study, performed in elderly without a 
myocardial infarction partidpating in the Framingham Heart Study, a low serum IGF-I level 
was assodated with an increased risk of heart fallure [SJ. 
Twin studies have shown that at least 40% of circulating IGF-I levels is genetieaUy 
determined [6]. A polymorphism in the IGF-J gene promoter region, comprising a variabIe 
length of a cytosine-adenosine (CA)-repeat sequence, may influence IGF-I product ion [7-
91. HarHer, we obsen'ed lower drculating total IGF-I levels in non-carriers of the wild type 
allele of this polymorphism than in carriers (8, 9]. \Ve also found an assodation between this 
genetic variant and diabetes mellitus, body height and myocardial infarction [8] and carotid 
intima-media thiekness in hypertensive individuals UA]. 13eC<lllSe serum IGF-I levels may 
fluctllate, this polymorphisn?- might be a better indicator for chronie IGF-I exposure in the 
body, both locally and systcmicaIly, than an incidental measurement of the actual senllll 
IGF-I concentrations. 
\Ve investigated the association between this IGF-I polymorphism and the incidence of 
heal1 failure in a prospective population-based cohort stud}'. 
Methods 
Setting and study population 
The Rotterdam Snlcly is a population-based cohort study in 7983 sllbjects of 55 years or 
older (1l}. The baseline examination was conducted in 1990-1993, dllfÎllg whieh information 
was obtained on age, gender, smoking, hypertension, diabetes mellitus, body m;:lSS index 
(131"11), verified history of myocardiaI infarction, cOfonary artery bypass graft (CABG) and 
percutaneous transluminal coronary angioplasty (PTCA). Hypertension was defmed as use 
of antihypertensives, or as a systolic blood pressure of 160 mm Hg or higher, or a diastolic 
blood pres~>ure of 100 mm Hg or higher. Participants are continuously monitored through 
autornated linkage with files from general practitioners for major cvents that occur during 
follow-up, including incidence of heart failure, myocardial infarction, CAl3G, PTCA and 
death, Information on vital status is also obtained regulady from munieipal hcalth authorities 
in Rotterdam. Furthermore, all drug prescriptions dispensed to participants by automated 
pharmacies are routinel}' stored in thc database. 
As serum IGF-I levels show an age-dependent dccline, whieh we fOllnd to be genotype 
dependent anel may be associated with longevity, we exclucled all subjects aged 75 years 
or older to avoid any bias in our results because of sclcctive mortality [9, 10, 12]. Hence, 
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the study population consisted of 4963 persons younger than 75 years, for whom blood 
specimens were available for IGF-I genotyping and who were free from hemt failure at 
baseline. Participants were followed from baseline until the earliest of incident heart failure, 
dcath, loss to follow-up, date of last data collection, or January 1, 2000. 
IGF-I genotype 
IGF-I genotyping was perfofllled as described elsewherc [8]. Two a priori defined 
dassifications for IGF-I genotypes were examined. First, we studied genotypes based upon 
the presence of the 192-bp allele (corresponding to 19 CA-repeats), as described in previous 
studies [7-9], resulting in participants homozygous (reference group) or hetcrozygous 
for the 192-bp aHele and non-carriers of this alleie. Second, we studied genotypes based 
upon the presence (reference group) or absence of one of the following genotypes: 192-
bp/192-bp, 194-bp/194-bp or 192-bp/194-bp. This second categorization was investigated 
because we found earlier that circulating serum IGF-I levels \Vere highest for persons with 
192-bp and 194-bp alleles, while both alleles shorter ,han 192-bp ancllonger ,han 194-bp 
seemed to have lower serum IGF-I levels, suggesting a broader optimum for IGF-I gene 
regulated transcriptional activity {Rietveld I. Functional aspects of a (CA)n polymorphism 
in the promoter region of the IGF-I gene. Presented at the Endocrine Society's 85th anntlal 
meeting, 19-22 June 2003, PhiladelphiaJ. 
Inddent heart failure 
Incident heart failure events were obtained by continuously monitoring pal1icipants of the 
Rotterdam Study for the occurrence of heart fallure during follow-up through automated 
linkagc with files from general practitioners. All available data on these events, such as 
hospital discharge letters and notes from general practitioners, were copied from the medical 
records. Apart from this systematic follow-up procedure, we uscd verifled hospital discharge 
diagnoses for case finding, gathered from all hospitals in the Rotterdam area. The definition 
of heart failure was based on the criteria of the European Society of Cardiology, which 
include the presence of typical symptoms of heart failure, such as pulmonary crepitations, 
and objective evidence of cardiac dysfunction IH 
Analysis 
\Ve used Cox proportional hazards regression analysis to estimate relativc risks and 95% 
confidence intervals (95% CI). Age in days was used as time-axis of the model instead 
of follow-up for optimal age-adjustment. Analyses were initially adjusted for gender anel 
follow-up. In the second model, we additionaUy adjlIsted for the following baseline factors: 
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smoking status, B.~U, diabetes mellitus, hypertension, atrial fibrillation, the ratio of semm 
totat cholesterol to high-density lipoprotein (HOL) cholesterol, history of myocardial 
infarction, CABG alld PTCA. Furthermore, this model was adjusted for the incidence of an 
ischemie heart disease event, consisting of either a myocardial infarction, CABG or PTCA. 
This model was also adjusted for the occurrence of a fust automated mied prescription of 
any anti-diabetic dmg during follow-up. as a proxy for incident diahetes mellitus, and of 
any antihypertensive drug. Men anel women were pooled in the analyses, as there was 
no significant effect-modification by geoder. Analyses were repeated in a sub-population 
without myocardial infarction. 
Results 
During a mean follow-up of 7.2 years (SD 1.7), 280 cases of incident heart fallure were 
identified. !\'Iean age of the 4963 participants was 65 years (SD 5.5). 57% were wamen 
and mean B~'li was 26.3 kglm2 (SD 3.6). Diabetes mellitus was present at baseline in 8%, 
history of myocardial infarction in 5%, and hypertension in 31% of participants. Based upon 
the 'traditional' IGF-I genotype classification, 2170 (44%) participants were homozygous 
anel 2196 (44%) were heterozygous for the 192-bp aIlcle, while 597 (12%) were classified 
as non-carriers. Having either an IGF-I 192-bp/192-bp, 192-bp/194-bp or 194-bp/194-bp 
genotype was present in 3586 (72%) and absent in 1377 (28%) participants. IGF-I genotype 
distributions were in Hardy-\Veinberg equilibrium. 
Table 1 shows that absence of the 192-bp aIlde was not significantly associated with 
incielent hcart fallure. Relative risk of healt failure was slightly, but non-significantly 
increascd in heteroZ}'gotes anel non-carriers of the 192-bp allele. Absence of 192-bp/192-
bI', 192-bp/194-bp and 194-bp/194-bp genotypes significantly increased the risk of incident 
heart failure (RR 1.39. 95% Cl 1.06-1.80. table 1). Results for both genotype categorizations 
did not change after restriction of the population to subjects without a prevalent myocardial 
infarction. Relative risk of heart failure for the absence of 192-bp/192-bp, 192-bp/194-bp 
and 194-bp/194-bp genotypes in this population was 1.41 (model 2, 95% Cl 1.05-1.89). 
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Table 1. Relative ,isks of incident heart failureand IGf-1 genotypes. 
IGF-I genotype model tt model U 
192-bp/19Hp present· 1.00 (reference) 1.00(reference) 
192-bp/194·bp absent" 1.38 (1.07-1.76) 1.39 (l.O6-1.80) 
Homozygous 192-bpaUe!e 1.00{reference) 1.00 (reference) 
Heterozygous 192-bpaHele 1.21 (O.94-1.56) 1.27 (O.98-1.65) 
Non-carrier 19z.bp a[[ele 1.26 (O.87-1.83) 1.16 (O.78-1.74) 
Heterozygousand non·carrier combined 1.22 (O.96-1.55) 1.l5 (O.97-1.60) 
Relative risk (95% confidenee interval) 
"present:presence of one of the following combination of genotype\: 192-bp/192-bp, 194-bp/194-bp and 192-bp/194-bp; 192-
bp/194-bp,absent: all other IGf-1 genotypes 
t adjustment for age, gender and follow-up 
t adjustment for age, gender, follow-up, smoking status, body mass index, diabetes mellitus, hypertension, atrial fibriUation, ratio 
serum total cholesterol to high-del1sity Ilpoproteln cholesterol, myocardial il1farcUon,coronary artery bypass graft, percutaneous 
transluminal coronary angioplasty, il1ddent ischemie heart diseases, first prescription anli-diabetic drug and first prescription 
antihypertensive drug 
Discussion 
In this large prospective population-based study, absence of IGF-I 192-bp/192-bp, 192-
bp/194-hp and 194-bp/194-bp genotypes was associated with an increased risk of incident 
heart failure in subjects aged between 55 and 75 years. No significant associatioll was found 
for the traditional division in genotypes based upon the presellCe of the 192-bp alleie. This 
might be explaineel by the existence of another genetically determined optimum in IGF-I 
serum levels than previously hypothesized. 
There is substantial cvidence that IGF-I plays a pivotal role in the pathophysiology 
of cardiac remodeling and healt t;lilure [3, 4]. Recently, \~1.san and colleagues found an 
association between Iow serum IGF-I levels anel increased risk of incident heart failure in 
elderly without a history of myocardial infarction participating in the Framingham Heart 
Study [SJ. Our study seems to confirm their findings, since the 100west serum IGF-I levels 
were fOllnd in non-carriers of the 192-hp and 194-bp IGF-I gene alleles and these subjects 
had a higher risk of incident heart fallure. In addition, our study suggests that to some extent 
thc risk of incident heart failure is genetically determined. 
Several studies have investigated thc potential functionality of the IGF-I polymorphism 
with conflicting results. This CA-repeat polymorphism has been associatcd with serum IGF-I 
levels, alheit with opposite directions [7-9, 13, 14J. Differcnces in popldation background 
(environmental- alld genetic factors), agc anel small sample sizes may all account [or 
contradictory results. Also, all studies used the conventional division of genotypes bascd 
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upon presence of the 192-hp allele, while we found earlier that there ma)' be a broader 
optimum for IGF-I gene regulated transcriptional activity. 
Confounding bias may provide an alternative explanation for our results. However, as 
we studied a homogeneous CallCasian population and potential confounding factors did not 
greatly influence our results) this explanation seems lcss likely. 
In conclusion) we found an association between a promoter polymorphism in the IGF-
I gene aod incident heart fallure in the Rotterdam Study population. Our study confirms 
recent findings in the Frarningham Heart Study that Iow serum IGF-I levels increasc the risk 
of healt failure in normal elderly individuals and suggests that to some extent the risk of 
incident heart failure is genetically determined. 
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Angiotensin converting enzyme Insertion/ 
Deletion polymorphism and risk of heart failure in 
hypertensive subjects 
Chapter 5.3 
Abstract 
Aims: Careliac angiotensin-I converting enzyme (ACE) activily is influenced by the ACE liD 
polymorphism. Evidence suggests that the DD-genot)'pe ma)' be a risk factor for cardiac 
hypel1rophy and heart fallure, especially in hypertensive subjects. \\7e assessed the relation 
between the ACE IlO polymorphism and the risk of incident heart failure in normotensive 
and hypertensive subjects. 
J\:Icthods and Rcsults: \'le invcstigated 4264 normotcnsivc and 2174 hypel1ensive participants 
of the Rotterdam Stud)'; a poplt1ation based prospective cohort stud)'. All subjccts were 
available for follow-up from 1990 until 2000. Incidence rates (IR) of heart failure in 
normotensive subjects were the same over all genotype strata (10 pcr 1000 person-years). 
In hypertensive subjects, the IR significantly increased with the number of D-alleles present 
(11: IR=13, 10: IR=18 anel DD: IR=20 pcr 1000 person-years). H)'pertensive subjects carr)'ing 
the U-genotype did not have an increased risk of heart failure compared to normotensivc 
subjects. However, h)'pertensive subjects carrying one or two copies of the O-allele did 
have a significantl)' incrcascd risk of hcart failurc (IO: RR: 1.4 (1.1-1.7) anel DO: RR: 1.5 
(1.2-2.0)). 
Conclusion: Our finelings suggest that the ACE liD pol)'morphism ma)' pIa)' a Illodifying role 
in thc dcvelopmcnt of heart failure in h)'pertensive subjccts. 
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Introduction 
Heart fallure is a complex clinical syndrome that can result from any stmchual or functional 
cardiac disorder that unpairs adequate ventricular fllling or ejecting of blood. Corona'1' 
artery disease and hypertension are among the most common risk factors. Regardless of the 
initial cause of cardiac damage, the heart will respond with a set of adaptive mechanisms 
in order to maintain its pumping function. Both clinical and experimental data suggest 
that activation of local renin angiotensin system (RAS) in the heart plays an unportant role 
in this compensat0'1' mechanism to maintain adequate hemodynamie function [1]. Recent 
studies have shown that cardiac expression of angiotensin-I converting enzyme (ACE) and 
angiotensinogen is increased in experimental heart fallure [2, 31. In patients with chronie 
heart fallure, cardiac expression of ACE was found to be increased up to threcfold compared 
to the hearts of subjects without heart fallure [4]. 
An Insertion/Deletion (VD) polymorphism, characterized by the presence or absence of 
a 287-base pair Alu repeat sequence in intron 16 of the ACE gene, has been reported to be 
responsible for about 50% of the interindividllal variability in serum ACE levels [5, 61. Both 
semm ACE levels and cardiac ACE activity were highest in subjects carrying two copies of 
the D-allele f5-7l. The DO-genotype has been put forward as a risk factor for left ventriclilar 
remodelling in hypertensive subjccts [8, 9]. Raynolds et al. observed an increased frequency 
of the DD-genotype in patients with both ischemie and idiopathic dilated cardiomyopathy 
[JOl. 
\Vc examined the roie of the ACE lID polymorphism in the devclopment of heart fai/ure 
in a population-based cohort study. Since several studies reported an effect ofthe D-allele on 
cardiac disease in hypertensive subjects only, we analysed nonnotensive and hypertensive 
subjects separately. 
Methods 
5tudy Population 
The study was conducted within the Rotterdam Shld}', a single-centre prospective follow-up 
study in which all residents aged 55 years and over of the Rotterdam suburb of On1lnoord 
were invited to take pati. The baseline examination of the Rotterdam Study was conducted 
between 1990 and 1993. Thc l\'ledical Ethics Conullittee of Erasmus Medical Centre Rotterdam 
approved the study. Written informed consent was obtauled from all patiicipants. The design 
of the study has been described previously [11). 7983 participants were examined (response 
78%). In 6869 subjects, the ACE IID polymorphism was genotyped successfully (86%). In the 
rernaining 1114 subjects, no genotypes were available. \Ve excluded 211 subjects because 
no information on blood pressure levels was available. 
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At baseline, information concerning medical history, medication use and smoking 
behavior was obtained with a computerized questionnaire [11]. Blood pressure was 
mcasured, after a minimum of 5 minutes rest, in the sitting pasitian at the right upper 
arm using a randam zero sphygmomanameter, Participants were asked to abstain from 
smoking and drinking alcahalic or caffeine-containing beverages at least twa hours befare 
blood pressure measurements were taken, The average of two measurcments was used tor 
analysis, Hypertension was defined as a diastolic blood pressure (DBP) of 100 mmHg ar 
higher and/or a systolic blood pressure CSBP) af 160 mmHg ar higher and/or use of anti-
hypertensive medication indicated for treatment of hypertensian (grade 2 and 3 of the 1999 
WHO/ISH criteria) [12, 13). 
Heart failure assessment 
Assessment af prevalent heart failure at the baseline cxamination in the Rotterdam Study has 
been described in detail earlier [14]. ·We excluded subjects with prevalent heart failurc from 
our study (n=220), All participants of the Rotterdam Study were continuously monitored for 
the occurrenee of heart [allure during folluw-up using automated linkage with files from 
general practitioners, All available medical data, such as hospital discharge letters and notes 
from general practitioners, were obtained from the medical recards in case of possible heart 
fallure, Apart from th is systematic follow-up procedure, we used verified hospital discharge 
diagnoses for case finding, gathered from all haspitals in the Ratterdam area as described 
above. The date of incident hemt failure was defined as the day of the first occurrence of 
symptoms sllggestive of heart failure or the date of the first prescription of a loop dillretic 
or an ACE-inhibitor. 
The diagnosis of heart failure was cIassified as definite, probable, possible or unlikely. 
Definite heart failure was defmed as a cambination of heart failure diagnosed by a medical 
specialist and the presence of typical symptoms of heart failure, such as breathlessness at 
rest or during exertion, ankle edema and pulmonary crepitations, confirmed by objective 
evidence of cardiac dysfunctian Cchcst X-ray, echocardiography). This definition is in 
accordance wHh the criteria of the European Society of Cardiology [15]. Probable healt 
failure was defined as heart failure diagnosed by a general practitioner, with at least two 
typical symptoms suggcstive of heart failure, and at least 1 of the following: histary of 
cardiovascular disease (e.g. myocardial infarction, hypertension), response to treatment for 
heart failure, or objective evidence of cardiac dysfunction j while symptoms could nat be 
attributed to anather underlying disease. 
Two research physicians independently cla&'iified aU information on potential heart 
failure events. If there was disagreement, a consensus was reached in a separate session. 
Finally, a cardiologist verified all probable and possihlc cases, and all cases in whieh the 
two physicians could not reach consensus. If the cardialogist disagreed with the research 
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physicians, the cardiologist's judgment was considered decisivc. The research physicians 
and the cardiologist based their decisions on thc same data. Only definite and probable 
cases were inc1uded in the analyses. 
Genotyping 
The 11, ID and OD genolypes were detected using thc polymerase chain reaction tcchnique 
(PCR) according to the method of Lindpaintner et al with some modifications [16]. In order 
to avoid misclassification of ID genotypes into OD genotypes, a sec011d PCR was performed 
using an I-specific primer. 
Statistical Analysis 
Overall general characteristics of norlllatensive and hypertensive subjects and thase stratified 
by ACE genotype, were compared using univariate analysis of variance for continuotlS 
variables anel chi-square statistics for dichotomous variables. Incidence rates were calculated 
as number of cases per 1000 person-years using the exact Poisson formula and presented 
with 95% confidence intervals (CI). Relative risks of incident heart fallure were assesseel 
using Cox proportional hazard regression analysis. All risk estimates are presented with 
95% Cl. NQrmotensive subjects were uscd as the reference group in these analyses. \X'e 
adjusted for age and sex in aU analyses. To assess the effect of the ACE IlO polymorphism 
independent of possible canfounding or mediating factors, analyses were repeated adding 
body mass index (13t-.H), diabetes mellitus, smoking, myacardial infarction, total and I-IDL-
cholesterol ta the model. F1Il1hennore, we tested for statistica I interaction between the ACE 
1/D polymorphism and hypertension by adding an interaction term to the regression model: 
hypertension (dichotomous) x ACE-genotype (categorical). \X'e pcrformed all analyses with 
SPSS version 11.0. 
Results 
A total of 6438 subjects were available for follow-up untilJanuary 1, 2000. Baseline descriptives 
of the tatal study poplllation are prcscnted in table 1. \X'e includcd 4264 normotensive 
subjects and 2174 hypertensive subjects in our study. Both groups followed Hardy-\\7einberg 
Equilibrium proportions for the ACE 1/D polymorphism. ["Iean follow-up was 6.9 ± 2.1 years 
for normotensive sllbjects and 6.4 ± 2.4 years for hypertensive subjccts. In hypertensive 
sllbjects, mean follow-up was significantly shorter for subjects carrying twa copies of the 
O-allele than for subjccts carrying two copies of the I-allele. Hypertensive subjects wcre 
significantly older anel less often male than normotensive subjects. This difference was 
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Normotensive subjects Hypertensive subjects " !! 
~ 
ACE genotype Overall [D DD Overall [D DD w 
Number(%l 4264 (66.D) 962 (22.6) 2106 (4904) 1196 (28.0) 2174(34.0) 441(20.3) 1116 (513) 617 (28.4) 
Mean follow-up (yrs) 6.9±2.1 6.9±2.0 6.9±21 6.9±2.1 6.4±204 6.6±204 6S±2.3 6.3±2.4 
Ag, (yrs) 68.0±8.9 67.6±8.8 68.1 ±8.8 68.4±91 71.0±8.8 70.6±9.0 71.1 ±8.6 71.2±9.l 
Sex (maJel 42.9 43.2 43.0 42.4 353 34.9 36.1 34.0 
5BP(mmHg) 130.7±16.l 130.6 ± 16.3 130.2 ± 16.4 1l1.4±15.8 156.S±22.4 156.3 ±22.7 1565 ±222 157.6±225 
DBP(mmHg) 70.9± 10.0 70.8±10.1 7D.6±9.9 71.4±9.9 SO.D± 12.0 80.4± 12.5 So.o± 12.0 79.4± 11.7 
Diabetes mellitu$ 7.1 65 8.0 6.0 15.0 15.9 15.8 13.0 
Myocardiallnfarction 113 lD2 11.8 11.3 15.6 14.6 16.D 155 
8M[ (kg!m~ 25.8±35 25.8±3.7 25.7±35 25.9±35 27.2 ± 3.9 275±3.8 271 ± 4.0 27.1 ±3.7 
Total cholesterol 6.6±1.2 65±1.3 6.6±1.2 6.6±11 6J±11 6.S±13 6J±13 6J±11 
HOL -cholesterol 1.4±0.4 1.4±O.4 1.4± 0.4 1.4±0.4 13±Oo4 1.3 ± 0.3 1.3±0.4 13±0.4 
Smoking (cuITent) 24.7 25.9 255 22.4 18.4 16.6 193 17.9 
All values are presented as percentage or mean ± standard deviation 
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the same over all genotype strata. Within the normotensive group, OBI' was significantly 
higher in subjects carrying the DO-genotype compared to subjects carrying the ID-gcnotype. 
Prevalence of diabetes mellitus and myocardial infarction, mean BJ\U and total cholesterol 
levels werC significantly higher in hypertensive subjects compared to normotensive subject. ... 
In the hypertensive group, Bl\H was signilicantly higher in subjects carrying the U-genotype 
compared to subjects canying the DD-genotype. HDL-cholesterol and percentage current 
smokers were significantly lower in hypertensive subjects than in normotensive subjects. 
This difference was the same over all genotype strata. 
Tablc 2 shows number of cases, person-years anel incidence rates (IR) of heart failure 
observed in nonnotensive and hypertensive subjects stratified by ACE genotype. During 
44,883.1 person-ycars of follow-up 543 participants developed hcart failure. In normotensive 
subjects, the IR of heart failure was about 10 per -1000 person-years, independent of 
genotype status. In hypertensive subjects, the IR of heart fallure significantly increased with 
the number of D-alleles present. In subjects carrying the U-genotype the IR of heart failure 
was 13 per 1000 person-years (9S0f0CI: 9-17). In subjects carrying ane or !wo copies of the 
D-allele Ihe IR of hcart failure increased up 10 18 (15-21) and 20 (16-24) per 1000 person-
years, rcspectively Cp for trend<O.OS). 
Table 2. Number of cases and inddence rates ofheart failure stratified by ACE genotype In normotensive and hypertensive 
subjects. 
NormotellsJon Hypeltellsion 
ACE genotype Numberofcases Person IR Number of cases Person IR 
years (95%0) years (95%(1) 
67 6823.4 10(8-12) 39 3010.1 13 (9-17) 
10 131 14970.7 9 (7-10) 138 7616.4 18 (15-11) 
00 88 8377.1 11 (8-13) 80 4075.2 10(16-24) 
Inddence fate (IR) presented as number of cases per 1000 person-years with 95% confidence Interval. 
Table 3. Risk ofheart failure in hypertensive subjectscompared to normotensive subjects:overall and stratified by ACE 
genolype. 
Model 1 Model 2 
NOlmotensive subjects:OveraJJ risk ofheart failure 1.0 (ref.) 1.0 (ref.) 
HypMensive subjects: 
Overal! risk ofheart failure 1.6(1.4-1.9) 1.4 (1.2-1.7) 
Risk ofheart faiJure stratified by ACE genotype 
lI-subJects 1.2 (0.8-1.6) 1.1(0.8-1.6) 
ID-subjeds 1.60,3-1.9) 1.4 (1.1-1.7) 
DD-subjects 1.7 (1.3-1.1) 1.5 (1.1-2.0) 
All risk estimates are compared to all normotensive subjects (reference group).Modell:adjusted for age and sex. ModeI2:adjus-
ted for age, sex,body mass index,smoking,diabetes mellitus, myocardiallnfarction, total and HOL-cholesterol. 
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In table 3, the relative risks (RH) of heart fallure for hypertensive subjects, overall and 
stratified hy ACE genotype, compared to normotensive sunjects are presented. Overall, 
hypertensive subjects had a significantly increased risk of heart failure of 1.4 0.2-1.7) 
compared to normotensive subjects (model 2). Hypertensive subjects carrying two copies of 
the I-allele did not have an increased risk of heart fallure compared to normotensiye subjects 
(RR: 1.2 (0.8-1.6) (model 2). However, hypertensive subjects carrying one or two copies of 
the D-allele had a significantly increased risk of heart failure compared to normotensiye 
subject" ID, RR 1.4 (1.1-1.7) and DD, RR, 1.5 (1.2-2.0) (model 2). Statistical intcmction 
between the D-allele of the ACE-genotype and hypertension was borderline significant, 
(p~0.059). 
Discussion 
\'(Te observcd an increased risk of heart fallure in hypertensiye suhjects compared to 
nOflllotensiye subjects that was dependent on the presence of the D-aUele of the ACE liD 
polymorphism. Hypertensive subjects did not have a significantly increased risk of healt 
failure cornpared to normotensive subjects, unless they carried one or two copies of the 
D-allele. The incidence rate of heart failure in hypertensive subjects significantIy iIlcreased 
with the Ilumber of D-alleles present. As thc inciclence of heart fallure marks the end 
of the follow-up pedod, this mayalso explain the shorter follow-up period observed in 
hypertensiye DD subjects comparcd to 11 subjects. 
Hypertension is the most common condition antedating heart fallure in the general 
population U7, 18]. Especially in the elderly, heart failure is often preceded by long standing 
high blood pressure and LVH 09, 201. However, the extent of cardiac remodelling does not 
always seem to correlate with the e:\1:ent of cardiac damage. In fact, mild hypertension may 
lead to severe healt fallure whereas severe hypertension may be without any perceiyable 
effects on cardiac function. As a consequence, it has been hypothesized that genetic factors 
may modlliate the manifestation or progression of cardiac renlOdeling [211. 
The ACE liD polymorphism is by far the most frcquently stlldied candidate gene in the 
developmcnt of lcft ventriCLtlar hypertrophy and heart failure. Homozygosity for the D-allele 
has been associated with higher prcyalence of LVH arrel increased heart weight in (untreated) 
hypertensive subjects [8, 9, 22-241. Raynolds ct al. were the flrst to report an association 
between the ACE IlO polymorphism and heart failure. They observed an increased frequency 
of the DD-genotype in subjects with ischemie and dllated cardiomyopathy [10}. Since Iocal 
formation of angiotensin 11 within the myocardium is thought to be involved in the cardiac 
remodelling process, elevated cardiac angiotensin 11 levels in subject .. carrying the D-allele, 
may partly explain the association between the DD-genotype and variotlS cardiac disorders 
(7). 
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Nevel1heless, findings remain controversial and so far positive and negative results 
seem to outweigll each other [25-27]. Many of the conflicting findings on thc ACE IlO 
polymorphism and cardiac disease are most likely due to small sample sizes alld large 
heterogeneity of the populations that were studied. Another reason for the inconsistent 
findings may be that the ACE liD polymorphism by itself does not have enough biological 
significance to exert an effect on cardiac tissue, especially since the RAS is normally under 
strict negative feedback inhibition. This has led to the hypothesis that an effect of the ACE 
I1D polymorphism on cardiac function may oniy become clinically relevant under specific 
conditions in whkh the cardiac growth machinely is already activated [28]. In linc with 
this hypothesis, Montgomery et al. obse .. ved increased len ventricular mass after rigorous 
exercise only in those participants who carried a copy of the D-allele [29J. Another study 
observed increased advcrse cardiac remodelling in subjects with the ACE 10- and DD-
genotype after they had experienced a myocardial infarction [301. 
\X'c believe our fllldings provide additional evidence for a modifying effect of the ACE 
liD polymorphism in the development of cardiac disease. In our study, the D-allele was 
associated with an increased risk of heart failure in hypertensive subjects only, which may 
suggest that the D-allele has an effect on the heart merely when local RAS is al ready 
activated because of increased heamodynamie load. Since asymptomatie cardiac remodelling 
usually precedes the development of clinically overt heart failure in hypertensive subjects, 
we believe Dur findings are in accordance with the observation that, especially in subjects 
with hypertension, the O-allele of the ACE liD polymorphism is associatcd with increased 
levels of various echocardiography measures of cardiac hypertrophy [8, 9, 31, 321. 
Until now, our study is the largest poptilation based study that assessed the roie of 
the ACE liD polymorphism in heart fallure in a reIatively homogenous population, as 
98% of the participants in our study are Caucasians and they all live in the same area of 
Rotterdam. In contrast to case-control studies on heal1 failure that have been conducted so 
far, the prospective nature of our study makes our results less prone to survival bias. Still 
several issues need to be addressed. In our study, we were not able to discern the different 
etiologies of heart fallure (idiopathie, ischemie or othef). However, we think that the ACE 
I/D polymorphism may be more important as a modulator in the way the myocardium 
responds to cardiac damage ("remodelling") than in the events leading to cardiac damage. 
The ACE liD polymorphism may increase the risk of heart failure through an effect on blood 
pressure or an increased risk of myocardial infarction; however, our results do not support 
th is. On the contra.", our findings suggest that hypertension by itself is not a real strong 
predictor of heart failure, unless one or two copies of the O-alicle are present. Furthermore, 
correction for baseline and incident i\U in our analyses did not change the association 
between heart failure and the ACE IlO polymorphism. In addition, the prevalence of MI did 
not dufer significantly between the genotype groups in hypertensive subjects. 
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In conclusion, our findings suggest that the ACE IID polymorphism may play a modifying 
role in the development of heart fallure in hypertensivc subjects, regardless of thc initial 
cause of cardiac damage. \XTe believe these findings may provide an additional genetic due 
as to whether some hypertensive subjects do develop cardiac hypertrophy resulting in heart 
failure, whereas others do not. 
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Mortality in patients with hypertension on 
angiotensin-I converting enzyme (ACE)-inhibitor 
treatment is influenced by the ACE Insertion/ 
Deletion polymorphism 
Chapter6.1 
Abstract 
Background: The response to angiotensin-I converting enzyme CACE)-inhibitor therapy is 
highl)' varia bIe. Residual ACE activity during treatment, potentially modified by the ACE 
Insertion/Deletion (I/D) polymorphism, ma)' explain part of this variability. \Ve studied the 
possible interaction belween ACE-inhibitor therapy in palients with hypertension and the 
ACE liD polymorphism in incident heart fallure and death. 
J\kthods: \XTe studied 3365 hypertensive pal1icipants of the population-based Rotterdam 
Study, without heart failure at baseline for whom ACE-genotyping was successful. Incident 
heart failure was defined according 10 established criteria. In addition, total and cardiovasclilar 
mOl1ality were stlldied as endpoints. A Cox regression model with use of ACE-inhibitors 
defined as timc-depcndent covariates was used for data-analysis. Interaction was tested in 
this model assuming an aUelc-effect relationship. 
Results: Although \ve could not demonstrate a beneficia I effect of ACE-inhibitors, there was 
significant interaction between the ACE liD polymorphism CII-JD-DD) and ACE-inhibitor 
use in the predîction of total and cardiovascular mortality. Mortality risk associated with 
treatment increased with the number of D aIleles present; e.g. for total mortality in the 
II genotype group, RR~0.95 (95% Cl 0.63-1.45), in the ID genotype group' RR~1.08 (95% 
Cl 0.84-1.38) and in the DD genotype group, RR~1.6I (95% Cl 1.I8-2.18). No statistically 
significant interaction was found for incident heart fallure. 
Condusion: The results of Dur study suggest a relative resistance to ACE-inhibitor therapy in 
subjccts with hypertension and the DD genotype compared to the 11 genotype, with the ID 
genotype in an intermediate position. 
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Introduction 
Heart failure is a complex clinicalsyndrome resulting in substantial morbidity and mortality 
[1, 2]. Especially in elderly subjects, heart failure is often preceded by hypertension [11- It is, 
however, difficlIlt to predict who will develop heart fallure or other end-organ damage in 
response to a high blood pressure. The renin-angiotensin-aldosterone system (RAAS) plays 
a major role in cardiovasclliar pathophysiology. An Insertion/Deletion (VD) polymorphism 
located in intron 16 of the angiotensin-I converting enzyme (ACE) gene is rcsponsible for 
approximately 50% of inter-individual variability in circulating ACE levels, whieh are highest 
in subjects with the DD genotype [3]. The ACE liD polymorphism has also been demonstrated 
to influeIlce ACE expression in cardiac tissue [4]. Therefore, maIly genetie association 
studies have investigated the ACE liD polymorphism as a risk factor for cardiovasclliar 
disease with, in general, contradietory results [5-81. However, promising results have been 
reported in studies examining the ACE polymorphism as a modifier gene in heart failure 
and hypertensionj hence, a roie for this variant in the development of cardiovascular disease 
may only become apparent under specific stressful conditions [5, 6J. 
ACE-inhibitors are widely used in the treatment of hypertension and heart fallure, 
because of their blood pressure lowering effects anel their positive effects on cardiovascular 
morbidity and mortality [9,10]. However, the individu al response to ACE-inhibitor therapy 
is highly variabIc and the RAAS is not unifofIllly suppressed during treatment with ACE-
inhibitors Ul]. This diversity in response is partially explained by environmental factors, 
such as salt intake [12]. In addition, residuallevels of enzyme activity during ACE-inhibition, 
potentially modified by ACE liD genotype, may be important [13, 14J. 
Studies on the interaction between ACE IID genotype anel the use of an ACE-inhibitor 
in subjects with hypertension have focused on thc efficacy of ACE-inhibitors in blood 
preSSllre redllCtion and regression of left ventrÎClllar hypertrophy [5, 13-171. Results have 
been inconclllsive 50 faro None of these sluclies incllldeel major carcliovascular endpoints. 
Therefore, we stuelied the possible interaction between ACE-inhibitor therapy and the ACE 
liD polymorphism in the prediction of incident heart failure and death in a large cohort of 
Caucasian elderly subjects with hypertension. 
Methods 
Setting and study population 
Thc Rotterdam Study is a population-based prospective cohort study in 7983 subjects of 55 
years anel oldcr and has been approved by the J\:lcdical Ethics Committee of the ErasmllS 
Medical Center [181. The baseline examination was conducted between 1990 and 1993. 
Participants were visited at home for a standardised questionnaire anel were subsequently 
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examined at the research center. At baseline, information was obtained on several 
characteristics, inclllding age, gender, smoking, blood pressure, diabetes mellitus, body 
mass index (B~n), medication llse, verified history of myocardial infarction, heart failure, 
coronary artery bypass graft (CABG), and percutaneous transluminal coronary angioplasty 
(PTCA). A research physician determined the indication for each dmg that was currently 
used by the participant. Hypertension was defined as use of antihypertensive dmgs for the 
indication of high blood pressure, or as a systolic blood pressure of 140 mm Hg or higher, 
or a diastolic blood pressure of 90 Hun Hg or higher. Hypertension was present in 3678 
participants. For the present study wc induded 3365 participants with hypertension, without 
prevalent heart fallure (n:=o-135), for whom ACE genotyping was successful. 
In the Rotterdam Study, participants are continuously monitored for major events that occur 
during follow-up, including heart failure, myocardial infarction, CAnG and PTCA. This occurs 
through automated linkage with fIles from general practitioners. All avallable infonnation on 
these events is copied from the medical records for verification of the diagnosis. Furthermore, 
all dmg prescriptions dispensed to participant .. hy all pharmacies in the snldy area are routincly 
stored in the database since January 1, 1991. Information on vital status is obtained reglllarly 
from municipal health authorities in Rotterdam and from the general practitioners in the study 
district, and was complete for all participant .. until January 1, 2000, 
ACE genotyping 
The ACE lI, ID and DD genotypes were detected using a polymerase chain reaction (PCR) 
technique according to the method of Lindpaintner et al. with same modifications [191. In 
order to avoid misclassification of ID-genotypes as DD-genotypes, a second independent 
PCR was perfornled with a prinler pair that recognises an insertion specific seqllence C5'TGG 
GAC CAC AGC GCC CGC CAC TAC3' and 5TCG CCA GCC erc CCA TGC CCA TAA3'). 
To optimÎse the secOlld PCR, 10% dimethyl sulfoxide CDiVISO), 0.35 units AmpliTaq Gold 
DNA polymerase and GeneAmp PCR Gold buffer (Applied Biosystems) were l..1sed in the 
PCR mix. This reaction yiclded a 335-bp amplicon onIy jf the I-allcle was present. Two 
independent investigators read picturcs from each gel and were not aware of the objective 
of the present study. All ambigllous samples were analysed a second time. 
Exposure to ACE-inhibitors 
Complete information on all prescriptions for ACE-inhibitors dispenscd to participants was 
available in automated form since January 1, 1991 ancl was used to create time-dependent 
variables of use and non-use of ACE-inhibitors, Participants were consiclered to be exposed 
if a prescription for an ACE-inhibitor was filled dllring follow-up, in the pcriod before the 
index date. Hereta, for every prescription, the length was calculated by dividing the number 
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of dispensed pills by the prescribed daily number. In this way the follow-up period for every 
participant was distinguished into periods of use and non-use. The index date was defined 
as the date on which an endpoint occurred for a participant of this study. 
Heart failure assessment 
Assessment of prevalent heart failure at baseline has been described in detail earlier [20J. 
Briefty, a validated score was used, similar to the definition of the European Society of 
Cardiology [1J. This score was bascd on thc presence of at least two symptoms suggestive 
of heart failure or treatment for heart failure, in combination with objectÏ\'e evidence of 
cardiovascular disease. This score was, however, not implemented from the first beginning 
of the Rotterdam Study, but was subsequently added. Consequently, this information 
was obtained in only 5540 participants. In addition, prevalent heart failure cases were 
obtained through a database containing hospital discharge diagnoses from all hospitals in 
the Rotterdam area. Furthermore, all medical records were screened in retrospect for the 
occurrence of heart fallure in the majority (97%) of participants. \Vith these three methods, 
information on prevalent heart failure was available for all participant ... 
Cases of incident heart failure were obtained by continuously monitoring participants of 
lhe Rotterdam Study for the occurrence of heart fallure during follow-up through automated 
linkage with files from general practitioners. All available data on these events, such as hospital 
discharge letters aod notes from general practitioners, were copied from the medical records. 
Apart [rom tlus systematie follow-up procedure, we used verilled hospital discharge diagnoses 
for case finding, gathered from all hospitals in the Rotterdam area as described above. The 
diagnosis of heart failurc was clas...,jfied as definite, probable, possible or unlikely. Definite 
heart failure was defmed as a combination of heart fallure diagnosed by a medical specialist 
and the presence of typical symptoms of heart fallure, such as breathlessness at rest or during 
exertion, ankle edema and pulmona'1' crepitations, confirmed by objective evidence of cardiac 
dysfunction (chest X-ray, echocardiography). This definition is in accordance with the criteria 
of the European Society of Cardiology [1J. Probable heart fallure was defined as heart failure 
diagnosed by a general practitioner, with at least two typical syrnptoms suggestive of healt 
failure, and at least 1 of the following: hist0'1' of cardiovascular disease (e.g. myocardial 
infarction, hypertension), response to treatment for llealt fallure, orobjective evidence of cardiac 
dysfunction, while symptoms could not be attributcd to another underlying disease, such as 
chronie obstructive pulmonaly disease. Two research physicians independently classified all 
information on potential heart fallure events. If there was disagreement, a consensus was 
reachcd in a separate session. Finally, a cardiologist vcrificd all probable and possible cases, 
and all cases in which the two physicians couid not reach consensus. If the cardiologist 
disagreed with the research physicians, the cardiologist's judgment was considcred dccisive. 
Only definite and probable cases were included in the analyses. 
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Analysis 
\Ve used Cox proportional hazards regression analysis to estimate rclative risks (RR) and 95% 
confidence intervals (95% CI) for exposure to an ACE-inhibitor in relation to the incidence of 
three predefined endpoints: heart failure, death and thc combined endpoint of heart fallure 
or death (whichever came first). Participants were followed from January 1, 1991 untU the 
earlicst of incident heart failure, death, 1055 to follow-up, date of last data collection, or 
January 1, 2000. Exposure to an ACE-inhibitor was represented in the model hl' a time-
dependent covariate to compare any use with non-use at different points in time. Ta ensure 
optimal adjustment for age, age in days was used as the time-axis of the model instead of 
follow-up. This resulted in a model that compares the exposure starrlS of each case with the 
starrIs of all other participants who arc alive and free of heart failure at exactly the age of the 
case at the index date. Analyses were performed stratified by ACE IlO genotype. 
Analyses were initialIl' adjusted for gender and calendar time. In the second model, we 
additionally adjusted for the foliowing baseline factors: smoking status (current/former/ 
never), BMI, diabetes mellitus, systolic blood pressure and historl' of ischemie heart diseasc, 
consisting of either a myocardial infarction, CABG or PTCA. Furthermore, tlus model was 
adjusted for incident ischemie heart disease events. We also adjusted this model in a time 
varying manner for the occurrence of a nrst automated filled prescription of any anti-
diabetic drug during the study period, as a proxy for incident diabetes mellitus, and of any 
other antihypertensive dmg, inclllding f3-blockers, diuretics, calcium antagonists and other 
antihypertensives. All incident cofactors were defined in the time-varying model using age 
in days as the time-axis. 
\Ve tested for interaction between the ACE JID polymorphism anel the llse of ACE-
inhibitors by adding an interaction term to the regression model: ACE-genotype (0-1-2: 
DD-ID-IJ) x ACE-inhibitor use (0-1), assuming an allele-effect relationship. A two-sided 
p-value < 0.05 was considered statistically significant. Adelitional analyses were performed 
with the enelpoint cardiovasclliar mortality (ICD10 codes 120-125, 146, 149, ISO and R96) and 
after exclusion of participants, who were exposed 10 an ACE-inhibitor in the first 100 days 
of follow-up, used as a proÀl' for prevalent exposure. 
Results 
A total of 3365 iodividuals with hypertension were inclllded in our sUldy population. 
Approximately 45% of these subjects used antihypertensive therapy according to their 
baseline interview. Table 1 presents baseline characteristics according to ACE genotype 
and the use of an ACE-inhibitor at any time during the study perioeI. Genotype and allele 
distributions were in Hardy-\Veinberg equilibrium for both groups aod for the total sludy 
poplliation (p=O.5). During a mean follow-up of 7.8 years (SD 2.1), 354 cases of incident heart 
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Table 1. Baseline characteristics according to the use of an angiotensin converting enzyme (ACE)-inhibitor during the study period: overall and stratitied by ACE genotype. 
ACE-inhibitor (-) ACE-inhibitor(+) 
ACE genotype Overall 10 DO Overall 10 DO 
Number 2410 500 (21%) 1211 (50%) 699 (29%) 955 206(22%) 4,'11 (50%) 268 (28%) 
Mean follow-up (years) 7.7 (2.1) 7.7 (2.2) 7.7 (22) 7.8(2.1) 8.0 (1.8)' 8.2 (1.7)- 8.1 (1.8)- 7.8(2.0)-
Age (yea") 69.6 (9.0) 69.4(9.1) 69.7 (8.9) 69.5(92) 68.4(8.0)" 67.9 (8.1) 68.60.9) 68.5 (8.1) 
Female 1500 (62%) 322(64%) 740(61%) 438 (63%) 563 (59%) 119(58%) 285 (59%) 159 (59%) 
5BP (mm Hg) 153 (17) 153 (17) 152 (17) 153 (17) 155(21)' 153 (21) 156 (21) 156(20) 
OBP(mm Hg) 78 (11) 78 (11) 78 (11) 78(10) 80 (12)* 80(12) 80 (12) 80(12) 
Diabetes mellitus 287(12%) 62 (12%) 156(13%) 69(10%) 143 (15%)' 27 (13%) 81 (17%) 35(13%) 
Myocardial infarction 117(5%) 25(5%) 63(5%) 29(4%) 83 (9%)" 13(6%) 50 (10%) 200%) 
Body mass index (kg/m2) 26.7 (3.8) 26.7 (3.8) 26.7 (3.8) 26.6 (3.7) 27.4(3.9)' 27.7 (4.4) 273 (3.9) 27.4(3.7) 
CABG 4,'1(2%) 6(1%)- 22(2%)- 20 (3%)- 37(4%)" 7(3%) 23(5%) 7(3%) 
PICA 18(1%) 2 (0.4%) 15(1%) 1(0.1%) 8(1%) 1 (05%) 7(2%) 8(3%) 
Smoking (euTrent) 472(20%) 94(19%) 253 (21%) 125(18%) 182 (19%) 31 (15%) 98 (20%) 53(20%) 
All values are presented as number (percentage) or mean ± standard deviation. ;<, Significantly differentfrom non-users, p<O.OS. "1Hf$ignificanttrend over genotypes in users or non-users, p<O.OS.OveraH 
no signiticant trend over genotypes, p>O.OS.SBP:systolic blood pressure, DBP: diastolic blood pressure,CABG: coronary artery bypass graft, PTCA: percutaneous transluminal coronary angioplasty.SBP and 
DBP: partiöpants who were treated with antihypertensive drugs at basenne were included 
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failure were identified alld 821 subjects died. Throughout the study period, 955 participants 
accumulated person-time in the exposed category, These subjects were on average younger 
at baseline and more likely to have diabetes mellitus, a history of myocardial infarction 
and a history of CABG Ctable 1), Also, blood presslIre levels and DMI were on average 
higher in these subjects. J\-Iean follow-up was 0.3 years langer for participants who received 
an ACE-inhibitor than for those who did not. The ACE I/D genotype distribution did not 
differ between the two exposure groups, Exposure to the other antihypertensive dmgs 
during the study period was also not associated with the ACE lID polymorphism. Overall, 
baseline characteristics were not significantly different between ACE lID genotypes (p-vailie 
trend>0,05\ In subjects who did not receive an ACE-inhibitor during the study period, a 
history of CABG was more frequent in the DD genotype group than in the 11 genotype 
group, with 10 heterozygotes in an intennediate position, In persons who were exposed to 
an ACE-inhibitor during the study period, mean follow-up increased with the number of I 
alleles present. 
Table 2 presents relative risk estimates for the associations between the use of an ACE-
inhibitor anel incielent heart failure, death anel the combineel end point of heart failure 
or death, stratified by ACE liD genotype, Despite the adjustment for a large number 
of cardiovascular risk factors, a beneficial effect of ACE-inhibitor therapy could not be 
demonstrateel in our stud)' population. ACE lID genotype did not modify the association 
between the use of an ACE-inhibitor and incident heart failure, There was, however, a 
significant interaction between the ACE IlO polymorphism and ACE-inhibitor use in the 
prediction of total mortality, The risk of death of any cause was elevated in users of ACE-
inhibitors compared to non-users in the DD group, while this was not observed in both ID 
and 11 genotype groups. The same trend over the tluce ACE genotypes was observed for 
the association between ACE-inhibitor therapy and the combined outcome of heart failure 
or death (tabie 2), 
\Vhen we rcstricted our analyses to cases of cardiovascular mortality (ICDIO codes 120-
125, 146, 149, ISO and R96; number of cases: 206), a similar worsening trend over ACE 
genotypes was detected: the relative risk for cardiovascular mortality with the use of an 
ACE-inhibitor was 1.15 (95% Cl 053-2.49) in the II genotype group, 1.58 (95% Cl 1.01-2.47) 
in the ID genotype group, and 2.97 (95% Cl 1.61-5.48) in the DD genotype group; p-value 
for interaction = 0,05, To investigate the effect of exposure misdassifIcation elue to prevalent 
use of ACE-inhibitors at baseline, we excludcd all participants who were exposed to an 
ACE-inhibitor in the first 100 days of follow-up, This yielded the same results: a significant 
interaction bel'ween ACE genotype and ACE-inhibitor use for death and the compound 
endpoint of heart fai/ure or death, but not for incident heart failure (results not shO\vn). 
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Table 2. Relative risks forthe associations between the use of an angiotensin converting enzyme (ACEHnhibitor and heart failure,death and the combined endpoint heartfailure or death,stratitied 
by ACE genotype. 
Heartfailure (n=354) Oeath* (n421) Heartfailure or death *t (n=989) 
Genotype stratum Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
11 130 (0.75-2.25) 1.01 (055-1.85) 1.06 (0.72-1.56) 0.95 (0.63-1.4~ 1.05 (0.74-1.49) 0.93 (0.64-1.36) 
ID 1.29 (0.91-1.83) 1.14 (0.79-1.6~ 1.22 (0.97-1S4) 1.08 (0.84-1.38) 1.22 (0.99-151) 1.09 (0.87-1.36) 
DD 1.58 (1.01-2.46) 1.20 (0.74-1.92) 1.93 (1.45-2.571 1.61 (1.18-2.18) 1.68 (1.29-2.19) 136 (1.02-1.80) 
Model 1 :adjusted for age, gender and calendartime; Model2:adjusted for age, gender, calendartime, body mass index,smoking status (current/former/never), prevalent and incident diabetes mel~ 
Iitus,systolic blood pressure, prevalent and incident ischemie heart disease, consisting of myocardial infarction, coronary artery bypass graft and percutaneous transluminal coronary angioplasty, and a 
fiTst prescription during the study period of a diuretic,a ·blocker,a calcium antagonist or an other antihypertensive drug 
'p-value < 0.05forthe interaetion term in multivariate models:ACE 110 genotype 10-1-2:11-10-00) x ACE-inhib~or 10-'), twhichevercamefirst 
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Discussion 
In this large prospective population-based study, we found a relative resistance to ACE-
inhibitor therapy in subjects with hypertension and the DD genotype compared to the 
H genotype, with the ID genotype in an intermediate position. !\'lortality risk associated 
wilh treatment increased w1th the number of D allcles present. 1'his trend was observed 
for both total and cardiovascular mortality. The risk of incident heart failure associated 
with ACE-inhibitor therapy was, however, not significantly different between strata of ACE 
genotypes. A potential explanation for this might be that our study lacked sufficient power 
to identify small differences between genotype strata in the rclative risk of heart fallure with 
the use of ACE-inhihitors. Another explanation l11ight be that subjects with the DD genotype 
could have died before they developed heart failure, and that these subjects would have 
developed hemt failure if they had lived longer. \\7e c011ld not demonstrate a beneficia! 
effect of ACE-inhibitor therapy in this observational setting. 
Clinical investigations on the presence of an interaction between ACE genotype and 
response to ACE-inhibitor therapy have focllsed on its hemodynamic effects in the treatment 
of hypertension and on the efflcacy of ACE-inhibitors in the redllCtion of proteinuria [5, 12, 
14-17,21,22]. Also, ACE-inhibition has been reported to influence the association between 
the ACE liD polymorphism and left ventricl..dar remodelling after myocardial infarction 
[231. Howc\'cr, studies on hard cardiovascular cndpoints arc lacking. So rar, findings have 
been highly inconsistent, mainly duc to lack of statistical power and heterogeneity of study 
populations. Although there have been a few studies that tested tor an interaction between 
ACE liD genotype and response to ACE-inhibitor therapy in patients with healt failure UI, 
13], our study is the first that tested for an interaction of this polymorphism with the cffects 
of treatment on the risk of incident heart failure and death in subjects with hypettension. 
Contrary to our findings on rnoltality in hypertensive subjects, post hoc analyses in a large 
trial in patients with stroke or transient ischemie attack did not dernonstrate Illodification of 
the effects of ACE-inhibitor therapy on mortality by ACE liD genotype (241. 
A major limitation of our study is its observational nanlre, which inevitably has led to 
confounding by indication of the effects of ACE-inhibitor use. Despite the fact that large 
clinical trials have established the efficacy of ACE-inhibitors in the treatment of hypertension 
and heart failure [9, 10], we could not dernonstrate a beneficia I effect of these drugs in 
our population-based study. As physicians were free to choose antihypertensive treatment 
strategies in this study, specific patient characteristics may have influenced treatment 
decisions. As was shown in table 1, baseline characteristics of persons who received an 
ACE-inhibitor during the study period were significantly different from those who did not. 
Although we adjusted for these varia bles in thc analyses, immcasurable residual confounding 
prevented the detection of a protcctive effect, probably becausc ACE-inhibitor treatment 
is not consiclered first linc therapy for hypertension and not all relevant characteristics 
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that lead to the in(lication for ACE-inhibitor tllerapy were identified . .rdoreover, optunal 
adjustment for the confounding effects of systo!ic blood pressure, as part of the indication 
for treatment, was not possible, since we included sllbjects who used antihypertensive drugs 
at baseline in our analysis and we did not have blood pressure measurements shortly before 
the start of antihypertensive treatment. Besides incomplete adjllstment for the 'confounding 
by indication' effects of blood pressure, the fact that our unexposed group consisted of both 
otherwise treated and untreated individuals may have confounded uur results. Adjustment 
for the use of other antihypertensive drugs during follow-up did affect the magnitude of the 
point estimates, but was not sufficient to show a protective effect of ACE-inhibitor thcrapy 
over the reference group. 
However, even though rcsidual confounding by indication probably affccted our risk 
cstimates for the effects of ACE-inhibitor treatment, we could still study the interaction 
between the use of ACE-inhibitors and the ACE liD polymorphism, because it is unlikely that 
residual confounding by indication was non-randomly distributed over ACE genotypes. Since 
genotyping is not part of routule clinical practice, the prescribing physicians were unaware 
of the individual's genotype. \':re did not find a difference in genotype distribution between 
users and non-users of ACE-inhibitors or other antihypertensive drugs, suggesting that the 
ACE polymorphism indeed did not affect the choice of antihypertensive treatment, as has 
been reported earlier by others [251. i\-Ioreover, baseline characteristics were not significantly 
different between ACE J/D genotypes. Therefore, it seems unlikely that confounding hy 
indication explains the interaction between ACE genotype and ACE-inhibitor therapy in our 
study. To ensure maximum power, we did not distinguish bctween different ACE-inhibitor 
types and there was heterogeneity in cumulative dose and duration of thc agents that were 
used. However, the affinity for tissue ACE varies among the different agents and drug 
dosage might be able to overcome genetically determmed ACE overactivity U2]. Therefore, 
our results may not be conclusive. 
Since the ACE IID polymorphism is located in an intron, it is probably not functional but 
in strong linkage disequilibrium with a functional mutation [SJ. However, there is substantial 
evidence that the DO genotype is associated with scrum ACE levels. ACE activity in lhe 
heart mayalso be associated with the ACE liD polymorphism [41. Todd and colleagues have 
demonstrated that subjects with the DD genotype, starting from greater initial values, had 
a significantly larger absolute decrease of serum ACE activity after enalapril administration 
than the other genotypes {14J. Nevertheless, residual enzyme activity remained higher in the 
DD genotype group. Therefore, individuals with the II genotype might benefit more from 
ACE-inhibitor therapy due to a more complete blockade of the RAAS. One could on the other 
hand also argue lhat DD individuals have greater benefit, because of the greater decrease in 
ACE activity after ACE-inllibitor administration [261. However, in the study by Todd et al., the 
hypotensive response did not differ between genotypes. Therefore, it is important to consider 
the question whether ACE is rate-limiting for the production of angiotensin II [12]. Although 
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under physiological conditions) renin mainly determlnes the production of angiotensin 11, it 
is not unlikely that in pathophysiological statcs ACE activity hecomes the rate-limiting step. 
Tissue ACE appears to be more important in the determination of RAAS activity than serum 
ACE levels and these are not necessarily corrclated U2l Beskies a differential effect on ACE 
activity, a relative resistance to the hemodynamic effects of ACE-inhibitors in thc DD genotype 
group might increasc their risk of heart failure or death. However, phanllacogenetic studies 
in hypertension have not consistently supported th is theory. Another potential mechanism 
is provided hy a study of Cicoira and coworkers [11). They fmmd rhat the DD genotype 
was associared with elevated plasma levels of aldosterone despite long-term ACE-inhibitor 
admlnistration. This aldosterone escape may be an important factor in the devclopment of 
ACE-inhibitor resistance and has been reported in up to 20% of patients with heart failure 
during long-term ACE inhibition [11, 271. Aldosterone has deleterious cardiovascular effects 
under pathophysiological conditions, including myocardial hypertrophy, and may serve as 
an important prognostic marker [27]. 
In conclusion, the results of our study suggest a relative resistance to ACE-inhibitor therapy 
in subjccts with hypertension and the DD genotype compared to the II genotype, with the 
ID genotype in an intermediate position. Although a statistically significant interaction in 
the prediction of incident heart fallure could not be demonstrated) there werc significant 
differences in rclative risks of total and cardiovascular mortality over genotype strata for thc 
use of an ACE-inhibitor. As this study was performcd in an observational setting, confirmation 
anel quantification of our results is necessary in an adequately powered randomised clinical 
trial, wbieh is specifically designed to study dmg-genotype interactions. 
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General dfscuss!on 
In dtis chapter, the ma in methodological limitations of pharmaco-epidemiological studies 
and genetic association studies are discussed to facilitate a proper interpretation of the studl' 
results lhat are described in this thesis. r ... loreover, a perspective is given on thc potential 
future directions and implications of pharmacogenetic research, a developing field with its 
own specific pitfalls, 
Pharmaco-epidemiology 
Pharmaco-epidemiology may be defined as the snld)' of the beneficial and adverse cffccts 
of dmgs in populations, bl' USillg the techniques of chronic disease epidemiologl' [11. In 
addition to the mam internal validity issucs in classical epidentiology, such as the role of 
chance, selection bias, information bias and confounding, pharmaco-cpidemiological studies 
have their own specific vaUdity issues. These problems will be addressed in the following 
section, This part of thc discussion will fOCliS on drug effectiveness studies, becausc the 
quantitative studies that are presented in this thesis investigate intended dmg effects. 
Observatiollal data are cOllsidered to be vcrl' useful to verifl' dmg safety issues and 
therefore, pharmaco-epidcmiologists usually studl' the unintended (adverse) cffccts of 
dmgs, where confounding bl' indication is usually not an issue [2]. Observational studies 
on the intended effects of drugs, such as dmg cfficacl', are far less frequently performeel. 
The gold stanclard in research on intended dmg effects is the randomised controlled clinical 
triaL The most important advantage of this design is that bascline prognoses of patient 
groups are made comparable by randomisation, to obtain unbiased estimates of the effects 
of a partiClilar intervention [31. However, there are some important drawbacks of controlled 
clinical trials that mal' justify the use of other designs to stud}' intcnded dmg effects. Clinical 
trials are usually verl' expensive to carry out and wil! not generalIl' be performed bl' the 
pharmaceutical industrl' for total drug classes and for dmgs for wltich the patent bas expirecl. 
For example, thiazide diuretics have widell' been used for many l'cars in the treatment of 
hypertension and heart fallure. Thiazicles reduce urinalY calcium excretion and therefore mal' 
also have beneficia I effects on bone. Consequentll', the use of thiazide eliuretics may reduce 
fracture inciclence. Since th is potential benefit of thiazides is probably a class effect and 
patents have expired, this topic will not be of special interest to individual pharmaceutical 
companies anel hence will not be studicd in a clinical trial setting, Therefore, academie 
researchers recentIl' snldied the association between the use of thiazjde diuretics and the 
risk of hip fracture in the Rotterelam Stud}' [41, For interventions with ver)' sfllaU postulated 
effects ancl for the investigation of rare but important outcomes, performance of adequately 
powercd randomised trials mal' even be unfeasible, given the c:x1:reme requirements of 
sample size and follow-up [SJ. In aeldition, randomisation mal' lead to ethical problems. For 
example, tor dmgs that have alreadl' sllOwn large beneficial effects, randomisation of these 
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drugs and the use of a placebo as a comparator may be questionable. Finally, an important 
drawback of the controlled clinical trial is that it typically involves subjects who are fit to 
enter anel are likely to finish the study [61. Certain types of patients, sueh as patients with 
severe disease, ehildren, or elderly patients, are mostly excluded. Compliance to the Shldy 
medication during these trials is maximÎ.zed and shldies arc performed in a highly eontrolled 
clinical setting, which may not mimic the setting in whieh the drug wHl ultimately be used. 
This eompromises the generalizability of the results of a clinical trial to patients that are not 
represented in the Shldy, and may result in a laek of effectiveness of an efficacious drug 
after it is introduced on lhe market [1, 2, 61. This might explain why heart failure remains a 
highly fatal disease, despite advances in treatments that have been proven to be efficacious 
in clinical trials. Therefore, additional information may be needed on whether, in the real 
world of daity medical practice, a drug that has been cvidenced to be efficacious in a clinical 
trial setting, actually achieves its intcneleel effects, i.e. is effective. 
A major threat to the internal "alidity of pharmaco~epidemiologieal studies on drug effects 
is eonfounding by indication, elue to the difficulty of ensuring comparability of prognosis 
across different treatment groups {3, 7]. In non-experimental studies, the allocation of 
treatment is by elcfinition not random. Therefore, if we assume that prescribing is rational, the 
prognosis of treated paticnts will obviously differ from the prognosis of untreated patients, 
be<'-'ause the untreated patients generally wiII not have an indication for the lreatment unelcr 
Shlely. So, treatcd patients will have a higher rate of any disease that the drug is intended to 
treat, which will manifest itself by maklng the dmg appear ineffective or even harmful [2, 3, 
7J. This phenomenon is known as confounding by inelieation anel makes lhe performance 
of pharmaco-epielemiological studies on intendcel elmg effects, at best, extremely cliffieult. 
The direction of confouncling may be hard to prediet, especially if two dmgs from the same 
class are compared or when drugs arc aelministrated for purposes of secondary prevention 
of disease f7]. A special farm of confounding by inelication is confounding by severity, in 
which the severity of thc disease that forms the indieation for treatment, rather than the 
mere presence of the disease itself, acts as a confounder. This bias is partielllarly impOltant 
to acknowledgc in studies thal compare subjccts wilh the same indieation but different 
treatments. AIlOther bias in pharmaco-epidemiology is protopathic bias, whieh occurs when 
the first symptoms of the disease outcome under study farm the indÎl'ation for treatment [8]. 
There are scveral methads that can be uscel in the design and analysis of a study to 
reduce the problems of confounding. In theory, the effect of confounding by inelicatian 
can be completely removed by adjustment for all patient (anel physician) characteristies 
that farm the hasis of the indieation for treatment [3]. This is aften not fcasible, as many 
factors are not measurable, anel residllal confounding wiII reslilt. In practiee, there is na 
conclusive test to prove that there is na resielual confounding. It may sometimes be useful, 
however, to examine the potentJal effect of residual confounding by means of sensitivity 
analyses that study the robustness of areslIlt to the pressure of unknown eovariates. This 
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can be done by imagining a certain confounder with different prevalence values and varying 
magnitudes of association with both exposure and outcome [71. It mayalso be useful to 
investigate the determinants of prescribing itself, bcfore doing a pharmaco-epidemiological 
study on intended drug effect,,>, because we have to be satisfied that we were able to create 
treatment groups that are similar with regard to important prognostic factors and lhat any 
dissimilarities that arise due to prescribing are known and can be properly adjusted for {3, 7J. 
l\nother approach 10 deal with confounding by inclication is to apply restriction criteria and 
include only those subjects who are similar for all prognostic factors except treatment [31. 
Also, exposed and unexposed suhjects can be matched on risk factors, whieh removes the 
confounding effect of these variables. One method that has been developed to reduce the 
problem of confounding by indication, and lhat appears to he especially useful as a matching 
criterion, is the propensity score [7, 9, lOl. The ielea of this score is to model all (known) 
determinants of exposure, usually by logistic regression, anel to predict the probability of 
receiving treatment for each person given his covariate pattern. This preelicteel probabiHty 
could then be used as a variabIe on which subjects can be matched or could be used as a 
cofactor in the analysis to aeljllst for confounding. However, a major disadvantage of the 
propensity score is lhat the researcher loses insight into which variables are responsible for 
the adjllstments that are made to the model, while this score does not redllce the problem 
of unmeasured residual confounding. lvloreover, matching on propensity score, or any other 
varia bIe, has the disaelvantage that it decreases statistica I power in case control sUldies. If 
confouneling by inclication Call110t he adequately controlled [or with these methods, it is 
not possible to interpret dmg-disease associations. However, an association in the opposite 
direction than explaincd by confounding by indication may still be meaningful, because 
it endorses a genuine protective effect. It must be emphasized, however, that such results 
should be interpreted with caution. 
Other major issues in pharmaco-epidemiological studies pcrtain to the definition of drug 
exposure. Accurate and complete information on drug exposure is essential to pharmaco-
epidemiological studies [11]. To avoid information bias due to exposure misclassification, the 
dmg exposure under study ShOlild be weIl defined in terms of dose, timing and duration. 
Different dosages and potencies of the same drug c1ass are lilcely to have different effects, 
ancl this should be taken into account when two compounds are compared. Reducing 
information into a dichotomous expression, that is exposed versus non-exposed, may 
increase the rate of exposure misclassmcation, which will bias the results [1]. Timing of the 
outcome of interest in relation to the stalt of the drug exposure is cmcial for causal inference. 
Obviously, the onset of an event must oCCUf af ter start of the exposure. A sequence of acute 
effects for every prescription can be defineel in a hazard function for each patient [12}. In 
case of adverse effects, there is uSllally a period of no effect, the induction pedod, followed 
by a period of high risk, then a pedoel of moderate risk, anel finally there is a rehlfll to the 
background incidence rate [131. Por beneficial effects, an opposite hazard curve may be 
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expected. Por many chronie treatments, the rate at whieh treatment-rclated outcomes occor 
varies with time since the start of therapy and with cumulative exposure [14]. This apparent 
tinle dependence of risk can result from the early depletion of patients who are susceptible 
to the adverse events of a drug, from drugs that have beneficial and adverse effects with 
different induction periocls, or from the physiologie adaptation lhat occurs during prolonged 
pedods of treatment [14]. Also, bias cOllld be introduced due to differing confounding 
effects of recent and distant past diagnoses, especially if, with evolving knowiedge, patterns 
of indications and contra-indications change. Hence, hazard ratios are usually not constant 
over time, especially when new and chronie users are mixed [2). 
In general, a pharmaco-epidemiological study preferably includes new uscrs of the drug 
of interest, whieh is called an inception cohort. Any previous experiences with a drug wiII 
influence decisions with regard to future exposure and, if associated with the olltcome of 
interest, will bias the study resllits [2]. Moreover, when two treatments are compared, the 
inclusion of prevalent lIsers can lead to exposure groups with different dllrations of therapy, 
whieh can introcluce bias if hazard ratios are not constant over time, as described above 
[141. Also, the inclusion of prevalent users complicates the control for potential confounders, 
since these factors can be influenced by the drug itself, as weil as form an indication for 
treatment. However, the exclusion of prevalent users will reduce sample size and thus limit 
the power of a study. This can potentially be addressed by assessing the magnitude of the 
potential biases that are introcluced when prevalent users are included in the analyses. If no 
evidence of material presence of these biases is found, prevalent users could be induded 
in the analyses [14]. Also, large computerised databases containing detailed infonnation 
on drug prescriptiolls and medical records for hundreds of thousands of subjects, such as 
the Integrated Prinlary Care Information (IPCn project in the Netherlands, are becoming 
increasingly available for pharmaco-epiclemiological research, making the new-user design 
lllore practieable. 
In lllany prospective fixed cohort studies, limited information is available on drug 
exposure, whieh is often obtained by interview, and sometimes only acquired at the 
beginning of follow-up [11]. Baseline information on drug use is not sufficient to snldy drug 
effects, because the exposure of interest, the drug, anel its effects naturally change over 
time. If sufficient information is available, stanclard time-varying approaches can be used to 
adequately analyse the data in cohort studies. Case control studies, in whieh information on 
previous drug exposure is typically obtained by interview after the outcome has occurred, 
may suffer from recall bias if patients remember their dmg exposure history better than 
healthy contrais. The use of pharmacy records bypasses the potential for recall bias, as these 
data are gathered before disease onset. Pharmacy records form an abundant, contintIOus 
and reliable source of information on drug exposure, providing that data are complete (15]. 
Pharmacy records supply data on a day-to-day basis, allowing for time-varying analysis 
of drug exposure. However, even with the use of phanllacy records, misclassification of 
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exposure may stiJl be an issue when the definition of the risk window is flawed .. Moreover, 
non-compliance may seriously thrcaten the results of a stud)' that uses pharmacy records. 
This wiII almost always be random and lead to an underestimation of the true effect (lS]. A 
final drawback of pharmacy data is thc lack of information on the use of over the counter 
drugs and non-reimbursed dmgs. 
Two quantitative studies that are presentcd in this thesis investigated the effectiveness 
of antihypet1ensivc treatment in an observational setting and may have suffered from the 
prohlcrns described above. \Ve dealt with possiblc confounding by indication in these 
studies by restricting our study populations to patients with hypertension, making the 
treatment groups more similar in terms of prognosis. Prevalent hemt failure cases were also 
excluded in both snldies. In addition, wc adjusted for several potential confounders that 
are known to be associatcd with the exposure to antihypertensive drugs, left ventricular 
hypertrophy and heart failure. In the Rotterdam Study, e:x'1cnsive information is available 
on many of these varia bles. Our study on the association between antihypertensive drugs 
and left ventricular geometry may have suffered from residual confounding by indication, if 
antihypertensive drugs were prescribed tor alternate indications than a high blood pressure. 
However, since we only selectcd participants with hypertension, anel vermed the indication 
of antihypertensive treatment, it seems fair to assllme that the antihypcrtcnsive drugs were 
indeed prescribed for tlus indication. Nevcrtheless, as physicians were free to choose 
antihypertensive treatment stratcgies in the Rotterdam Stud)', specific patient or physician 
characteristics may have influenced the decision to treat paticnts for an increased blood 
pressure. However, these characteristics would have led to higher relative risk estimates, 
and do not explain the negative association that we found in dus study. Tlus endorses the 
presence of a genuinc beneficial effect of antihypertensive dmgs on left ventricular geometry, 
corresponding to the results of large randomised clinical trials. Our study on the interaction 
between angiotensin-converting enzyme (ACE)-inhibitors and the ACE Insertion/Deletion 0/ 
D) polymorphism suffered from immeasurable resiclual confouncling by indication, despite 
our cfforts to diminish this problem. Therefore, we could not demonstrate a beneficial effect 
of ACE-inhibitors in this study. However, it was still possible to study the possible interaction 
between the llse of ACE-inhibitors and the ACE liD polymorplusm, because it was unlikely 
that this residu al confounding was non-randomly distributcd over the ACE genotypes. 
In the Rotterdam Study, all drug prescriptions dispensed to participants by all pharmacies 
in the study area are routincly stored in the database. This means that complete infonllation 
is available on dispensed dmg prescriptions, including the product name, the number 
of tablets or other velucles in the filled prescription, the date of delivery, the prescribed 
daily number of tablcts to he taken and the drug dosage. \\7ith these data it is possible to 
create time-dependent variables for dmg lIse on a day-to-day basis. \'\'e used these data in 
our snldies 10 calculate prescription lengths, by dividing the total number of filled tablets 
of consecutivc prescriptions of a elmg by the prescribed daily number. In this way the 
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follow-up perioeI could be elivideel into periods of use anel non-use of the drugs under 
study. Potential misclas .. <;ification of drug exposure may have occurred, because we dicl not 
clistinguish bet\veen dmg types of the same class, and because there was heterogeneity 
in dosage and duration. This could have biaseel the results of OUf studies towards the null 
hypothesis. To enhance the power of our analyses, we diel incltlde prevalent users in our 
shldies, because leaving them out did not materially change our conclusions. 
In conclusion, despite the fact that non-experirnental studies on intended drug effects 
are very difficuit to perform, mainly due to confounding by inelication and difficulties in 
drug exposure elefinition, there is definitely a place for pharmaco-':epidemiological shldies 
besicles the gold standard, the ranelomised controlled clinical trial. Nevertheless, conclusions 
of these studies should not be accepted without criticism, especially when prognostic factors 
are very different for treated anel untreated patients. 
Genetic epidemiology 
Genetic epidemiology focuses on the role of inherited factors in discase aetiology [161. 
Traditionally, the family-bascd study design has been used to investigate genetie components 
of disease, in partiClllar in monogenic disorders. \Vith respect to genetic factors in heart 
failure, the mie that heritable gene mutations have in (familiaD çardiomyopathies is 
increasingly well understood [17,18]. However, these rare single gene mutations are not the 
only potential causes of healt failure and, although they are important for the understanding 
of discase mechanisms, they are of lirnited significance at the level of populations [19J . 
. Many genes and environmental factors pmbably play a roie in the pathophysiology of the 
complex synelrome of heart failure. To study genetic components of mlilti-factorial disorders 
such as heart fallure, the most commonly applied strategy is the genetic association Shldy. 
In this approach, candidate genes are seleçted based upon their biological plausibility, 
whieh imp lies prior knowledge of the involvement of their products - i.e. proteins - in the 
pathogenesis of the disease. This design allO\vs for the identifiçation of gene polymorphisms 
direct!y involved in the aetiology of heart failure (susceptibility genes), or scquence variants 
involved in the modifkation of its phenotypic expression (modifler genes). Because the 
studies that are described in this thesis deal with this alternative approach to shldy genetic 
determinants of heart fallure anel cardiac abnormalities, the discussion in the next section 
will concentrate on the main limitations of genetic association studies. 
In general, results of genetic association studies have been highly inconsistent and their 
use has therefore been widely debated [16, 19-221. Initial positive genetic assoCÎations have 
often been difficlilt to replkate. There are several explanations for this. A major problem 
in çandiclate-gene studies is the possihility of generating false-positive reslilts f16, 21, 231. 
These shldies generally evaluate one genetic polymorphism at a time. For most conunon 
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complex discases, however, hundreds of known genes arc potential candidates, and in most 
genes, dozens of polymorphisms can be identified (21]. Even if none of the genotypes is 
actually associated with the outcome, one can expect many significant associations to occur 
by chance alone, when all these variants arc tested and treated independently (21, 23J. 
pal1icularly studies with ill-defined candidate markers suffer from dlis problem, since a low 
prior probability is more likely to lead to false positive results [19]. How to handle this issue 
of multiple testing in genetic association studies is still a matter of debate. The formation of 
haplotypes, combinations of multiple markers in a gene that arc locateel closely together anel 
that tend to be inherited together, may proviele a solution, because it decreases the number 
of genetic markers that arc tested. Fllrther overestimation of the tme effect of a genetic 
marker might occur due to publication bias, as negative results are generally less Iikely to 
be submitted for publication. 
Probably the most important problem so far in genetic association studics has been 
the lack of power to detect the typically small cffects in genetic association studies of 
multi-factorial disorelers (21]. Common, complex disorders are under the control of many 
(jnteracting) genes of minor individual effect, interacting widl a numher of environmcntal 
factors (20). Therefore, the effect of individual genetic polymorphisms wiII be small. Hence, 
large populations are needeel in genetic association snldies to avoid generation of false-
negative resllits. Besides increasing the sample size of a study papulation, statistical power 
may be increased by the formation of haplotypcs over multiple markers in a candidate 
gene, as oppased to the examination of single genetic markers [231. Another cause of false 
negative results is that several genetic association studies have used unconditional statistical 
methods for data analysis, despite the fact that they matched their cases and controls on 
poptdation characteristics. This coulcl have biased the results of these studies towards the 
null hypothesis. 
As in classical epidenliology, misclassification of the outcome may weaken associations 
in candidate-gene studies and heterogencity in outcome measures between studies 
may account for many of the contradictory findings .. Misclassification of exposure, that 
is genotyping error, mayalso affect the results of genetic association studies, and is the 
most conunon cause of deviations from the Hardy-\Veinberg equilibrium [241. Deparnlfe 
from Hardy-\'\'einnerg equilibrium, a fundamental mie of population genetics, increases 
the chance of finding a spurious association, but can also lead to false-negative results. 
AIthough random nlisclassification can be caused by DNA contamination from plates, 
primers and ather environmental components of a laboratory, the possibility of systematic 
errors due to un-blinded genotyping is pal1icularly troubling [241. Another well-known 
example of exposure nlisclassification due to genotyping error that is relevant to this thesis 
is the underestimation of ACE liD heterozygotes that may occur with the conventional 
genol}'ping method [25]. Most genetic assodatian studies have usecl this non-I-allele-specific 
method for ACE genotyping, which may have led ta an underestimation of the true effect 
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of the DD genotype. In the Rotterdam Study, mistyping of ACE liD genotypes was avoided 
by applying modifications to the conventional procedure, including the performance of a 
second polymerase chain reaction (peR) with an Insertion-specific primer pair. 
An important issue in genetic epidemiology is the phenomenon of population stratification. 
\Vhen the study population comprises a mi:x'ture of subgroups that have different allele 
frequencies and disease risks, genetic associations can be confounded b)' population 
stratification [21]. This distortion is only present if the differences in discase prevalence 
between subgroups are not caused by the allele under study. The most important example 
of population stratificalion is a difference in genetic make-up betwcen subpopulations 
with different ethnicity [19, 20, 261. Allele frequencics at random marker loci are known 
to vary between ethnic groups [261. It is possible to detect population stratification by 
t)'ping additional unlinked genetic markers, which should also show associations with the 
disease under snldy if this bias is present (26J. One solution to the problem of population 
stratification is to match study subjects on ethnicity or genetic background [19, 201. Another 
wa)' to minimize the possibility of stratification is the use of genetically homogeneous 
populations, such as genetically isolated populations, which originate from a limitcd number 
of ancestors (founder populations, e.g. leeland). Complex traits arc expected to be more 
homogeneous in these populations. However, a drawback of studies in founder populations 
is thal isolation ma)' have caused these populations to have a more or less private make-up 
of thc genome. This may limit the gencralizability of these studies. Therefore, clisease-relatecl 
mlltations or polymorphisms detected in isolated populations also need to be snldied in 
other poplliations (161. Finally, family-based designs are generally accepted to definitively 
control for confounding by poptdation stratification [271, Howcver, these studies also have 
some important drawbacks. For example, a major limitation of llsing parents or siblings as 
controls is loss of power because of overmatching [19, 271, Also, relatives may be unavailable, 
especially if late-onsel diseases arc studied. Nevertheless, there is now substantial evidence 
that well-designed and appropriately interpreted population-based snldies with unrelated 
conlrols are largely robust to confounding from population stratification (20], 
An association between a genetic polymorphism and a disease phenotype may merel)' 
be caused hy its linkage disequilibrium with a mutation of a nearby gene that is the actual 
functional gene, Patterns of linkage disequilibrium over chromosomal regions can var)' 
significantly between populations due to several factors, including poptllation admixture 
and the age of a mutation [28}. Additionally, the genetic structure of a population can 
lead to linkage disequilihrillm between unlinkcd loci, causing false-positive signals (29]. 
If a polymorphism is not fllnctional, but simply acts as a genetic marker, vatying degrees 
of linkage disequilibrillm ma)' explain variations in association hetween populations. 
Polymorphisms located in coding or promoter regions of a gene may alter the fllnction 
or expression level of proteins encoded by the gene and arc a priori more likely to be of 
functional significancc. Even if these genetic variants are not functional, they are more likely 
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to be in linkage diseqllilibrium with the true causative alleles [191. However, the ultimatc 
cvidence of these genetic polymorphisms being more than just risk markers depends on the 
characterization of intermediate phenotypes that can be linked to the disease [30]. 
Although replication of a genetic association in different (cthnic) poplilations provides 
support for a causal association, its absence does not necessarily exclude it (19]. True variation 
in thc presence or size of an association between a polymorphism and a disease in different 
poplIlations could result in non-replicable associations. This heterogeneity can result from 
effect modification by other genetic or envÎfonmental factors, if these vary between study 
settings, and from differences in background risks [21]. However, in populations of similar 
genetic b;lckground and with similar disease rates and life styles, it is unlikely that gene-
gene or gene-environment interactions play an important role in explaining heterogeneity 
of effect size between studies [211. 
The genetic association studies described in this thesis are potentially limited by the 
methodological problems presented in the previous section. Although our work represents 
some of the largest candidate-gene studies in the general popldation perfarmed until 
nO\v, we cannot entirely rule out the possihility that chance mal' provide an alternative 
explanation for our positive results; especialll', since wc studied ane genetic polymorphism 
at a time. Also, the mechanisms hy which the polymorphisllls that were investigated in 
this thesis mal' exert their effects on the pathophysiology of heart fai/ure or len ventricular 
abnormalities are largely unknown. The ACE JID polymorphism, for examplc, is located 
in an intron and therefore is probably not functional itself, but rather in strong linkage 
disequilibrium with another functionalmutation [31). A1so, the functionality of the insulin-
like growth factor-I (IGF-I) promoter poll'morphism has been debated, sincc studies sa 
far have provided conflicting results [32-351. However, findings in the Dutch population 
have been highly consistent, strongll' suggesting that the IGF-I polymorphism can be used 
as a genetic marker, at least in Dutch subjects [33, 34, 361. Replication of our finclings is 
therefore needed in other populations. As already mentioned ACE liD mistl'ping was dealt 
with in the Rotterdam Study by the use of I-specific primers. Confounding by poplilation 
stratification was not an impOltant issue in the studies presented in this thesis, hecause we 
used data from a relatively homogeneous poplllation living in the same area in Rotterdam, 
in which approximately 98% is Caucasian. A1so, wc adjusted our analyses for factors that 
were potentially associated with the polymorphisms under studl' anel heart failurc or left 
ventricldar abnormality. FinaUy, in aU studies, genotype and allele distributions were in 
Hardy-\Veinbcrg equilibrium, suggesting na effect of migration or selection pressllfe in our 
study populations. 
In 1995, the departments of genetic epidemiologl' and clinical genetics started the 
research program "Genetic Research in Isolated Populations" (GRIP) in a genetically isolated 
poplJ!ation in the Southwest of the Netherlands, to study sevcraI complex genetic disorelers, 
including hypertension. In 2002, the ERF-study (Erasmus Rucphen Familieonderzoek) was 
177 
Chapter 7 
started, whieh includes tluee-generation families selected from the same population as the 
GRIP study. Tbe combination of the detection of disease-related mutations or polymolphisll1s 
in these two studies with the possibility of replieating these results in the population-
based Rotterdam Study provides a unique opportllnity to study genetic causes in complex 
diseases. 
In conclusion, genetic association studies offer a potentially powerflll approach to identify 
genetic factors that influence the sllsceptibility to comman ll1ulti-factorial diseases, sueh as 
heart failure, or modify their phenotypic expression. However, lack of replieability of thc 
results has caused the use of th1s design to be widely debated. False-negative, undcrpowered 
studies have been a major problem. Other important issues indude false-po5itive results due 
to multiple testing, genotyping error, population stratification, population-speeilie linkage 
disequilibrium, gene-gene/gene-environment interactions, and insufficient knowledge 
about the functionality of genetic polymorphisms. However, if all these issues are properly 
addressed, there is clearly all important role for thi5 study design in the genetic epiclemiology 
of heart t:'lilure. 
Pharmacogenetics 
Heterogeneity in the indiviclual response to drugs is a major prohlem in clinical practice and 
drug development [37, 381. When several patients are prescribed the same recommended 
daily dosage of a drug, the dmg can be efficacious in most, have little or no effect in others, 
and/or result in adverse drug reactions - occasionally fatal - in a small group of patients 
(391. Beskies the importance of clinical factors that detennine variability in drug response, 
induding agc, organ function, concomitant therapy and patient compliance, it is now dear 
that inherited factors can have an even greater influence on the efficacy and toxicity of 
drugs [37, 401. Unlike environmental factors, inherited determinant') generally remain stable 
throughout a pcrson's lifetime [411. Two main strategies are currently being used to identify 
genes that cause individual variations in drug response. Pharmacogenetics studies the 
variabilily in drug responses attributed to hereditary factors, such as genetic polymorphisms, 
in different populations [38, 421. Pharmacogenomics encompasses a genome-wide search for 
genes relevant for the application of drugs in humans and involves analysis of the genomc 
and its products (RNA and proteins) as they rdate to dmg response [42-441. Although both 
approaches represent different tacties, they share technologies and the terms are commonly 
used interchangeably. Research in these fields is developing into two direetions. First, 
genetic variants are investigated, which may affect the individual response to drugs that 
are cUfrently marketed. Second, studies are perfofilled to identify specifk genes and thcir 
products that may provide targets for the dcvelopment of new drugs [37]. 
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Pharmacogenetics studies both efficacy and drug safety. Essentially, there are tllfee 
mechanisms by which genes can influence the response 10 pharmacotherapy: inherited 
variability in phannacokinetics, variability in pharmacodynamics, and gene-drug interactions 
in the causal pathway of disease [431. Pharmacokinetic variability in pharmacogenetics 
refers to inhcrited differences in dlUg metabolising enzymes, such as the cytochrome P4S0 
enzyme family, and in drug transport molecules that mediate dnIg uptake into, and efflllx 
from, intracellular sites [451. Inherited differences in dmg mctabolising enzymes have been 
extensivcly shldied and generally present as monogenic traits. Genetic polymorphisms have 
now been identified in over 20 of these enzymes in humans, severaI with sllbstantial ethnic 
differences in frequencies, many of which translate into functional changes in the encoded 
proteins [37, 411. Inherited differences in dmg metabolism can affect the response to a 
drug by influencing the concenlration of the active compound. This can result in profound 
toxicity for medications with a narrow therapeutie index that are not adequateIy inactivated 
by a polymorphic enzyme, or redllced efficacy of medieations that are rapidly metabolised 
into inactive compounds [38, 401. Reduced efficacy can also result from inactivity of a 
polymorphic enzyme, when drugs reqllire activation to an acth'e mctabolite for their 
effect. Por many of these polymorphisms, there is no evident phenotype in the absence of 
phannacothcrapy. An example of a drug-metabolising cnzyme thal may have implications 
in the response to cardiovascular phannacotherapy is the cytocllfome P450 enzyme CYP206 
[37, 38]. This enzyme is highly polymorphic and is inactive in about 6% of Caucasians. 
CYP2D6 is responsible for lhe metabolism of many drugs, including antiarrhythmics and 
certain IS-blockers. 
Infonnation on thc effect of genetie polymorphisms in transporter proteins on drug 
response is scarce. Studies of polymorphisms in the .MDRI gene, whieh codes for the ATP-
dependent transmembrane efflux pump P-glycoprotein, suggest an impact of this gene 
on requirements of dose adjustments of digoxin anel verapamil [38]. Pharmacodynamic 
variability refers to differences in drug effects at the molecular site of action [45J. lvlost 
dmgs interact with specific target proteins 10 exert their effects, including receptors and 
proteins involvecl in signal transeluction. ]\'Iany gencs encocling these targets exhibit genetic 
polymorphisms, which may alter their sensitivity to specifk drugs anel hence affect elrug 
efficacy anel toxicity [401. Examplcs include polymorphisnls in B2-adrenergic receptors and 
their effect on sensitivity to IS-agorusts in astlullatics (46J, and the ACE I/D polymorphism 
affecting the renoprotective effect of ACE-inhibitors [471. Finally, genetie polymorphisms 
that underlie disease pathogene sis anel are neither direct targets of drugs nor involved in 
their clisposition, can also be detenninants of drug response; e.g. the apolipoprotein E 
polymorphism may affect the efficac)' of lipid lowering drugs (40]. 
Because pharmacogenetics combines the techniques of pharmaco-epidemiology and 
genetic epielemiology, it faces, in principle, the methodological issues of bath netels, which 
are described in the previous sections of this discussion. The problem of confounding by 
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inclication in pharmacogenetic cfficacy studies will probably be less important, since a 
physidan will usually not be aware of the genetic profile of a patient before prescribing a 
drug. However, there are some addilional critical issues that must be considered when studies 
are conducted on inherited determinants of drug effects. First, most common disorders 
have a polygenctic origin and therefore different pathways may contribute to the same 
clinical phenotype. These genetic differences, together with gene-environment interactions, 
mayalso lead to different responses to pharmacotherapy [43]. This might cxplain, for 
example, the ntJIl1erous inconsistent studies on the potential interaction between the ACE 
IlO polymorphism and ACE-inhibitor therapy [48]. Second, most drug effects are determincd 
by the interplay of several gene producL~ anel environmental factors that influcnce the 
pharmacokinetics (metabolism and disposition) and pharmacodynamics (targets) of drugs 
{41J. Very large study populations may be needed to detect a significant pharmacogenetic 
effect. Another complication of pharmacogenetic strategies is that knowledge of the 
pharmacokinetics and mechanisms of action of many dmgs is incomplete {41J. This may lead, 
together with the enormous qllantity of genetic polymorphisms that have been identified 
in the hllman genome, to a large number of false positive findings. Besides polymorphisms 
in coeling regions, variants in regulator)' regions, including promaters, 3' untranslated 
regions and spike sites, are particularly Iikely to influence dmg response by controlling the 
level and site of expression of dmg targets [491. Biomedical research is now putting great 
effOlis in elefining Illolecuhlr mechanisms of pharmacological effects anel ielentifying genetic 
determinants of disease pathogene sis anel phannacokinctics, facilitating the performance of 
future candidate-gene studies in pharmacogenetics [401-
Substantial illvestments are now being made by pharmaceutical and biotechnology 
industries to use the approach of pharmacogenomics in the discovely of novel therapeutic 
compounds [40, 441. Single nucleotide polymorphism (SNP) mapping teclmology enables 
the cntire human genome to be scarched to ielentify SNP profiles rhat are associated with 
responses to pharmacotherapy [44, SOl Genes lhat are identificd by genomic strategies 
generally require functional validation anel replication in different radal or ethnic groups (41, 
441 By incorporating whole genome Sl\TP linkage disequilibrium mapping to patients during 
phase IE c1inic.al trials, it Illa)' be possible to select smal! regions of SNP !inkage disequilibrium 
that are associated with efficacy and COnllllOl1 adverse event phenotypes. These abbreviated 
SNP profiles could then form the basis for selection criteria of patients in phase III clinical 
trials. This would limit unnecessary exposure of non-rcsponsive patients in phase III studies, 
who would only cxperience the ad\'erse effects of the new chemical entities llllder study. 
I."loreover, phase III clinical trials could then be perfonned faster, with fewer patients and 
higher cast-efficiency [44, 50]. Afso, information from genetic profiles of non-respanders 
will identify new targets [or drug research. There is a risk that new Illcdicines will only be 
dcveloped for the most comman, anc! therefore commercially attractive, gcnotypes. Also, 
pharmaceuticaI companies might wocry that they are limiting their markets, by scgmenting 
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the patient groups for whieh a drug is indieated. However, focusing thc dcvelopment of 
new drugs on subgroups of patients who are selected by specific disease phenotypes or 
medicine response profiles will provide additional opportunities to develop morc drugs for a 
larger proportion of patients with common multi-factorial disorders than currently available 
[441. As drug efficacy and toxicity become more predictable, this will maximize the value 
of each prescribed rnedicine and reduce total health care expenditure. Another frequcntly 
heard argument against the application of phannacogenomics in drug development is 
that, in clinical practiee, newly marketed dmgs may be prcscribed to patients who do not 
meet the pharmacogenetic criteria that were used to select patient subgroups in phase III 
trials, and thus \vithout proper knowledge of the potential benefit-risk ratio of these agents 
[44]. Thc assessment of pharmacogenetic profiles before prescribing a particular drug to 
a patient mal' be able to prevent this. It is, however, difficlIlt to predict to what extent 
pharmaceutical industries are willing to incorporate mandatory pharmacogenetic testing 
into future prescribing schedules. This will to same extent be influenced by the attihlde of 
regulatorl' authorities [37J. Therefore, regulatorl' authorities and pharmacelltical industries 
will need to work togcther to devclop guidelincs for thc application of pharmacogenomics 
in drug development and post-marketing strategies. The abbreviated SNP profiles that 
are developed during the pre-marketing phase can potentially be extended during post 
marketing sUiveillance, including phase IV trials, to cncornpass further efficacy phcnotypes 
and adverse event profiles [44]. 
In the far future, pharmacogenomics and pharmacogenetics are expected to yield 
standardised screens of genetic variants that wil! become routine tools in thc selection of 
medieations and drug dosages for each individual patient [41, 44]. A patient's genotype will 
need to be determmed onIy once for any given gene, because it will not change, except 
for some rare somatic mutations [411. The kcy factor in determining the success of these 
strategies, besides economical reasons, will include access to data on patient genotypes 
and other relevant molecular markers [431. However, we are still a long wal' from having a 
personal pharmacogenetic DNA chip that can be used hl' physicians to predict individual 
drug responses. Also, before any genetic-based prediction is accepted in clinical practiee, 
its clinical utility needs to be obviated [501. Potentially, pharmacogenetics can streamline the 
treatment of complex disorders such as heart fallure, in whieh treatment is largeIl' on a trial-
and-error basis and polypharmacy is a common problem, which of ten leads to decrcased 
compliance. If genetic information can be used to identify the combination of heart failure 
drugs that provicles the maximum benefit-risk ratio for each patient separately, drug regimens 
can be simplified, costs will be rcduced and patient compliance may improve, potentialIl' 
Icading to improvement of patient outcomes [48]. The term 'genetic profile' or 'genetic test' 
suggests that, in the future, it will be possible to include all relevant genetic information into 
a single test, and then precisely predict the response to pharmacotherapy for any individual 
patient. I-Iowever, this view mal' be too optimistic and it is important to bear in mind that, 
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even in the case of fairIy obvious bimodalily in responses, individu al patients will still fall 
into a distribution pattern of responses, and all predictions will be of a probabilistic nature 
[51]. In addition, based upon our cllfrent understanding of the heterogeneous nature of 
complex disorders, wc wili only be able to exclude those gene variants that do not appcar to 
contribute to the disease, and therefore mIe out certain treatments. So, physician experience 
will continue to play an important roie in future pharmacotherapy [51]. 
Pharmacogenetics presents future challenges with respect to physician's ethical and 
professional responsibilities, Tllere is a dear need for guidelines and regulatory policies 
to avoid the misuse of genetic information in ways that could harm people; for example 
by denying them access to health insurance, employment, or loans [52, 531. This fear for 
the implications of breaching confidentiality is futther fuelled hl' the notion that limiting 
access to medical records to the patient and the treating physician is not possihle and aften 
undesirabie. Peopie tend to think of genelic information as more deflllitive and predictive 
than othcr types of data, Howcver, physicians usually have a limitcd ability to predict 
when, how, and even whether a person with a genetic predisposition to a certain disorder 
will actllally become diseased [53]. Also, it is important to distinguish bet\veen disease 
susceptibility genes and genes that only influence the response to certain dmgs, The farmer 
can help diagnose the disease, determine the carrier status of patients and their relatives 
anel/or predict the occllrrence of the disease at an early stage, Genetic tests to determine 
disease susceptibility mal' therefore have greater ethica! and social implications on the 
patient and his or her family than genetic profiles that predict an individual's response to 
pharmacotherapy, However, insurance companies mal' also misllse information on inherited 
differences in drug response, if this information will detennine the c:x'1ent of future health 
care costs [44). It is not unthinkable that in the future, it mal' even be unethical not to carry 
out pharmacogenetie tests on a routine basis, to avoiel the exposure of patients to potentially 
harmflll anel/or inefficacious drugs [371. 
In conclllsion, heterogeneity in individual drug response is a major problem in clinical 
practice anel drug development. Pharmacogenetics and pharmacogenomies offer great 
opportunitics to rcmovc much of thc unccrtainty in CUlTent drug prescribing, and to 
improve the discovery and development of new dmg compounds [50), Sllch devclopments 
will enable inelividllal patients to be classified according to their likely response to a dmg 
allel hence, maximize the utility of cach medidnc. Although most of the developments in 
phannacogenetics anel pharmacogenomics He far ahead, there are already same examples 
of their application in clinical practice todal', mostly restrieted to academie centres, The most 
widely acccptcd application of pharmacogenetic testing is the use of CYP2D6 genotyping 
to appropriately dose psychiatrie dmgs [371. The potentialof predictabie efficacy, Iimitcd 
adverse events, luwer complications dlle to targeted delivery, and increased cost-effectiveness 
of mcdicines wili likely improve future health-care delivery [441. 
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In the near future, pharmacogenetic research in heart failure in the Rotterdam Stud)' ma)' 
focus on several genetic pol)'morphisms that have been assodated with heart failure and 
ma)' have fllnctional consequences for the Ontended) response to pharmacotherap)'. Future 
pharmacogenetic studies could, for instance, investigate the interaction between the use of 
(3-blockers and (3-adrenergic receptor polymorphisms in heart failure. Also, the potential 
modification of the effects of lipid lowering therapy in heart failure by the apolipoprotein E 
polymorphism couid be studied. However, several othel' combinations of dmgs that are used 
in the treatment of heart failure and genetic polymorphisms are conceivablc. Also, inherited 
differences in drug metabolising enzymes ma)' be studied in relation to dmg-indllced hemt 
failurc, or in relation to the prevention of sudden cardiac death in heal1 failure patients. 
Finally, the interaction between genetic polymorphisms in the ~'IDRI gene and digoxin use 
ma)' be studicd as detcrminants of illcreased mortality in heart failure patients. 
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Summary 
Hcart failure, a complex clinical syndrome, constitutes a major public health problem in the 
western worIe!. Prevalenee and incidence of heart fallure are substantial and wiII continue 
to grow as populations age, and because the survival of cardiovascular diseases that lead 
to this disorder improves. The most comman causes of heart fallure are coronary artery 
disease, including myocardial infarction, hypertension, valvular heart disease and idiopathic 
cardiomyopathy. There is also substantial evidence for a genetic contribution 10 the 
pathophysiology of heart fallure. Despite the advances in its treatment, heart failure is still 
a highly fatal discase. Hetcrogeneity in the individual response to dmgs and polypharmacy 
are major problems in clinical practice. This thesis comprises a number of epidemiological 
studies that were <timed at gaining insight into the effects of drugs and genetic determinants 
on the occurrence of heart failure in the general population. All quantitative studies were 
perfonlled in the Rotterdam Study, a large-scale prospective population-based cohort study 
among 7983 individuals aged 55 ycars and older. 
Af ter a general introduction in chapter 1, chapter 2 focuses on the magnitude of the 
problem of heart failure in the community. This chapter also presents age- and sex-specific 
reference values for the detection of left ventriCldar hypertrophy on the electrocardiogram 
(ECG) in lhe elderly. Chapter 2.1 provides population-based estimates of lhe prevalenee, 
incidence, lifetime risk and prognosis of heart failure. In the Rotterdam Study, the incidence 
of heart failure is identified through general practitioner's medical records and hospita I 
discharge leners on a continuOlIS basis, Presence of heal1 failure is delermined according la 
criteria of the European Society of Cardiology, Information on vital status is ohtaincd from 
municipal health authorities and general practitioners. \'(fe observed a higher prevalenee of 
heart fallure in men than in women. Prevalenee increased with age from 0,9010 in subjects 
aged 55-64 years to 17.4% in those aged ;;: 85 years, The incidence rate of healt failure was 
substantial: 14.4/1000 person-years (95% confidence interval (CI) 13.4-15.5) and was higher 
in men 07.6/1000 man-years, 95% Cl 15,8-19.5) than in women 02.5/1000 woman-years, 
95% Cl 11.3-13,8), The incidence rate increased with age from 1.4/1000 person-years in 
those agcd 55-59 years to 47.4/1000 person-years in those aged ;;: 90 years. Lifetime risk 
was 33% for men and 290/0 for women at the age of 55. This means that in individuals aged 
55 years, almost 1 in 3 will develop heart failure during their remaining lifespan. Heart 
failure was highly fatal, with survival after incident heart failure being 86% at 30 days, 63% 
at 1 year, 51% at 2 years and 35% at 5 years of follow-up, Chapter 2.2 provicles age- and 
sex-specific norm<11 limits in elderly subjects for thc Corncll, Sokolmv-Lyon anel 12-1ead 
summed QRS voltage and voltage-duration products, which are used to detect left ventrictdar 
hypertrophy on the ECG, Voltage amplitudes on lhe ECG vaf)' according to age and sex, 
However, reference values for left yentricular hypertrophy are lacking in the clderly, At 
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baseline, l2-lead ECGs were digitally recorded for 6193 participants. Age- and sex-specific 
normal limits were calculatcd parametrically in 2915 apparently healthy participants. The 
981h percentile was taken as the upper limit of normal. Additionally, the prognostic value of 
all pal1ition values for left ventricular hYPcl1rophy on the ECG, the traditional values and 
those established in this stud)', was tested for heart failure and cardiovascular mortality. 
NewI)' assessed reference values for left ventricular h)'pertroph)' on the ECG were higher 
than traditional partition values, except for the Camel! voltage in mcn. 98th Percentiles 
were lower in women than in men up to the age of 75 years. In wamen, norlllal limits 
and voltage (-duration) criteria increascd with agc. In contrast, Sokolow-L)'on- and 12-
lead summed voltage and voltage-duration criteria decreased with advancing age in men, 
whereas the Cornell voltage and voltage-duration product was not substantially influenced 
by age. Left vcntricular hypertrophy on the ECG was significanti)' associated with heart 
failure and cardiovascular mortality for all partition values. Except for the Sokolmv-Lyon 
voltage-duration product, all normallimits established in the present stud)' showed stronger 
associations for left ventrictdar hypettrophy on the ECG than the traditional partition valucs. 
Differences were more pronOllllced in women than in men. 
Chapter 3 presents two studies on dmgs as determinants of heart faiJure. In chapter 3.1, an 
observational snId)' is presented on the association between current use of antihypertensive 
drugs and len ventricular geometry on the echocardiogram. In the Rotterdam Stud)'J 
echocardiography was pcrformcd in 2823 participant.."i. \X'c studied 740 participants with 
at least mild hypertension or on antihypertensive monotherapy, without heart failure. Of 
these, 646 had an adequate echocardiogram for analysis of relative wall thickness and 642 
for left vcntricular mass index. Participants wcre followed from]anuary 1, 1991 until the date 
of echocardiography, between September 1992 and June 1993. Outcome measures were 
defllled as being in the highest gender-specifIc quintile of left ventriClIlar mass index and 
as having a relative wall thickness higher than 0.43. A Cox regression model wilh·dllration 
of use of antihypertensive drugs defined as time-dependent covariates was used for data-
analysis. Antihypertensive trealment lowered the risk of increased left ventriclIlar mass index 
(relative risk (RR) 0.6, 95% Cl 0.4-0.9) and also, although non-signifIcantly, decreased the 
risk of high rclative wall thickness (RR 0.8, 95% Cl 0.6-1.0). In chapter 3.2, an cÀ"tcnsive 
review of the medica I literature is given of recent findings on the association between the 
use of nonsteroidal anti-inflammatory dmgs (NSAIDs) and the occurrence of heart fallure. 
NSAIDs may impair rcnal function in patients with a dccrcascd cffective circulating volume 
by inhibiting prostaglandin synthesis. Consequently, water and sodium retention, and 
decreases in renal blood flow and glomemlar fijtration rate may occur, affecting the lInstable 
cardiovascular homeostasis in these patients. In patients with pre-existing hcal1 failure, 
this may lead to cardiac decompensation. Plitative renal-sparing NSAIDs, sllch as c)'clo-
oxygenase-2 selective inhibitors have similar effects on renal function as the traditional 
190 
Summary/Samenvattlng 
NSAIDs, and can likewise be expected to increase the risk of heart failure in susceptible 
patients. 
Chapter4 consists of studies on the association between genetie polymorphisms and structural 
heart disorders that aften precede the development of heart failure. Thc apolipoprotein E 
(APOE) E4 aIleIe has been associated with cardiac dysfunction in Alzheimer's disease and 
B-thalassemia. \Yfe studied the association between APOE gcnotypes and left ventrictilar 
systolic dysfunction, assessed by echocardiography, in the general population. This study 
is described in chapter 4.1. A baseline echocardiogram and blood specimens for APOE 
genotyping were available for 2206 participants. Cardiac dysfunction was considered 
present if fractional shortening was 25% or le~s. \"XTe found that the APOE E4 allele is an 
indcpendent risk factor for cardiac dysfunction in thc clderly. Our study results also suggest 
that, besides well-known effects on atherosderosis and cholesterol levels, there may be other 
mechanisms through whieh dus allele exerts negative effects on myocardial performance. 
The association bctwcen a cytosine-adenosine (CA) repeat polymorphism in the promoter 
region of the insulin-like growth factor I (IGF-I) gene and left ventrieldar hypertrophy on 
the echocardiogram is described in chapter 4.2. Altered serum levels of IGF-I have been 
associated with adverse cardiac remodelling, and the IGF-I promotcr polymorphism may 
influence circlllating IGF-I levels. Analyses were perfofHled with baseline measurements in 
1678 subjects aged between 55 and 75 years, without a history of myocardial infarction. Left 
ventricular hypertrophy was defincd as a Icft ventricular mass index 2 104 glm2 in women 
and 2 116 glm2 in men. \X'e found that non-carriers of a 192-base pair (bp, 19 CA repeats) 
polymorplusm in the IGF-I gene are more susceptible to the development of left ventricular 
hypertrophy than individuals homozygous for this aIlele. 
Studies on the association between genetic polymorphisms and heart failure are presented 
in chapter 5. A comprehensive review of the medical literature on the role of genetîc 
polymorphisllls of thc major neurohormonal systems in heart failure is given in chapter 5.1. 
The majority of genetîc association studies have focused on the angiotensin-I converting 
enzyme Insel1ion/Deletion (ACE I/D) polymorphism. Initial genetie associations have often 
been difficult to replicatc, mainly due to problems in study design and lack of power. 
Pronusing reslllts, however, have been obtained with genetîc polymorphisms of the renin-
angiotensin-alelosterone system (RAAS) anel the sympathetic system. Considering the 
evidence so far, a modifying roie for these polymorphisms seems more likely than a role of 
these variants as sllsceptibility genes in the general population. Chapter 5.2 contains a study 
on the association between the CA repeat polymorphism in the promoter region of the IGF-
I gene alld incident heart failure. Data were used from 4963 participants of the Rotterdam 
Study without healt failure at baseline aged 55 10 75 years. IGF-I genotypes were c1assified 
based upon presence or absence of the 192-bp aIlde 09 CA repeats, traditional classilication) 
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and upon presence or absence of the following combination of genotypes: 192-bp/192-bp, 
192-bp/194-bp and 194-bp/194-bp. This second categorization was investigated bccausc 
earlier it was found, in subjects from the Rotterdam Stud)', that circlllating senUll IGF-I 
levels were highest for persons with 192-bp and 194-bp allelcs, whilc bath alleles shorter 
than 192-bp and longer than 194-bp seemed to have lower serum IGF-I levels. This sllggests 
that there is a broader optimum for IGF-I gene regulated transcriptional activity. Persons 
with any other genotype than 192-bp/192-bp, 192-bp/194-bp and 194-bp/194-bp had an 
increased risk of heart fallure (RR 1.39, 95% Cl 1.06-1.80). Therefore, our findings suggest 
that genetically determincd chronic exposure to low IGF-I levels is associated with an 
increased risk for heart failure in elderly individuals. In chapter 5.3, the relation between the 
ACE liD polymorphism and the risk of incident healt fallure in 4264 normatensive and 2174 
hypertensive subjccts (at least moderate hypeltension) is described. Incidence rates of heart 
fallure in nonllotensive subjects were the same aver all genatype strata. In hypertensive 
suhjects, the incidence rate increased significantly with the numbcr of D-alleles present. 
\'\fe observed that hypertensive subjects carrying one or twa copies of the D-allele had a 
signifIcantly increased risk of hemt failure campared ta narmatensive subjects (relative risk 
ID 1.4, 95% Cl 1.1-1.7 and DD 1.5, 95% Cl 1.2-2.0), whilc hypcttensive subjccts canying 
the II-genotype did not have an increased risk of heart faHure compared to individuals with 
a normal blood pressure. These findings suggest that the ACE liD polymarphism plays a 
modifying role in the developmcnt of healt failure in hypertensive suhjects. 
In chapter 6, a pharmacogenetic study is presented. The potential interaction between ACE-
inhibitor therapy and the ACE liD polymorphism in the predictian of incident healt failure 
and death was studied in a subgroup of subjects with hypertension. We used data from 
3365 patients with mild to severe hypertension, 'without heart fallure at baseline for whom 
ACE-genotyping was sllccessful. Incident heart faillIre, total mortality and cardiovasclI1ar 
mortality were studied as endpoints. A Cox regression model with any use of ACE-inhihitors 
defined as time-dependent covariates was used for data-analysis. Interaction was tested in 
this model assuming an allele-effect relationship. Although we could not demonstrate a 
beneficial effect of ACE-inhibitor use in this observational setting, possible pharmacogenetic 
interaction could still be investigated. The results of this study suggest rhat there is a relative 
resistance to ACE-inhibitor therapy in subjects with hypertension and the DD genotype 
compared ta the 11 genotype, with the 10 genotype in an intermediate position. Mortality 
risk associated with treatment increased with the number of D-alleles present; e.g. for total 
1l10rtality in the 11 genotype group: RR=O.95 (95% Cl 0.63-1.45), in the ID genotype group: 
RR~1.08 (95% Cl 0.84-1.38) and in the DD genotype group: RR~1.61 (95% Cl 1.18-2.18). No 
statistically significant interaction was fotilld for incident heart failure, probably due to low 
statistical power. 
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In the general discussion in chapter 7, methodological limitations of phannaco-
epidemiological and genetic association studies are discussed to facilitate a proper 
interpretation of the study results that are described in this thesis. lvioreaver, a perspectÎ\'e is 
given in this chapter on the potential future directions and implications of pharmacogenetic 
research, a dcveloping field with Us own specific pitfalls. 
Samenvatting 
Hartfalen is een complex klinisch syndroom en vormt een belangrijk probleem voor de 
volksgezondheid in the westerse wereld. De prevalentie en incidentie van hartfalen zijn 
aanzienlijk en zullen verder stijgen als een gevolg van de vergrijzing van populaties en 
een verbeterde overleving van de cardiovasculaire ziekten, die deze aandoening kunnen 
veroorzaken. De meest voorkomende oorzaken van hartfalen zijn coronaire hartziekte, met 
name het myocard infarct, hypertensie, kleplijden en idiopathische cardiomyopathie. Er 
zijn tevens sterke aanwijzingen voor een belangrijke bijdrage van genetische factoren aan 
de pathofysiologie van hartfalen. Ondanks de enorme vooruitgang in de behandeling van 
hartfalen, blijft de prognose van deze aandoening slecht. In de klinische praktijk vormt de 
vaak sterk wisselende respons van individuen op geneesmiddelen tegen hartfalen een groot 
probleem. Dit proefschrift bevat een aantal epidemiologische studies, die tot doel hadden 
om inzicht te verkrijgen in de effecten van geneesmiddelen en genetische determinanten 
op het optreden van hartfalen in de algemene bevolking. Alle kwantitatieve studies werden 
uitgevoerd met behulp van data afkomstig van het Erasmus Rotterdam Gezondheid en 
Ouderen (ERGO) onderzoek, een grootschalig bevolkingsonderzoek van 7983 personen 
van 55 jaar en ouder. 
Na een algemene inleiding in hoofdstuk 1, wordt in hoofdstuk 2 een schatting gegeven 
van het optreden van hartfalen in de algemene bevolking. In dit hoofdstuk worden ook 
leeftijds- en geslachtsspecifieke referentiewaarden gegeven, die gebruikt kunnen worden 
voor de detectie van linker ventrikel hypertrofie op het electrocardiogram (EeG) in een 
oudere populatie. Hoofdstuk 2.1 verschaft schattingen van de prevalentie en incidentie 
van hartfalen, het cumulatieve risico op hartfalen gedurende het leven en de prognose 
van hartfalen in de algemene bevolking. Het medisch dossier van personen die deelnemen 
aan het ERGO onderzoek wordt continu onderzocht met betrekking tot het optreden van 
hartfalen. Dit dossier bevat onder andere aantekeningen van de huisarts en ontslagbrieven 
van ziekenhuisopnames. Of een deelnemer van het ERGO onderzoek werkelijk hartfalen 
heeft, wordt bepaald aan de hand van criteria die zijn opgesteld door de "European Society 
of Cardiology". Informatie over overlijden wordt verkregen via de gemeentelijke autoriteiten 
en de huis311Sen van de deelnemers. \Vij vonden een hogere prevalentie van hartfalen bij 
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mannen dan bij vrouwen. De prevalentie steeg van 0.9%) in personen van 55-64 jaar oud 
naar 17.4% in personen van 85 jaar en ouder. De incidentie van hartfalen was aanzienlijk: 
14.4 per 1000 persoonsjaren (95% betrouwbaarheidsinterval (BI) 13.4-15.5) en was hoger 
bij mannen (17.6/1000 man-jaren, 95% BI 15.8-19.5) dan bij vrouwen (12.5/1000 vrouw-
jaren, 95% BI 11.3-13.8). De incidentie steeg met de leeftijd van 1.4 per 1000 persoonsjaren 
bij individuen van 55-59 jaar oud naar 47.4 per 1000 persoonsjaren bij individuen van 
90 jaar en ouder. Het cumulatieve risico op hartfalen gedurende het leven bedroeg 33% 
voor mannen en 29010 voor vrouwen van 55 jaar. Dit betekent dat ongeveer 1 op de 3 
personen van 55 jaar hartfalen zal ontwikkelen gedurende zijn of haar resterende leven. 
Hartfalen had een zeer slechte prognose in onze studie. De overleving bedroeg 86% na 30 
dagen, 63% na 1 jaar, 51% na 2 jaar en 35% na 5 jaar volgend op een eerste diagnose van 
hartfalen, Hoofdstuk 2.2 geeft Ieeftijds- en geslachtsspecifieke normaalwaarden voor de 
detectie van linker ventrikel hypertrofie op het ECG in ouderen voor de Cornell, Sokolow-
Lyon en de "12-lead summed" QRS voltage en voltage*duur produkten. Amplitudes van 
voltages op het ECG variëren met leeftijd en geslacht. Rcferentiewaarden voor linker 
ventrikel hypertrofie op het ECG ontbreken echter bij ouderen. Tijdens de eerste ronde 
van het ERGO onderzoek zijn van 6193 participanten digitale ECGs opgeslagen. Leeftijds-
en geslachtsspecifieke normaalwaarden voor linker ventrikel hypertrofie op het ECG 
werden bepaald met behulp van een. parametrische methode bij 2915 gezonde deelnemers 
van ERGO. Het 98e perçentiel gold als de bovengrens van normaal. Tevens werden de 
traditionele en de door ons bepaalde afkappunten voor linker ventrikel hypertrofie op het 
ECG getest op hun relatie met het optreden van hartfalen en cardiovasculaire m0l1aliteit. 
De door ons bepaalde rcferentiewaarden voor linker ventrikel hypertrofie op het ECG 
waren hoger dan de traditioneel gebruikte afkappunten, behalve voor het Cornell voltage 
bij mannen. Vrouwen hadden lagere waarden voor de 98e percentielen dan mannen tot aan 
de leeftijd van 75 jaar. Normaalwaarden en voltage(*duur) criteria stegen met de leeftijd bij 
vrouwen. Echter, bij mannen daalden de Sokolmv-Lyon en "12-lead summed" QRS voltage 
en voltagctduur criteria met het toenemen der leeftijd, terwijl het Cornell voltage en het 
voltagetduur product bij mannen niet noemenswaardig werd beïnvloed door de leeftijd. 
Linker ventrikel hypertrofie op het ECG was significant geassocieerd met het optreden 
van hartfalen en met cardiovasculaire mortaliteit voor alle afkappunten. Associaties waren 
sterker voor de normaalwaarden die waren bepaald in onze snldie dan voor de traditioneel 
gebmikte afkappunten, behalve voor het Sokolmv-Lyon voltage*duur product. Verschillen 
waren meer uitgesproken bij vrouwen dan bij mannen. 
In hoofdstuk 3 worden twee onderzoeken gepresenteerd, waarin onderzocht werd in 
hoeverre geneesmiddelen determinanten vormen van hartfalen. Hoofdstuk 3.1 bcvat een 
observationele studie naar de associatie tussen het huidige gebruik van antihypertensiva en 
linker ventrikel geometrie op het echocardiogram. Een echocardiogram was vervaardigd 
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bij 2823 deelnemers in de eerste ronde van ERGO. \X'ij bestudeerden 740 deelnemers 
zonder hattfalen met tenminste milde hypertensie en/of het gebruik van maximaal 
één antihypertensivum. Van deze participanten hadden 646 personen een deugdelijk 
echocardiogram voor de analyse van relatieve wanddikte en 642 voor de analyse van linker 
ventrikel massa index. Deelnemers werden gevolgd vanaf 1 januari 1991 tot de datum 
van echocardiografie, tussen september 1992 en juni 1993. Uitkomstmaten werden op de 
volgende manier gedefinieerd: het zich bevinden in het hoogste geslachtsspecifieke quintiel 
van de linker ventrikel massa index en het hebben van een relatieve wanddikte groter 
dan 0.43. Een Cox regressie model met de duur van het gebruik van antihypertensiva 
gedefinieerd als tijdsafhankelijke variabele werd gebruikt voor analyse van de data. Het 
gebruik van antihypertensiva verlaagde het risico op het hebben van een verhoogde linker 
ventrikel massa index (relatief risico (RR) 0.6; 95% BI 0.4-0.9) en, hoewel niet statistisch 
significant, verlaagde het ook het risico op een hoge relatieve wanddikte (RH. 0.8; 95% BI 
0.6-1.0). In hoofdstuk 3.2 wordt een uitgebreide beschouwing gegeven van de recente 
medische literatuur over de associatie tussen het gebruik van niet steroïde anti-inflammatoire 
geneesmiddelen CNSAID's) en het optreden van hartfalen. NSAID's kunnen de nierfunctie 
schaden bij patiënten met een verminderd effectief circulerend voltlIue door een blokkade 
van de synthese van prostaglandines. Als gevolg hiervan kan retentie van water en natrium 
optreden en een vermindering in de doorbloeding van de nier en van de glomerulaire 
filtratie. Hierdoor kan de instabiele cardiovasculaire homeostase bij deze patiënten verder 
negatief beïnvloed worden. Bij patiënten met hartfalen kan dit leiden tot verschijnselen van 
decompensatie. NSAID's met een veronderstelde nier-sparende werking, zoals de cyclo-
oxygenase-2 selectieve remmers, hebben gelijkwaardige effecten op de ruerfunctie als de 
traditionele NSAID's en zullen derhalve een verhoogd risico op hartfalen geven bij daarvoor 
gevoelige patiënten. 
Hoofdstuk 4 bevat enkele onderzoeken waarin associaties worden bestudeerd tussen 
genetische polymorfismen en structurele aandoeningen van het hart welke vaak voorafgaan 
aan hartfalen. Het apolipoproteïne E CAPOE) E4 allel is in eerdere studies geassocieerd 
met cardiale disfunctie in patiënten met cle ziekte van Alzheimer en in patiënten met B-
thalassemie. \X'i; bestudeerden de associatie tussen APOE genotypes en systolische disfunctie 
van de linker ventrikel op het echocardiogram in de algemene bevolking. Deze studie wordt 
beschreven in hoofdstuk 4.1. Een echocardiogram en bloedmonsters waren beschikbaar 
voor 2206 deelnemers. Cardiale disfunctie was gedefinieerd als een "fractional shortening" 
van 25% of minder. \X'ij vonden in onze studie dat het APOE E1 allel een onanlankelijke 
risicofactor is voor cardiale disfunctie in een oudere populatie. Onze bevindingen suggereren 
tevens dat cr naast de algemeen hekende effecten van dit polymorfisme op atherosclerose 
en cholesterol andere mechanismen zijn, die de negatieve effecten van dit allel op de 
prestaties van het myocard kunnen verklaren. De associatie tussen een cytosine-adenosine 
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(CA) repeat polymorfisme in de promoter regio van het insuline-achtige groeifactor (IGF)-I 
gen en linker ventrikel hypertrofIe op het echocardiogram wordt beschreven in hoofdstuk 
4.2. Veranderingen in IGF-I bloedspiegels zijn geassocieerd met nadelige remodeling van 
het hart. Het IGF-I promoter polymorfisme zou de IGF-I bloedspiegels kunnen beïnvloeden. 
Analyses werden uitgevoerd met de metingen van de eerste ERGO ronde van 1678 
deelnemers van 55 tot 75 jaar oud, zonder een voorgeschiedenis van myocard infarct. Linker 
ventrikel hypertrofie was gedefinieerd als een linker ventrikel massa index ~ 104 glm l in 
vrouwen en ~ 116 glm2 in mannen. Wij vonden in deze studie dat non-carriers van het 192-
base paar allel (bp, 19 CA repeats) polymorfisme in het IGF-I gen vatbaarder waren voor 
het ont\vikkelen van linker ventrikel hypertrofie dan personen die homozygoot waren voor 
dit allel. 
In hoofdstuk 5 worden onderzoeken gepresenteerd naar de associatie tussen genetische 
polymorfismen en hartfalen. Een uitgebreid overzicht van de medische literatuur over de rol 
van genetische polymorfismen van de belangrijkste neurohormonale systemen in hartfalen 
wordt gegeven in hoofdstuk 5.1. Een rneerderheid van de genetische associatie studies in 
de medische literatuur is gericht op het angiotensin-I converting enzyme Insertion/Deletion 
(ACE VD) polymorfisme. Genetische associaties, die aanvankelijk werden gevonden, bleken 
vaak moeilijk om te reproduceren in latere studies, voornamelijk vanwege problemen in 
het ontwerp van de betreffende onderzoeken en een gebrek aan onderscheidingsvermogen 
("power"). Veelbelovende resultaten zijn echter geboekt met genetische polymorfismen van 
het renine-angiotensine-aldosteron systeem (RAAS) en het sympathische systeem. Uitgaande 
van de huidige kennis lijkt een modificerende rol van deze polymorfismen op hartfalen 
in de algemene bevolking waarschijnlijker dan een rol van deze genetische varianten als 
ontvankelijkheids genen. Hoofdstuk 5.2 bevat een onderzoek naar de associatie tussen het 
CA-repeat polymorfisme in de promoter regio van het IGF-I gen en incident hartfalen. Voor 
deze studie werden data gebruikt van 4963 deelnemers aan ERGO van 55 tot 75 jaar oud, 
zonder hartfalen bij het begin van de studie. IGF-I genotypes werden geclassificeerd op basis 
van de aan- of afwezigheid van het 192-bp allel (19 CA repeats, traditionele classificatie) en 
op basis van de aan- of anvezigheid van de volgende combinatie genotypes: 192-bp/192-bp, 
192-bp/194-hp en 194-bp/194-bp. Deze tweede categorisatie werd onderzocht in deze studie 
omdat er in een eerdere studie in de ERGO-populatie was gevonden dat IGF-I bloedspiegels 
het hoogst waren voor deelnemers met 192-bp en 194-bp allelen, terwijl deelnemers met 
zowel kortere allelen dan het 192-bp allel als deelnemers met allelen langer dan het 194-
hp allel lagere IGF-I bloedspiegels hadden. Deze bevinding suggereert dat er een breder 
optimum is voor de regulatie van de transcriptionele activiteit van het IGF-I gen. Personen 
met elk ander genotype dan 192~bp/192~bp, 192~bp/194~bp en 194~bp/194~bp hadden een 
verhoogd risico op hartfalen (RR 1.39; 95% BI 1.06-1.80). Onze resultaten suggereren derhalve 
dat een genetisch bepaalde chronische blootstelling aan lage IGF-I spiegels het risico op 
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hartfalen verhoogt bij oudere individuen. In hoofdstuk 5.3 wordt de relatie beschreven 
tussen het ACE liD polymorfisme en het risico op incident hartfalen bij 4264 participanten 
van het ERGO onderzoek met een normale bloeddruk en 2174 deelnemers met hypertensie 
(ten minste matige hypertensie). De incidentiecijfers van hartfalen waren gelijk voor alle 
genotypes bij mensen met een normale bloeddruk. Bij deelnemers met hypc11ensie steeg 
het incidentiecijfer echter significant met het aantal D-allelen. Wij vonden dat personen met 
hypertensie en één of twee D-allelen een significant verhoogd risico hadden op ha11falen ten 
opzichte van deelnemers met een normale bloeddmk (relatief risico ID 1.4.95% BI 1.1-1.7 en 
DO 1.5, 95% BI 1.2-2.0). Hypertensieven met het 11 genotype hadden geen verhoogd risico 
op hartfalen ten opzichte van personen met een normale bloeddruk. Onze bevindingen 
suggereren dat het ACE liD polymorfisme een modificerende rol speelt bij de ontwikkeling 
van hartfalen bij patiënten met hypertensie. 
In hoofdstuk 6 wordt een farmacogenetische studie gepresenteerd. Het bestaan van een 
mogelijke interactie tussen behandeling met ACE-remmers en het ACE IlO polymorfisme bij 
het optreden van hartfalen en overlijden werd bestudeerd bij een groep ERGO deelnemers 
met hypertensie. Hiertoe maakten wij gebruik van de data van 3365 patiënten met milde tot 
ernstige hypertensie, zonder hartfalen bij het begin van de studie, voor wie de genotypering 
van het ACE polymorfisme succesvol was verricht. Als eindpunten werden incident hartfalen, 
totale mortaliteit en cardiovasculaire m0l1aliteit bestudeerd. Een Cox regressie model met 
het gebmik van ACE-remmers gedefinieerd als tijdsafhankelijke variabele werd toegepast 
voor analyse van de data. Hoewel wij geen gunstig effect van het gebruik van ACE-remmers 
konden aantonen in deze obselvationele studie, kon het bestaan van een mogelijke 
farmacogenetische interactie wel worden bestudeerd. Onze bevindingen suggereren 
dat er een relatieve resistentie is tegen de effecten van ACE-renuners bij personen met 
hypertensie en het DD genotype ten opzichte van het 11 genotype. Het ID genotype neemt 
hier een middenpositie in. Het overlijdensrisico geassocieerd met de behandeling steeg 
met het aantal D-allelen; bijvoorbeeld voor totale mortaliteit (alle doodsoorzaken) in de II 
genotype groep' RR~0.95 (95% BI 0.63-1.45), in de ID genotype groep, RR~1.08 (95% BI 
0.84-1.38) en in de DD genotype groep, RR~1.61 (95% BI 1.18-2.18). Er werd geen statistisch 
significante interactie gevonden voor incident hartfalen, waarschijnlijk vanwege een te laag 
onderscheidingsvermogen van onze studie. 
In de algemene discussie in hoofdstuk 7 worden methodologische beperkingen van 
farmaco-epidemiologische en genetische associatie studies besproken, teneinde een 
juiste interpretatie mogelijk te maken van de onderzoeken die in dit proefschrift worden 
beschreven. Daarnaast wordt in dit hoofdstuk een perspectief gegeven van de potentiële 
toekomstige richting en consequenties van farmacogenetisch onderzoek. 
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erkentelijk. Zonder de medewerking van al deze mensen zou dit proefschrift (en dat van 
vele anderen) niet tot stand hebben kunnen komen. Daarnaast wil ik op deze plek alle 
dames van het ERGO-centrum in Ommoord bedanken voor hun nimmer aflatende inzet en 
het opfleuren van de 'ERGO-diensten' en de technische en administratieve ondersteuning 
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op de afdeling Epidemiologie & Biostatistiek, met name voor de hulp bij het opzetten van 
de hartfaleIlValidatie. 
Hier ook een blijk van mijn dankbaarheid aan alle co-auteurs van de verschillende 
hoofdstukken in dit proefschrift voor hun intellectuele inbreng en vervolmaking van de 
teksten. In het bijzonder wil ik Jaap Deckers noemen voor zijn hulp als 'supercodeur' bij 
het hartfalen cohort, Peter Rijnbeek, jan Kors en Ge van Herpen voor hun expertise met 
betrekking tot de EeGs, Bert Hofman voor de laatste noot bij elk manuscript en zIjn altijd 
aanwezige interesse in de voortgang van mijn promotie, Jaap Deinum en Arend J\-Iosterd 
voor de (morele) ondersteuning bij mijn allereerste studie, joop janssen voor het delen 
van zijn grote kermis op het gebied van IGF-I en Anna Schut en Cock van Duijn voor de 
vruchtbare samenwerking op het gebied van hypertensie, hartfalen en genetica. 
Een speciaal woord van dank wil ik richten aan mijn paranimfen: Loes Visser en Rascha 
Koek. Meiden bedankt dat jullie de zware taak op je wilden nemen om mij bij te staan in de 
laat')te fase van mijn promotie. Loes, je bent er vanaf het eerste moment bij geweest hoe ik 
als broekie vanuit het Ziekenhuis zonder enige kennis van de epidemiologie en onderzoek 
bitmenkwam en werd klaargestoomd tot klinisch epidemioloog en wetenschappelijk 
onderzoeker. Eerst als kamergenote en bondgenoot, later zeker ook als lotgenoot, ook al 
was het één kamer verderop. Veel succes met jouw eigen toekomstige promotie en verdere 
carrière als onderzoeker. Ook wens ik je succes in het bereiken van jouw doelen in je 
andere werk als ziekenhuisapotheker en heel veel geluk met je gezin: Jeroen, Famke en 
Fleur. Rascha, jij hebt al een aantal jaren eerder toegezegd, na een fantastische reis door 
r-,'Iexico, om mij bij te staan als paranimf en te helpen met de laatste loodjes. Bedankt voor 
de al vele jaren van vriendschap die we samen delen. Ik kan altijd op je bouwen en hoop 
dat je nog vele jaren in de buurt blijft (letterlijkO. Lieve Ras, jij ook veel succes met je carrière 
als huisarts en de keuzes die je hebt gemaakt en nog moet maken voor de toekomst. 
De collega's van de farmaca-epi hebben mijn verblijf op de hoogbouw in de afgelopen 
jaren verrijkt. Door de jaren heen zijn dat er heel wat geweest. In den beginne waren daar 
Anke-Hilse, lias, Fernie, Geert, Ingo, Jeanne, Mei<mie en natuurlijk Loes. L'l.ter kwamen ook 
Bert, Bettie, Cornelis, Dika, Georgio, Hedi, Katia, Mariëtte en Sabine. Allen bedankt voor 
de leuke momenten tijdens de staf en de ISPE en voor het nuttige commentaar op mijn 
artikelen. [vlijn kamergenoten wil ik hierbij speciaal bedanken. Cornelis, Mariëtte en Sabine, 
we konden altijd heerlijk tegen elkaar aanzeuren over van alles en hebben veel gelachen en 
gefilosofeerd. Het ga jullie goed. 
Alle collega's van de afdeling Epidemiologie & Biostatistiek wil ik bedanken voor 
de gezelligheid tijdens werktijd, lunchtijd, borreltijd en de sporadische maar historische 
avondjes uit. Een speciaal bedankje is op zijn plaats voor mijn buuv en buum, oftewel 
Annete van den E. en Hok-Hay O. Bij hen kon ik altijd binnenlopen voor een praatje, kopje 
koffie/thee/soep en advies op allerlei gebied, hetgeen ook op dagbasis gebeurde. Ik ga 
jullie zeker missen. 0 ja, ook nog bedankt voor de practical joke rond valentijnsdag, die ik 
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nooit zal vergeten (dus .... ) en de heerlijke lunch die jullie daarna uit schuldgevoel hebben 
betaald. Ook wil ik hier Stephanie niet vergeten, met wic ik naast Hok de laatste periode 
van promotie stress heb gedeeld en alle spanning rond de sollicitatie voor de opleiding 
Inwendige Geneeskunde en Lonneke, die de laatste periode op de afdeling extra leuk heeft 
gemaakt. 
Mijn overgang van AGNIO naar arts-onderzoeker en nu weer naar AGIO is te danken 
aan het vertrouwen dat aan rnij is gegeven door Dr. A.C.l.,,!. van Vliet, opleider Inwendige 
Geneeskunde in het Albert Schweitzer Ziekenhuis te Dordrecht. Adrie, ik verwacht veel 
van je te leren in de komende jaren en hoop op een plezierige samenwerking. Daarnaast 
wil ik Hans Feenstt'<l hier bedanken voor het e:i\"tra zetje in de rug om te beginnen aan dit 
promotietraject. 
Ik mag me gelukkig prijzen dat ik een aantal bijzondere mensen in mijn leven heb 
gekregen, die ik mijn vrienden mag noemen. Vriendinnen vanaf het eerste moment en 
lotgenoten in de promotie stress, \'\'endy en Aagje, ik zal onze lunches gaan Illissen nu 
ik in Dordt zit, maar ik weet dat ik jullie zeker niet hoef te missen, Daarnaast squash-, 
bel-, borrel-, feest-, weekendje-weg vriendinnen, eigenlijk vriendinnetjes voor het leven, 
Annemieke, ]\'lirjam en Sonia, waarbij natuurlijk de reeds genoemde vriendinnetjes Aagje en 
Rascha (en de volledige aanhang) niet mogen ontbreken. Annemiek, ik hoop dat we altijd 
verhoogd associatief blijven denken! Daarnaast waardeer ik ook zeer het contact met de 
meiden van mijn jaarclub Baloe, Al weer zo'n 11 jaar bijeen, dat is toch een hele kunst. 
De belangrijkste plek in dit dankwoord en in mijn hart wordt ingenomen door mijn 
familie, !\'la, pa, Mélanie, Henriëtte, Bram, Marc, Esmé, Femke en Madeion, jullie vormen 
de belangrijkste schakels in mijn leven, Zonder jullic tocwijding en liefde zou ik niet zijn 
geworden tot wie ik nu ben, Ik ben trots op jullie en hou van jullie allemaal. Dikke kus. 
qysHe 
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